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ABSTRACT 
Peptidomimetic compounds are becoming increasing important as medicinal 
agents. This thesis describes the design and synthesis of a novel class of non-
hydrolysable peptidomimetic isosteres, the tetrazole-based amide bond isosteres. These 
new structural mimics have been developed for incorporation into enzyme inhibitors and 
biological probes where a non-hydrolysable cis- amide bond mimic is required. 
Chapter one provides a general outline of conformational restriction and how this 
concept has been advantageously applied to the design of bioactive peptidomimetics. 
Conformational restriction, when used to pre-organise peptidomimetic ligands into a 
desired bioactive conformation, gives ligands that bind to target receptors with a greater 
affinity. The tetrazole heterocycle has obvious structural similarities to the cis-
conformation of the amide bond and has been used to lock amide bonds in an equivalent 
conformation. Hence, the 1,5-disubstituted tetrazole ring is a popular constrained, planar 
cis- amide bond mimic and its use as such is reviewed in chapter one. 
Chapter two outlines the design of the tetrazole-based isosteres, the a-methylene 
tetrazole (2.5.1),t a-hydroxymethylene tetrazole (2.5.2), and a-keto tetrazole isostere 
(2.5.3). The tetrazole-based isosteres incorporate the design features of a non-
hydrolysable amide bond isostere and the conformational restriction of the 1,5-
disubstituted tetrazole ring, to generate the first examples of non-hydrolysable tetrazole-
based cis- amide bond mimics. 
Chapter three reviews the synthesis of N-Z-(2RS,3S)-3-amino-2-hydroxy-4-
phenylbutanoic acid [N-Z-AHPBA, 3.1.1], a key amide bond isostere used in potent 
protease inhibitors and a synthetic building block of the a-hydroxymethylene tetrazole 
isostere (2.5.2). We have investigated the synthesis of 3.1.1 by functionalisation of N-Z-
L-phenylalaninal, 3.2.3. Due to shortcomings in this published procedure we have 
developed a new, generally applicable synthesis of this important amide bond isostere by 
t Compound numbering is based on chapter number, ego 2.5.1 represents compound 1 of Chapter 2.5. 
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hydroxylation of an enolate derived from methyl (3S)-N-Z-3-amino-4-phenylbutanoate 
(3.4.2) with the oxodiperoxymolybdenum (pyridine) (hexamethyl phosphoric triamide) 
complex (MoOPH). 
Chapter four describes the synthesis and spectral analysis of diastereomeric 
tetrazole-based compounds. We have synthesised two series of a-methylene tetrazole-
based compounds, 4.1.4a-4.1.7a and 4.1.4b-4.1.7b, derived from L-alanine and D-
alanine, respectively. We have used this analysis to establish trends in the IH and 13C 
NMR of the diastereomeric series as an aid to the assignment of configuration of 
tetrazole-based ligands. We have also been able to monitor epimerisation of the C6 
stereocentre adjacent to the tetrazole by IH NMR under the conditions of peptide 
coupling. 
Chapter five outlines the synthesis of (2S)-I-(benzyl ethanoate)-5-[2-(N-
benzyloxycarbonylamino )-3 -phenylpropane ]-tetrazole, t 5.2.1, an a-methylene tetrazole-
based dipeptide mimic. We have incorporated 5.2.1 into extended substrate sequences of 
IllVp and tested these compounds for in vitro activity againstBIVp. The modestly potent 
IllVp inhibitors 5.4.1, 5.4.2, and 5.4.3 represent a step-wise elongation of the C-terminal, 
and gave ICso values against HIVp of 94 JlM, 47 JlM and 18 JlM, respectively. 
Chapter six describes the synthesis of the a-keto tetrazole isostere, by 
direct alkylation of (IRS,2S)-5-[2-(N-tert-butyloxycarbonylamino )-I-hydroxyl-3-
phenylpropaneJ-IH-tetrazole, 6.3.13, with benzyl bromoacetate, followed by a TEMPO 
oxidation. The desired 1 ,5-disubstituted dipeptide mimic, (2S)-I-(benzyl ethanoate)-5-[2-
(N-tert-butyloxycarbonylamino )-I-oxo-3-phenylpropane ]-tetrazole, 6.3.16, was isolated 
from the 2,5-disubstitiuted dipeptide mimic, (2S)-2-(benzyl ethanoate)-5-[2-(N-tert-
butyloxycarbonylamino )-I-oxo-3 -phenylpropane J-tetrazole, 6.3.17. This outlines a new 
and generally applicable synthesis of the tetrazole-based isosteres. 
Chapter seven describes the solid state structures of three tetrazole..;based 
dipeptide mimics. The a-methylene tetrazole based isostere has been observed in the x-
ray structure of the dipeptide mimiC, (2S)-I-(benzyl ethanoate )-5-[2-(N-
:t Naming of tetrazole-based compounds is non-nJP AC and follows Zabrocki et al. J. Am. Chern. Soc. 1988, 
110,5875. 
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benzyloxycarbonylamino)-3-phenylpropane]-tetrazole and the cyclic 
tetrazolodiazepine analogue, cyclo-{[(2S)-5-(2-amino-3-phenylpropane)-1-
ethanamide ]tetrazole}, These are the first examples of the solid state structure of 
the <x-methylene tetrazole isostere. We have also observed the solid state structure of the 
2,5-disubstituted tetrazole, (2S)-2-(Benzyl ethanoate )-5-[2-(N-tert-
butyloxycarbonylamino)-1-oxo-3-phenylpropane]-tetrazole, 6.3.17. 
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1.0 PEPTIDOMIMETICS 
A peptidomimetic is a compound that incorporates secondary structural features 
analogous to a naturally occurring peptide, thus enabling it to mimic the biological 
function of the parent peptide. 1,2,3,4 Peptidomimetics have become increasingly important 
in the development of therapeutic agents due to their ability to resist enzymatic 
degradation and hydrolysis,S while displaying enhanced bioavailability and bioselectivity. 
The advantageous therapeutic profile ofpeptidomimetic compounds has made this class 
of compounds an attractive synthetic target and encouraged their isolation as natural 
products.6 
Modem advances in the development of peptidomimetics as medicinal agents, 
and as biological probes, have been attributed primarily to the development of two key 
areas of modern drug discovery. First, the synthetic technology that is combinatorial 
chemistry,7 which allows the generation of vast libraries of organic compounds, in 
conjunction with the hardware for mass screening of these libraries to identify new lead 
compounds,s The advent of solid phase organic chemistry has been critical to the 
preparation of these compound libraries, which range from those purely peptidic in nature 
to libraries ofnon-peptidic mimetics. The activity of lead compounds, identified through 
mass-screening, can in tum be optimised by structural and functional variation of the 
original peptidomimetic platform. Mass screening can also be used to identify lead 
compounds derived from libraries of natural products, which in turn can undergo 
refinement through investigation of the structure-activity relationship. 
The second key development in the rise in popularity of peptidomimetic agents 
has been the development of modern chemical tools that allow the structural biologist to 
'visualise' target receptors and native peptides. With this technology comes an 
understanding of the topochemical, conformational, and electronic properties of native 
peptide ligands, or correspondingly, the receptors. By combining modern nuclear 
magnetic resonance (NMR) spectroscopy, computer modelling and the data from X-ray 
structural analysis of peptides it has become possible to design tailor-made 
peptidomimetic compounds. 
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The pharmacophore* which can be obtained with this technology is considered to 
be a 'blue-print' for biological activity against the target receptor. The pharmacophore 
maps the structural and functional requirements that are necessary for favourable 
interactions to occur between the peptidomimetic compound and the target receptor. Ifa 
peptidomimetic compound can match this blue-print then there is a high chance that it 
will be able to displace the native peptide from the receptor. Armed with this information, 
the synthetic chemist can undertake a rational-based approach to the design and synthesis 
of peptidomimetic compounds which take into account the steric and functional 
requirements for interaction with the target receptor. Compound libraries are often 
analysed at this stage in compuo for compounds which match the requirements of a 
derived pharmacophore, thus reducing synthetic expenditure. 
A large number of peptidomimetic compounds have proven to be successful as 
therapeutic agents, or have been utilised as probes to determine the structure or biological 
function of receptors and proteins. 
1.1. PEPTIDOMIMETIC ENZYME INHIBITORS 
Enzymes catalyse molecular transformations in many physiological processes. It 
is possible, in some instances, to block or inhibit the action of the enzyme, so that it is 
unable to perform its usual physiological role. This concept has been utilised in the 
development of medicinal agents. Drugs which inhibit an enzyme are used to treat 
disease where the catalytic action of a specific enzyme leads to the diseased state. 
The native enzyme substrate is a rational starting point in inhibitor design, as its 
structural and electronic features specify structural requirements of target peptidomimetic 
inhibitors. The native substrate generally has high specificity and affinity for an enzyme 
and as such it can be used as a pharmacophore for inhibitor design. Many naturally 
occurring enzyme inhibitors are peptidic in nature. Unfortunately, peptides themselves 
make poor enzyme inhibitors due to their low metabolic stability and poor bioavailability. 
* A phannacophore maps the structural and electronic features of a bioactive compound. 
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Peptides are susceptible to enzymatic hydrolysis in the gastrointestinal tract and serum 
and are rapidly excreted through the liver and kidneys. Due to their relatively high 
molecular mass and lack of specific transport system they are not readily absorbed after 
oral ingestion. 
A logical extension in rational drug design is to convert the three dimensional 
structural information contained in a native peptide substrate into a smaller non-peptidic 
compound. Such peptidomimetic compounds would be expected to retain the favourable 
selectivity of the native peptide whilst showing improved pharmacological properties. 
Researchers have successfully designed potent peptidomimetic enzyme inhibitors using 
this idea in conjunction with structural information regarding enzyme topography. There 
is an increasing number ofpeptidomimetic inhibitors being presented in current literature 
that contain one or more of the conformationally restricting motifS discussed in the next 
section. Conformational constraint is used in the pre-organisation of inhibitor 
peptidomimetics into bioactive conformations. This technique has been proven to give 
potent, selective, and proteolytically stable enzyme inhibitors. 
1.2. CONFORMATIONAL RESTRICTION 
A stretched out or randomly orientated protein is generally devoid of biological 
activity. Protein function is achieved through the spatial arrangement of the peptide 
backbone, which in tum is defined by the amino acid sequence. Confonnation defines 
biological activity. This highlights an important concept applicable to peptidomimetic 
research. Enhanced biological activity can be achieved by mimicking the biologically 
active conformation of the native substrate. Additional structural elements can be 
incorporated into peptidomimetic design to force rigidity and achieve the desired 
bioactive conformation. These rigid structural features ensure the correct positioning of 
specific functionalities in order to optimise hydrogen bonding, electrostatic and 
hydrophobic interactions between the peptidomimetic ligand and the receptor. 
To this effect, peptidomimetic ligands can be designed to be preorganised into a 
bioactive conformation by the inclusion of rigid structural elements. Rigid 
peptidomimetic analogues pay a lower entropy cost upon binding to the target receptor, 
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and therefore should bind more avidly, assummg a preorganised placement of 
pharmacophoric residues. 
What follows is a discussion of some of the design strategies employed to force 
rigidity in peptidomimetic compounds. 
1.2.1. MODlFICATIONS OF THE PEPTIDE BACKBONE 
Modification of the peptide backbone refers to the generally isosteric t or 
isoelectronic exchange of units in the peptide chain, and the introduction of additional 
fragments. Some of the more general replacements are outlined on Table 1 1.1. 
R 
depsl aza thiol 
reduced 
keto-methylene bora n=I,2 
N-hydroxyl 
reiro-inverso 
Table 1.2.1.1. General modifications to the peptide 
backbone 
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Conforrnational restriction is imparted from these modifications by electronic and 
steric effects of the backbone replacements. Backbone modifications lower the peptide 
character of the ligand, thereby increasing proteolytic stability, whilst retaining 
favourable properties of the parent peptide. 
1 MODIFICATIONS TO AMlNo ACID SIDE-CHAINS 
A well established method of incorporating conformational restriction into 
peptidomimetics is through the modification of naturally occurring amino acid side 
chains. Conformational restriction is possible by introducing sterically demanding groups 
so as to limit free rotation of the amino acid residue. Modification of the tyrosine, 
side chain by introducing methyl groups in the 2'-,6'-, and f3-positions hinders free 
rotation about the CP-C bond restricting the analogue, 1.2.2.2, to a preferred 
conforrnation.9 Phenylalanine (1.2.2.3) derivative, 1.2.2.4, has been incorporated into 
potent peptidomimetic ligands of the angiotension II receptor as a constrained 
phenylalanine mimic. lO Compound 1.2.2.5 is a phenylalanine analogue that is 
conforrnationally constrained, so that the dihedral angle about the Ca_C~ bond has a very 
narrow range. This unnatural amino acid, 1.2.2.5, has been incorporated into various 
opioid antagonists. l1 
fH OH H'C:8 P ~ y- '?:B ~ h H3C CH3 ~ ~ H2N f:\COOH N uCOOH H2N COOH H2N COOH H2N COOH H 
1.2.2.1 1.2.2.2 1.2.2.3 1.2.2.4 1.2.2.5 
t Used to compare structural elements of a similar volume. 
CHAPTER ONE-INTRODUCTION 7 
1 CONFORMATIONALL Y -STABILISING RINGS 
The conformation of ligands can be fixed by the introduction of short and long-
range cyclisations within the peptidomimetic backbone. 12 The bridging can occur within 
a single amino-acid residue (eg. 1.2.3.1),13 or may involve several amino acid residues 
(eg. 1.2.3.2).14 In general the bridging unit will link two side chains (eg. 1.2.3.3),15 or a 
side chain bridged to the backbone (eg. 1.2.3.4);6 or between two backbone units (eg. 
17 
1.2.3.1 1.2.3.2 1.2.3.3 
1.2.3.4 1.2.3.5 
1 MACROCYCLIC PEPTIDOMIMETICS 
Many biologically active macrocyclic peptides are found in nature. Their 
biological activity, in contrast to their acyclic counterparts, is due in part to the inherent 
conformational restriction provided by a cyclic system. The relatively restricted 
conformation of the macrocyclic peptides can offer enhanced binding selectivity with 
receptors as the availability, and orientation of peptide side-chains is constrained within a 
macrocyclic ligand. As with all constrained peptidomimetics, the macro cyclic motif 
offers an entropic advantage over an acyclic peptide, as the bioactive conformation of the 
constrained peptide is reached from a smaller population of random conformers. 
Somatostatin (1.2.4.1) is a macrocyclic peptide hormone,18 formed in the hypothalamus, 
that regulates the release of growth-hormone. It also acts in the pancreas, preventing the 
release of glucagon and insulin, leading to a lowering of blood glucose concentrations. 
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The regulatory action of somatostatin is due to interaction of the macrocyclic loop 
with a receptor site. Structure-activity studies and conformational probing has led to the 
rational design and synthesis of a variety of simplified peptidomimetic somatostatin 
analogues, including 1.2.4.2,18,19,20 which shows similar potency to the parent peptide, 
1.2.4.1. The activity of the mimic is attributed to the conserved cyclic array (shown in 
bold, 1.2.4.1 and 1.2.4.2), which forms a peptide recognition epitope, or loop, and leads 
to receptor recognition. 
1.2.4.1 
1.2.4.2 
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The notion of macro cyclic peptidomimetic inhibitors has also been successfully 
applied to the inhibition of protease (HIVp),21 a key proteolytic enzyme in the 
replicative cycle of IDV (see Chapter 2.2). This proteolytic enzyme selectively 
recognises and cleaves extended substrate conformations. Structural information derived 
from the X-ray structure ofIDVp-inhibitor complexes has enabled researchers to design 
and synthesise existing IDVp inhibitors that are constrained within a macrocyclic array. 
IDVp inhibitors 1.2.4.3,22 and 1.2.4.423 have been incorporated into cyclic analogues 
1.2.4.5 and 1.2.4.6.24 The N-terminal macrocycles of these new IDVp inhibitors (shown 
in bold 1.2.4.5 and 1.2.4.6) were designed to link residues that are spatially close when 
bound to the active site ofIDVp. Researchers have also been able to generate C-terminal 
macrocyclic replacements,25 and bicyclic hexapeptide analogues,z6 This has resulted in 
cyclic arrays that constrain segments of the peptidomimetic inhibitor in a bioactive 
conformation. 
1.2.4.4 
1.2.4.5 1.2.4.6 
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X~ray stmcture analysis of the macro cyclic inhibitors have shown that their 
conformation closely mimics that of the HIVp~bound conformation of the extended 
substrate inhibitors, and 1.2.4.4. This stmctural mimicry leads to functional 
mimicry, since it has been shown that the macrocyclic analogues, 1.2.4.5 and 1.2.4.6, are 
potent inhibitors of HIVp. These compounds have a high binding affinity and an 
enhanced pharmacological profile in comparison to their acyclic counterparts, 1.2.4.3 and 
The macrocyclic linkage reduces the susceptibility to proteolytic cleavage and 
increases the lipophilicity of 1,2.4.5 and 1.2.4.6, thus increasing their antiviral activity in 
vivo. 
1.2.5. CIS- AMIDEBoNDMlMIcs 
Pauling L. and Corey R. (1930) did pioneering work with X-ray crystallographic 
studies on the structure of amino acids and peptides. One of their significant findings was 
that the peptide unit was planar and rigid, such that the hydrogen of the substituted 
nitrogen is nearly always trans- to the carbonyl oxygen. This has been attributed to the 
partial double bond character of the amide bond. Delocalisation of the nitrogen electrons 
limits free rotation about the amide bond, and consequently limits the rate of 
interconversion between the cis- and trans- coplanar forms (Figure 1.2.5.1). t 
slow 
trans- cis-
1.2.5.1. Geometry of the amide bond. 
j: Cis- and trans- nomenclature reflects the relative conformation of the peptide backbone, where oxygen 
has no priority. 
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The conformation of the amide bond is of crucial importance to the binding mode 
of an extended ligand to a receptor. In a normal amide bond the trans- conformation is 
energetically favoured over the cis- confonnation by approximately 10 kcalmorl, due to 
less steric congestion between adjacent amino acid side chains. Extended peptide ligands 
are often seen bound to a receptor with a preference for either the cis- or trans-
conformations. In some cases ligand binding will occur with a cis- conformation, even 
though this is energetically disfavoured in the unbound extended conformation. 
L-Proline is the most common naturally occurring N-alkylated amino acid. The 
amide bond proceeding proline in a linear peptide sequence will adopt a cis-
confonnation in a large number of cases (see Figure 1 .2). As a result, Xaa§-cis-proline 
amides are seen in 10-30% of short propyl peptides, while a further 6% of Xaa-proline 
amide bonds in peptides are known to adopt the cis- conformation?7 X-Ray data for a 
number of proline containing bioactive peptides reveals that the unbound ligands adopt a 
cis- confonnation in 10% of examples studied. 
trans- cis-
Figure 1.2.S.2. The cis-trans- proline equilibrium. 
In the angiotension II analogue, 1.2.5.1, cis-trans-propyl isomerism has been 
observed by NMR, 28 and the confonnational preference for cis- or trans-proline 
correlated with biological activity. The result obtained suggest that the peptidomimetic 
analogue binds in a cis-proline confonnation to the receptor, and the histidine-cis-proline 
(shown in bold, conformation is responsible for the observed activity. 
§ Where Xaa is any amino acid. 
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On the time scale of protein folding thermal cis- trans-propyl interconversion 
(Figure 1.2.5.2) is slow, leading to slow steps in the protein folding, of propyl peptides. 
This limits the use of a proline amide as a cis- amide bond mimic as it cannot be 
considered preorganised into the required cis- conformation. This fascit, and the 
hydrolytic instability of the proline amide bond, disfavours the use of the proline residue 
in conformationally restricted peptidomimetics. For the design of constrained ligands and 
biological probes it is obviously advantageous to have access to cis- residue mimics. In 
response, peptidomimetic chemists have developed a series of cis- amide bond surrogates 
which have been successfully used in this application. 
Although a cis- olefin would be a logical mimic for the cis- amide bond, the 
synthesis of such dipeptide analogues has proved extremely difficult because of the 
propensity of the cis-~,y-unsaturated carbonyl system to isomerise to the energetically 
favoured trans-cx,~-unsaturated carbonyl system, even under the relatively mild 
conditions of peptide synthesis?9 Many cis- amide bond mimics have been presented in 
the literature as alternatives to the cis-olefin analogue, 30 and some of these will be 
discussed here. 
Many N-alkylated amides are found in naturally occurring bioactive peptides,6 
and others have been synthesised as constituents of conformationally constrained 
peptidomimetics. The energy difference between cis- and trans- conformations of N-
alkylated amides is small, as both conformers have similar 1,4-steric interactions. The 
energetic accessibility ofthe cis- confonnation is reflected in the binding modes of many 
N-alkylated peptidomimetics, which have shown a preference for the cis- conformation 
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for recognition and binding to a receptor. N-Methylated amino acids are found in 
naturally occurring bioactive peptidomimetics and many have been shown to bind in a 
cis- conformation. ConfOlmation calculations and NMR studies on the N-methylated 
dipeptide, 1.2.5.2, revealed that the cis- isomer is only 0.6 kcalmor1 higher in energy than 
the corresponding trans- isomer?1 The energetic accessibility ofthe cis- conformation to 
N-alkylated amides has made this conformational constraint a popular cis- amide bond 
mImiC. 
H 0 H ~ CH 
N il OR ==="",H c,N~N/ 3 
H3C' ~~lr 3 l ~O 
CR3 0 r 
. OR 
clS-I,l.S.2 trans-I.2.S.2 
The peptidyl-propyl isomerase inhibitor, 1.2.5.3, has been synthesised as an aid to 
understand the mechanistic action of the isomerase enzyme. 32 It has been shown from an 
X-ray structure of the enzyme-ligand complex that the isomerase substrate binds the 
active site in a cis- conformation. 33 A cis-alkene proline mimic (1.2.5.3. shown in bold) 
has been developed and subsequently incorporated into an isomerase substrate sequence. 
The cis- amide bond can also be mimicked by constraining the amide bond within 
a heterocyclic ring. The synthesis of the 1,2-disubstituted pyrrole-based dipeptide 
analogue, 1.2.5.4, has been developed in our laboratories, as a generally applicable cis-
amide bond surrogate. 34 Duncia ef al. have synthesised trisubstituted pyrazoles (1.2.5.5), 
1 ,2,4-triazoles (1.2.5.6) as cis- amide mimics, and incorporated these into peptidomimetic 
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boronate inhibitors ofthrombin?5 de Luca et al. have prepared 1,3-disubstituted (1.2.5.7) 
and 1,5-disubstituted (1.2.5.8) pyrazolyl rings as peptidomimetic building blocks.36 The 
synthesis allows for the regio- and stereoselective synthesis of substituted pyrazoles as 
analogues of the cis- amide bond. Somatostatin (1,2.4.1)18 analogues have been 
synthesised with a variety of conformational constraints to force the recognition epitope 
(see Chapter 1.2.5). The disulphide linked cis- amide analogue, 1.2.5.9, was shown to 
retain high potency.37 van Binst et al. prepared the ortho-substituted benzene ring 
(1.2.5.10) to replace the proline-phenylalanine dipeptide in a cyclic somatostatin 
analogue.38 Branalt et al?9 have used a similar ortho-substituted benzene as a cis- amide 
mimic in potent HIVp inhibitors. Abell et al. 40 have used the ring closing metathesis 
reaction41 to prepare a generally applicable cis- phenylalanine analogue, 1.2.5.11. The 
solid state structure of analogue, 1.2.5.11, revealed that the residue possessed a rigid cis-
conformation. Another popular cis- amide mimic is the cis- epoxide, 1.2.5.12. A variety 
of peptidomimetic examples exist in current literature that have used the cis- epoxide to 
produce pseudo-C2 symmetric,42 and asymmetric inhibitors ofHIVp.43 
1.2.5.4 
~o ~ HO I. N N 0 
PgHN R"",--( 
OCH3 
1.2.5.7 
1.2.5.10 
~ 'OtT 0 ;) f_~ N~COEt 
1.2.5.5 
R 
~N~OCH3 
HO N 0 
PgHN 
1.2.5.8 
.. CAo 6 OCH, 
-Y'I 
:::".. 
1.2.5.11 
Bn1 N"N o-rN~ 
1.2.5.6 
I'N()-~I 
H N 
o H 
1.2.5.9 
G /'N :--.' ~
H \1' 
l.2.5.12 
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1 TRANS- AMIDE BOND Mnvrrcs 
Another important constraint incorporated into peptidomimetics is the trans-
amide bond mimic. The substitution of a trans- amide bond mimic for a dipeptidyl unit in 
peptidomimetic ligands has produced bioactive compounds that have been used to probe 
conformational requirements of receptor recognition and binding. The trans-double bond 
isostere, has been used in numerous peptidomimetic ligands. 44 The similarity of 
to the trans- amide bond was recognised early on in the development of trans-
amide mimics. A number of novel synthetic procedures have been developed to 
incorporate side chain residues (Rl and R2) into the isostere 1.2.6.1 with stereocontrol. 45 
The E-alkene isostere, 1.2.6.1, has been incorporated into the C-terminal of the potent 
neurotensin binder, 1.2.6.2.46 The fluorinated analogue of 1.2.6.1 [(Z)-fluoro alkene], has 
been incorporated into the dipeptidyl protease IV inhibitor, 1.2.6.3.47,48 A trans- alkene 
proline mimic has been incorporated into the tripeptide mimic, 1.2.6.4, which has shown 
modest inhibitory activity against the peptidyl-propyJ isomerase enzyme. 
1.3. THE 
1.2.6.1 
PgNH--GI p--oT
NHPg 
1.2.6.3 
~ N ,OCH3 
Pg Q 
OBn 1.2.6.2 
1.2.6.4 
"~""'JL"_, RING AS A RIGID CIS- AMIDE BOND MIMIC 
There are many examples in the literature of the tetrazole ring being used in 
medicinal agents. 49 The tetrazole function is metabolically stable and has an acid strength 
similar to aliphatic carboxylic acids. This close proximity in acidic character has inspired 
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the syntheses of the (lH)-tetrazole nng, 1.3.1, as a carboxylic mImIC m medicinal 
h . 50 t erapeutlcs. 
N;N t~;N 
H 
1.3.1 
N;N t~~N 
v-
1.3.2 
Marshall et aT. 51 originally proposed the 1 ,5-disubstituted tetrazole, 1.3.2, as a cis-
amide bond surrogate to lock a dipeptide analogue in an equivalent conformation. To 
study the amount of geometric and steric similarity between the 1,5-disubstituted 
tetrazole ring and the cis- amide bond, Marshall et al. determined the conformational 
mimicry index based on solid state structure of 1.3.3. 52 The conformational mimicry 
index is a measure of the orientations available to the analogue 1.3.3, which are in turn 
available to the parent dipeptide, 1.3.4. For the tetrazole surrogate the conformational 
index is 88%. As the receptor bound conformation of a target peptide is not always 
known, such statistical arguments for the suitability of analogues are usefuL During these 
studies it was also shown that tetrazole 1.3.3 had more conformational freedom than the 
parent dipeptide, 1.3.4. This has been attributed to the increased valence angle between 
the C!l-C=N of the tetrazole compared with the C!l-C=O of the cis- amide bond. Marshall 
et al. 52 concluded that the tetrazole ring is an excellent mimic of the cis- amide bond and 
recognised its potential to probe the binding mode ofbioactive ligands. 
1.3.3 1.3.4 
Yu et al. 53 reported a synthesis of 1 ,5-disubstituted tetrazoles based on the direct 
modification of peptide amide bonds with phosphorous pentachloride and hydrazoic acid. 
Subsequently, Marshall et al. 52,54 reported the stereoselective synthesis of a tetrazole 
dipeptide mimic by the simple addition of quinoline to the phosphorous pentachloride 
reaction. 
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Several tetrazole dipeptide analogues have been synthesised and their solid state 
structures characterised by X~ray diffraction. All of these show a remarkable resemblance 
to the cis- amide bond in their orientation of the peptide backbone and adjacent amino 
acid side chains. The tetrazole ring represents a good geometrical mimic, with bond 
angles and lengths reasonably close to the cis- amide conformer. In linear tetrazole 
dipeptides (eg. 1.3.5 and 1.3.6) the critical cu. ___ Cu. separation between adjacent residues 
is only 0.3 angstrom greater than that typical of a cis- amide bond. This small variation is 
the result of a larger bond angle at the Cu. -C=N bond, itself a consequence of the 
increased steric bulk of the tetrazole moiety. The tetrazole does not offer the unique 
arrangement of adjacent hydrogen-donor and acceptor found in the amide bond. 
However, the tetrazole ring and its 1,5-substituents adopt an essentially planar 
arrangement, such that the torsion angle, m, approximates zero in all three solid state 
examples presented to date m=2.9°). The results 
of these structural determinations illustrate the rigidity of the tetrazole ring when it is 
incorporated into a peptide backbone. In addition, it is clear that there is a high degree of 
geometric similarity with linear structures containing the cis- amide bond. 
1.3.5 1.3.6 
The tetrazole amide surrogate has been incorporated into oxytocin (1.3.8) 
analogues to replace the leucine-glycine amide bond (shown in bold, 1.3.8).57 Analogues 
were synthesised to detennine the favoured binding mode, cis- or trans-, of the leucine-
glycine amide bond to the receptor. A comparison of the biological activity of the 
tetrazole analogue, with the corresponding trans- olefin analogue, 1.3.10, suggests 
that the trans-leucine-glycine conformation (eg. 
oxytocin analogues. 
is favoured for binding of 
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1.3.8 1.3.9 1.3.10 
Bradykinin mimicss8 incorporating a tetrazole constraint are reported to give 
reduced bioactivity relative to the parent peptide, indicating that the trans- amide was the 
active form or that the steric bulk of the tetrazole ring restricted fuvourable ligand 
binding.59 Hruby et al.60•61 synthesised a tetrazole-based mimic, of a 
cholecystokinin pentapeptide, 1.3.12, to probe the importance of the conformation at the 
tryptophan-norleucine amide bond (shown in bond, 1.3,12). It had been suggested that the 
cis- conformation about this amide bond is responsible for conferring high affinity and 
selectivity against the cholecystokinin receptor. However, the tetrazole analogue, 1, 
showed reduced activity relative to the parent peptide. 
1.3.11 1.3.12 
A tetrazole surrogate has also been incorporated into the somatostatin analogue, 
as a replacement for the phenylalanine-N-methyl-alanine amide bond of the potent 
somatostatin analogue, 62,63 NMR studies showed a close similarity between the 
conformation of the te1razole analogue, 1.3.14, and the active somatostatin analogue, 
The tetrazole analogue showed slightly reduced biological activity, which led the 
researchers to conclude that it is the cis- amide bond that exists in the biologically active 
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conformation of the somatostatin analogue, 1.3.13. The slight decrease in activity may 
represent the increased steric bulk of the tetrazole ring within the active site of the 
somatostatin receptor. 
1.3.13 1.3.14 
The thymidylate synthase inhibitor, 1.3.15, was synthesised with a tetrazole 
mimic on the glutamate side chain in an attempt to stabilise the glutamyl bond to 
enzymatic hydrolysis.64 The inhibitory potency of the tetrazole derivative was broadly 
similar to the parent compound, 1.3.16. 
H 0 \~OH 
o OH 
1.3.15 1.3.16 
Garofalo et al.65 incorporated the tetrazole surrogate into which was 
derived from the heptapeptide substrate of HIVp, 1.3.18. They were interested in 
determining whether the cis- proline amide bond (shown in bold, 1.3.18), which had been 
shown to exist in 30% of available conformers of the native substrate, was 
important in HIVp recognition. Molecular modeling showed a positive correlation 
between the cis-proline amide bond of 1.3.18, and the tetrazole cis- amide mimic, 1.3.17. 
However, the tetrazole analogue was found not to inhibit HIVp. This may reflect the 
increased sterie bulk of the tetrazole ring which, in tum, may prevent effective binding to 
the active site ofHIVp. Abell et al.66 have synthesised four conformationally constrained 
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tetrazole analogues of the potent lllVp inhibitor (1.2.4,3).20 This early study on 
tetrazolembased peptidomimetics forms the basis of much of the work presented in this 
thesis. 
X=H,OH 
1.3.17 1.3.18 1.3.19 
The above examples illustrate the general application of the tetrazole ring as a cis-
amide bond mimic. The ability of the tetrazole ring to spatially mimic the cis- amide 
bond and its metabolic stability have endeared this heterocycle to peptidomimetic 
research as a rigid, constrained cis- amide bond mimic. 
1.4. WORK DESCRIBED IN THIS THESIS 
Chapter two ofthis thesis describes the design of the tetrazole-based amide bond 
isosteres. This novel class of conformationally restricted, non-hydrolysable isosteres has 
been designed around the bioactive conformation of the potent lllVp inhibitor JG-365, 
1.2.4,3. This chapter discusses the specificity and selectivity of the aspartic protease 
lllVp, and also discusses important structural and electronic features of successfullllVp 
inhibitors. The novel class of tetrazole-based isosteres, which includes the a-methylene 
(2.5.1), a-hydroxymethylene (2.5.2), and the a-keto tetrazole (2,5.3), isosteres are the 
first examples of non-hydrolysable amide bond isosteres to incorporate conformational 
restriction from a 1 ,5-disubstituted tetrazole ring. 
Chapter three describes the synthesis of N-Z-(2RS,3S)-3-amino-2-hydroxy-4-
phenylbutanoic acid, (N-Z-AHPBA, 3.1.1) which has been incorporated into numerous 
protease inhibitors as an amide bond isostere and which is a key synthetic component of 
the a-hydroxymethylene tetrazole isostere (2.5.2). Different synthetic methodologies 
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have been investigated for the synthesis of3.1.1, and a new generally applicable synthetic 
method has been developed during the course of this investigation. 
Chapter four describes an investigation into the configuration of tetrazole-based 
ligands which have been synthesised to incorporate the a-methylene tetrazole isostere 
(2.5.1). To aid the stereochemical assignment of tetrazole-based HNp inhibitors, 
diastereomeric tetrazole-based ligands have been synthesised and trends established in 
the IH and BC NMRspectra of the compounds. This work has also allowed us to monitor 
epimerisation of stereocentres adjacent to the tetrazole heterocycle under the conditions 
of peptide coupling. 
Chapter jive describes the synthesis of HNp inhibitors that contain the a-
methylene tetrazole-based isostere, 2.5.1. A step-wise elongation of the C-terminal of a 
tetrazole-based dipeptide mimic has generated three tetrazole-based HNp inhibitors of 
modest potency. We have been able to observe the solid state structure of the a-
methylene tetrazole isostere and have compared this to the bioactive conformation ofJG-
365 (1.3.4.3) which formed the basis of our isostere design. The tetrazole-based inhibitors 
have also given us insight into the preferential binding mode of the tetrazole-based 
isostere and the optimisation of inhibitor potency through filling the 83-83' subsites of 
HNp. 
Chapter six describes the synthesis of the a-keto tetrazole isostere, 2.5.3. Two 
approaches have been taken to the synthesis of this isostere, direct introduction of the a-
keto functionality to an appropriate a-methylene tetrazole-based dipeptide mimic and by 
direct alkylation of a (lH)-a-keto tetrazole. Problems encountered with the first approach 
have led us to develop a move efficient synthesis oftetrazole-based dipeptide mimics and 
this has been applied to the synthesis of the a-keto tetrazole isostere, 2.5.3. 
Chapter seven describes the solid state structures of three tetrazole-based 
dipeptide mimics. The 1 ,5-disubstituted tetrazole-based dipeptides, 5.4.1, and the cyclic 
analogue, are the first examples of the a-methylene tetrazole isostere for which X-
ray structures exist. Compound 7.2.1, belongs to a medicinally important class of 
compounds, the tetrazolodiazepines, of which no X-ray structures exist. The third X-ray 
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structure is of the 2,5-disubstituted tetrazole-based dipeptide, 
a-keto tetrazo Ie isostere, 
22 
a regioisomer of the 
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L HIV AND AIDS 
Since the onset of the Acquired Immune Deficiency Syndrome (AIDS) epidemic 
15 years ago, the causative agent, the Human Immunodefiency Virus (HIV), has infected 
more than 47 million people in the world. With more than million deaths in 1998, 
AIDS has now become the fourth leading cause of mortality and its negative impact on 
global health is set to increase.] An enormous amount of research has focused on the 
development of therapeutic agents to treat HIV. Until recent years AIDS has been an 
inevitably fatal and incurable disease. The advent of HIV protease inhibitors, 
administered in combination with the more established HIV reverse transcriptase 
inhibitors, such as AZT and 3TC, has enabled IllY positive patients to manage their 
disease. Unfortunately this combination therapy is not a cure, although it has been shown 
to reduce viral load, an indication of the level of infection to a manageable leveL 
HIV PROTEASE 
IllY protease (HIVp) is a virally-encoded enzyme necessary for the assembly and 
maturation of infectious virons.2 HIVp is specifically responsible for the post-
translational processing of viral polypeptides encoded by the viral gag and pol genes. 
Proteolytic cleavage of the polypeptides by HIVp yields protein fragments which are 
required for structural elements of the infectious virons. Inactivation ofHIVp by a single 
mutation of the catalytic aspartate (Asp25) residue results in non-infectious virons and 
implicates HIVp as a key enzyme in the replication of HIV. 2 This observation led 
researchers to target the inhibition ofHIVp as a viable strategy for the treatment ofHIV 
infection. 
HIVp belongs to the class of aspartic proteases that includes the well 
characterised proteolytic enzymes renin and pepsin. Considerable effort has been directed 
towards developing renin inhibitors as hypertensive drugs, based on knowledge of the 
catalytic action of aspartic proteases. This collective information proved invaluable in 
providing an understanding of the catalytic mechanism ofHIVp and in the development 
of early HIVp inhibitors. 
CHAPTER TwO-DESIGN OF THE TETRAZOLE-BASED ISOSTERES 30 
Figure 2.2.1. HIVp complexed with the inhibitor, acetyl pepstatin. 
HIVp is an unusual proteolytic enzyme in that it cleaves phenylalanine-proline 
and tyrosine-proline amide bonds. The amide bonds of proline residues are not usually 
susceptible to enzymatic hydrolysis by other mammalian endopeptidases. The rational 
design of HIVp inhibitors has been greatly aided by the availability of solid-state crystal 
structures of HIVp in its native form/ and in inhibitor-HIVp complexes (eg. Figure 
2.2.1 ).4 These structures reveal that HIVp is a homodimer comprising two identically 
folded polypeptides of ninety-nine amino acid residues. The monomeric polypeptides 
interact non-covalently along a dimerisation zone, marked by a C2 symmetric axis 
(running through the vertical plane as shown in Figure 2.2.1). Two conformationally 
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flexible flaps are able to close around the substrate and 'lock' the substrate in the 
hydrophobic binding cleft. 
Two key catalytic aspartate residues (Asp 25) are centered at the base of a 
cylindrical substrate binding cleft (Figure 2.2.1). One residue acts as a base (Figure 
2.2.2), initiating nucleophilic attack on the scissile amide bond of the substrate by a 
bound water molecule (see Figure 2.2.1). The other aspartate residue acts as an acid, 
stabilising the carbonyl oxygen of the tetrahedral intermediate (Figure 2.2.2). 
a:J 
aKAsp2S HJ 
52 \ 5" o H ( a ~ H 0 P"',io5<,(5) 
-s-wtYN~,N~(N~ 5,b",," 
H 0 F'1 aH H 0 P2' ~ ~2' Protein Site (S) 
;H Tetrahedral Intermediate 
a) 
ASP2SJ0 
Cleaved PolypepUde 
a 
-y-a-H 
Asp2S 
Figure 2.2.2. Amide bond hydrolysis by the proteolytic 
enzyme, HIVp. 
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2.3. HIVp INHIBITORS 
To date the U.S. Food and Drug Administration (FDA) has approved four HIVp 
inhibitors for clinical use (Figure 2.3.1). The number of available HIVp inhibitors is set 
to grow in an effort to offset viral resistance and a need to provide a more comprehensive 
array of inhibitors for combination therapy. 
OR 
1.2.4.4, Saquinavir, Inverase™, Roche 2.3.2, Indinavir, CrixivanTM, Merck 
Q -r 
o s °iNH HOyVlN-lr8T l) H OR R 
R 
2.3.3, Ritonavir, NorvirTM, Abbott 2.3.4, Nelfmavir, Viracept™, Agouron 
Figure 2.3.1. FDA approved IDVp inhibitors. 
An examination of the clinically available IDVp inhibitors (Figure 2.3.1) reveals 
some common design features which have been refined in the development of these 
potent HIVp inhibitors. A classic strategy in the design of peptidomimetic protease 
inhibitors is the incorporation of a non-hydrolysable amide bond isostere into the natural 
enzyme substrate at the PI-PI' (notation of Schecter5) cleavage site. The idea of using 
such isosteres was developed from the naturally occurring peptidomimetic compound 
pepstatin (2,3.5), a potent mechanism-based inhibitor of aspartic protease. 6 Pepstatin 
contains the amide bond isostere, statine (shown in bold 2,3,5), which mimics the Sp3 
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hydroxymethylene tetrahedral intermediate formed during normal amide bond hydrolysis 
Figure 2.2.2). 
2.3.5 
It is now well established that enzymes bind more favorably to ligands resembling 
the tetrahedral intermediate of an enzyme catalysed reaction than to ligands resembling 
the substrate? The application of tetrahedral intermediate mimicry has been used in the 
design of approved lllVp inhibitors by the incorporation of the hydroxymethylene 
isostere between the PI-PI' residues (Figure 2.3.1).2 A variety of isosteric replacements 
have been presented in the literature (Figure 2.3.2) and incorporated into lllVp inhibitors 
of varying potency. 
RI H 0 RI 0 RI' I'N~N~I methylene j'NVN~\ hydroxy amide 
H RI' H OH H 0 
Rl 
vti I'N~\ statine I-N N \ a-ketoamide H OH 0 H 0 H 0 
RI 0 Rl Rl' 
j'NYY; hydl'oxyethylene j'NYN~\ aminoketone 
H OR RI' H 0 H 0 
hydroxyethylamine 
2.3.2. Non-hydrolysable amide bond isosteres. 
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Potent and selective HIVp inhibition is possible by mimicking the tyrosine-
proline or phenylalanine-proline (PI-PI') cleavage site that is unique to retroviral 
proteases. Since this cleavage site is rare in mammalian endopeptidases such inhibitors 
have a selective advantage for HIVp and are not readily degraded by other proteolytic 
enzymes. Incorporation of the hydroxyethylamine isostere into the minimum substrate 
sequence (S4-S/) required for HIVp recognition gave the potent HIVp inhibitor, JG-365 
(1.2.4.3),7 where phenylalanine and proline occupy the SI and SI' subsites, respectively. 
JG-365 is a potent inhibitor in vitro but failed to inhibit HIVp in cellular assays, 
possibly due to its largely peptidic character which would limit its ability to penetrate cell 
membranes. Smaller inhibitors (eg. Figure 2.3.1) that occupy only four or five positions 
in the active site (S3-82') were designed to display reduced peptide character and are 
more potent in cellular assays. These inhibitors (Figure 2.3.1) still retain the 
phenylalanine residue at Pl for enzyme recognition and a sterically demanding residue at 
PI' to maximise interaction with the 81' subsite. 
Wlodawer et al. s extracted the structures of twelve HIVp inhibitors from solid 
state HIVp-inhibitor complexes and superimposed these structures to illustrate the HIVp 
binding cleft (Figure 2.3.3). It can be seen from this that the conformationally flexible 
inhibitors adopt a common conformation on binding with the enzyme cleft. The structural 
superimposition defines the 84-84' subsites of the cleft and the shape and binding 
properties of the cleft. Potent inhibitors have been generated by optimising binding 
interaction between inhibitor residues (P 4-P /), and individual subsites (84-8/), of the 
catalytic cleft. 
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Figure 2.3.3. A superimposition of twelve HIVp inhibitors. 
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2.4. BINDING MODE OF mvp INHIBITORS 
Two distinct binding modes are observed in the solid state structures determined 
for HIVp-inhibitor complexes of JG-365 (1.2.4.3), and Saquinavir (1.2.4.4).9 JG-365 
(1.2.4.3) binds to the active site of IDVp with a pseudo cis- conformation about the C-C 
bond adjacent to the proline residue. The torsion angle (indicated by a broad arrow, 
Figure 2.4.1) about this bond is 11 0, implying an essentially planar conformation. The 
ligand binds in an extended confonnation, with the isoleucine-valine residues (P2'-P3'), 
occuping the S2'-S3' subsites as expected. The binding mode favours a (3S)-configuration 
of the central hydroxymethylene tetrahedral intermediate mimic. The corresponding (3R)-
OR epimer shows greatly reduced activity as this configuration places the central 
hydroxyl group out of range for a favourable interaction with the catalytic aspartate 
residues. 
cis-
Figure 2.4.1. JG-365 (1.2.4.3) extracted from the HIVp active site, shown bound in a pseudo cis-
conformation (left). The torsion angle (shown in bold) ofthe bound inhibitor is essentially planar (right). 
Analysis of the solid state bound conformation of Saquinavir (1.2.4.4) shows a 
distinctly different binding mode from JG-365. It may be expected that the bulky tert-
butyl C-ierminal of Saquinavir (1.2.4.4) would fill the binding cleft in an extended 
confonnation. However, the solid state structure (Figure 2.4.2) reveals that the tert-butyl 
group specifically twists to fill the S2' subsite, with the large decahydroisoquinoline (Diq) 
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ring occupying the entire 81' subsite, with some interaction with the 83', The binding of 
the tert-butyl group to the 82' subsite twists the backbone and places the C-C bond 
adjacent to the Diq ring in a pseudo trans- confOlmation. The trans- binding mode shows 
a clear preference for the (3R)-OH configuration for interaction between the central 
hydroxyl and the catalytic aspartate residues. The corresponding (3S)-OH configuration 
shows greatly reduced activity, in direct contrast to the configurational preference of JG-
365. 
trans-
Figure 2.4.2. Saquinavir (1.2.4.4) extracted from the HlVp active site, shown bound in a pseudo trans-
conformation (left). 
2.5. DESIGN FEATURES OF THE TETRAZOLE-BASED ISOSTERES 
We have designed a series of isosteric replacements that are conformationally 
constrained to force the pseudo cis- binding mode observed in JG-365 (1.2.4.3).10 The 
1,5-disubstituted tetrazole ring has been used as a conformationally constrained cis~ 
amide bond mimic to probe the preferential binding mode of a variety of peptidomimetic 
ligands (see Introduction 1.3). Our idea was to use the tetrazole ring as a rigid cis- amide 
bond mimic in the design of a generally applicable isosteric replacement, fur 
incorporation into HlVp inhibitors and for use as a conformational probe. Our tetrazole-
based isosteres are the first example ofthe tetrazole heterocycle being incorporated into a 
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non-hydrolysable amide bond isostere. Our design considerations are outlined in Figure 
2.5.1. 
Tetrazo/e dipeptide 
mimic 
N-tel'minal protection 
amenable to peptide 
synthesis 
Non-hydrolysable amide 
bond isostere 
X=Y=H (methylene) 
X=OH, Y=H ((2S)-a-hydroxyl) 
X=Y=O (a.-keto) 
Figure 2.5.1. Design features of the teu'azole-based dipeptide mimic. 
JG-365 core 
dipeptide 
Planar cis-amide 
bond mimic 
C-terminal protection 
amenable to peptide 
synthesis 
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The target isosteres (Figure 2.5.2) use a 1 ,5-disubstituted tetrazole ring to provide 
a rigid, planar, cis- amide bond mimic to pre-organise the ligand into a conformation 
designed to approximate the bioactive conformation of JG-365. The design of the 
tetrazole-based dipeptide mimics also incorporate a non-hydrolysable amide bond 
isostere (see Chapter 2.3) adjacent to the tetrazole heterocycle. The a-methylene 
[CH2CN4] (2.5.1), a-hydroxymethylene [CHOHCN4] (2.5.2), and a-keto isosteres 
[COCN4] (2.5.3) (see Figure 2.5.2) have been included, based on the proven potency of 
these isosteric replacements in IllVp inhibitors. A phenylalanine residue has be 
incorporated at PI for selective recognition by IllVp. The isosteres are generally 
applicable to the design of peptidomimetics by selection of suitable natural or unnatural 
sidechains, incorporated through elongation of the C- and N-terminals. This requires a 
protecting strategy that is amenable to peptide synthesis. 
P N-N 
, I /I .' ~NPgHN N' 
Pt"\,·~O 
OPg 
2.S.1 
P N-N X.J!.. 'N 
PgHN T N~' 
OR " 0 
P ,'" 
I OPg 
2.5.2 
Figure 2.5.2. The target tetrazole-based isosteres. 
2.6. CONCLUSION 
P N-N X~N 
PgHN If N' 
o "l ___ o 
Pt" T 
OPg 
2.5.3 
The tetrazole-based isosteres have been designed as generally applicable mimics 
of the cis- amide bond. The design of the isosteres, 2.5.1-2.5.3, was based on the 
observed binding mode of the potent IllVp inhibitor, JG-365, and brings together the 
principles of ligand pre-organisation through conformational restriction and non-
hydrolysable amide bond isosteres. The tetrazole-based isosteres (Figure 2.5.2) are the 
first example of non-hydrolysable amide bond isosteres that incorporate conformational 
restraint from a tetrazole heterocycle. We have incorporated this mimic into inhibitors of 
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lllVp, and foresee it as an important conformational probe to investigate the binding 
preference ofpeptidomimetic ligands. 
The body of this thesis deals with the development of synthetic routes to the 
tetrazole-based dipeptides and incorporation of the mimic into lllVp inhibitors. Work has 
also focused on addressing stereochemical problems encountered in earlier work on the 
synthesis oftetrazole-based lllVp inhibitors. lo 
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3.1. INTRODUCTION 
In previous work on tetrazole-based peptidomimetics the a-hydroxymethylene 
tetrazole isostere [CHOHCN4] (2.5.2) has been synthesised by incorporation of the a-
hydroxy acid, 3-amino-2-hydroxy-4-phenylbutanoic acid [(2RS,3S)-AHPBA] (3.1.1), into 
the tetrazole-based dipeptide mimic, 3.1.3, according to Scheme 3.1.1.1 
Q 
ZHNVOH 
OH 
3.1.1a (lR) 
3.1.1h (25') 
i., ii. 
2.5.2 
Q 
ZHN¥N\r°Bn 
OAc H ° 
3.1.2 
iii., iv. J):-N I N 
ZHN OH ~>-f 
., OBn 
3.1.3 
Scheme 3.1.1. Reagents and conditions; i. L-Ala OBn.HCI, DCC, HOBt, 
EhN, rt; ii. AC20, pyridine, rt; ill. PCIs, Quinoline, HN3, rt; iv. K2C03, rt. 
Chiral 3-amino-2-hydroxy acids (eg. 3.1.1) are also of considerable importance 
being crucial components of many medicinally useful molecules such as taxot,2 
immunological response modifiers,3 and several small peptides possessmg 
antihypertensive activity.4 Many examples exist in the literature where 3-amino-2-
hydroxy acids have been incorporated into short peptide sequences to produce potent 
protease inhibitors. 5 As part of this current study we have investigated the synthesis of 
AHPBA and developed an improved method for the synthesis of this important amide 
bond isostere. 
We have designed the tetrazole-based isostere, 2.5.2, to incorporate the (X-
hydroxy functional motif as this motif has been shown to mimic the tetrahedral 
intermediate of a hydrolysing amide bond under protease catalysis, and as such has been 
shown to increase the potency of protease inhibitors (see Chapter 2.3.).6,7 Mimoto et al. s 
have used (2RS,3S)-3-amino-2-hydroxy-4-phenylbutanoic acid, 3,1.1 [(2RS,3S)-AHPBA] 
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in the synthesis of a potent HNp inhibitor, 3.1.4 (ICso=2,3 nM), which is based around 
the non-hydrolysable hydroxyethylamide isostere. The a-hydroxy amino acid, 3.1.1, is 
also a component of the naturally occurring low molecular weight peptidomimetic 
enzyme inhibitor, Bestatin (3.1.5).9 Bestatin is a potent inhibitor of leucine 
aminopeptidase and aminopeptidase B. Bestatin has reported antitumor and antimicrobial 
properties, associated with its ability to inhibit cell surface aminopeptidases. 
3.1.5 
There is often a marked difference in biological activity between epimeric a-
hydroxy peptidomimetics due to the stereospecific nature of a receptor. A receptor often 
requires the interacting ligand to have complimentary stereochemistry for potent binding 
to occur. The stereochemistry of the hydroxyethylamine isostere is important for tight 
binding of HIVp inhibitors to the catalytic cleft of IllVp (see Discussion 2.4). For 
example, JG-365 (1.2.3.2a ICso=O.24 nM) is an order of magnitude more potent than its 
hydroxyethylamine epimer, 1.2.3.2b (ICso=20 nM), due to a more favourable interaction 
of the hydroxyl oxygen with the catalytic aspartate residues. A similar activity 
dependency is seen by a comparison of the activity of the a-hydroxymethylene tetrazole-
based HIVp inhibitors, 3.1.6a and 3.1.6b, where the (3R)-epimer (3.1.6a IC50=60 J.tM) is 
1.2.3.2a (3S)- ICso=O.24 nM 
1.2.3.2b (3R)- IC50=20 nM 
3.1.6a (3S)- ICso=200 11M 
3.1.6b (3R)- IC50=60 11M 
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an order of magnitude more potent against IllVp than the (3S)-epimer (3.JL.6b ICso=200 
~). 
Leukotriene ~ hydrolase inhibitors have also been synthesised that are based 
around AHPBA. Yuan et al. IO showed that the stereochemistry of both the C2 and C3 
centres have a direct bearing on the relative potency of the hydrolase inhibitors, 3.1.7-
3.1.10. (2R,3S)-AHPBA methyl ester (ICso>O.5 mM) (3.1.7), was an order of magnitude 
less potent than its C2 epimer, (2S,3S)-AHPBA methyl ester (ICso=50 /lM) (3.1.8), 
against leukotriene ~ hydrolase. Control of the C3 stereochemistry is important for 
mimicking either the natural L-phenylalanine residue, or as is sometimes required the 
unnatural D-phenylalanine residue. The dipeptide (2S,3S)-AHPBA-Gly-OH (3.1.9) has 
the same C3 stereochemistry as naturally occurring L-phenylalanine and was shown to be 
a more potent hydrolase inhibitor than its C3 epimer, 3.1.10. 
B Q 1) q R2N °OCR3 o 0 _ 0 0 R:zN N~OR H2NVN~OH R2N 3: OCR3 
OR OR OR R OR R 
3.1.7 3.1.8 3.1.9 3.1.10 
The obvious importance of AHPBA for the preparation of peptidomimetic 
compounds is reflected in the variety of synthetic procedures which have been published 
for the synthesis of this a-hydroxy amino acid. The essential problem in the synthesis of 
AHPBA is the construction of the desired diastereomeric C2, C3 portion, which has been 
shown to have a direct bearing on the activity of the derived peptidomimetic ligands (see 
examples above). A variety of strategies have been developed to overcome this synthetic 
challenge. What follows is a brief discussion of some of these synthetic methods that 
have been presented in the literature. 
Kobayashi et aT.ll prepared N-Z-(2S,3R)-AHPBA, 3.1.14, by the 
iodocyc1ocarbamation of the allylamine, 3.JL.ll, which was derived from N-protected D-
phenylalanine (Scheme 3.1.2). The configuration of the C2 and C3 stereo centres was 
introduced during formation of the key iodocyclocarbamate intermediate, 3.1.13. This 
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compound then underwent a series of functional group interconversions to yield the 
oxazolidone, 3.1.13, which was ring opened by alkaline hydrolysis and the free amine 
reprotected to give 3.1.14. 
3.1.11 3.1.12 3.1.13 3.1.14 
Scheme 3.1.2. Preparation of N-Z-(2S,3R)-AHPBA by the iodocyc1ocarbamation of an 
allylamine. 
Nishizawa et a/. 12 have developed a non-stereoselective synthesis of AHPBA 
through condensation of N-acyl-a-aminoacetophenone and glyoxylic acid, followed by 
catalytic hydrogenation and resolution of the racemic product, 3.1.15, by salt formation 
with S-(-)-a-methylbenzylamine (Scheme 3.1.3). Diastereomerically pure (2S,3R)-
AHPBA was obtained following acidic cleavage of the N-acyl protected 3.1.16. 
3.1.16 
Scheme 3.1.3. Preparation of N-acyl-(2S,3R)-AHPBA by condensation of N-acyl-a-
aminoacetophenone and glyoxylic acid. 
(S)-Malate diethyl ester, 3.1.17, has been used as a precursor of defined C2 
stereochemistry in the synthesis of (2S,3R)-AHPBA. 13 The phenyl side chain was 
introduced stereoselectively by direct alkylation of the C3 carbon of 3.1.17 (Scheme 
3.1.4). Selective saponification of the C4 ester of 3.1.18 according to the procedure of 
Miller,14 gave the required C4 acid, 3.1.19. A subsequent Curtius rearrangement of the 
mono-acid gave an intermediate isocyanate, which was trapped by reaction with the C2 
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hydroxyL The synthesis of (2S,3R)-AHPBA was completed by saponification of the 
oxazolidone, 
o 
EIO«OEt 
o OH 
3.1.17 
formed during Curtius realTangement. 
p p 
~ 0 = 0 EtONoE~ HoNOEt -
o OH 0 OH 
3.1.18 3.1.19 
90 
~OEt 
HN
yO 
o 
3.1.20 
Scheme 3.1.4. Preparation of(2S,3R)-AHPBA by direct alkylation of(S)-malate diethyl ester. 
Pearson and Hines lS reacted phenyl acetaldehyde with a spirocyclic 1,3-dioxolan-
4-one, to give stereoselectively, the aldol adduct, 3.1.22, with the desired C3 
stereochemistry (Scheme 3.1.5). The anti- aldol adduct, 3.1.22, was then converted to the 
azide, 3.1.23, via a Mitsunobu interconversion and the chiral auxiliary removed with 
ethanolic HCI to give the azide ethyl ester, 3.1.24. Finally, catalytic hydrogenation of the 
azide, 3.1.24, gave the desired (2S,3R)-AHPBA ethyl ester. 
3.1.21 3.1.22 3.1.23 3.1.24 
Scheme 3.1.5. Preparation of (2S,3R)-AHPBA ethyl ester by alkylation of spirocyclic 
1,3 -dioxolan-4-one. 
Angelastro et al. 16 prepared the AHPBA isostere for incorporation into HIVp 
inhibitors by ozonolysis and reduction of peptirlyl a-ethoxy vinyl ketones (Scheme 
3.1.6). The vinyl ethyl ester, was prepared by reacting N-Z-L-phenyialanine 
Weinreb amide, with (a-ethoxyvinyl)magnesium bromide in the presence of ten-
butyl lithium. Ozonolysis of gave the a-keto ethyl ester, 3.1.27, which was 
subsequently reduced with sodium borohydride to give the desired N-Z-(2RS,3S)-
AHPBA ethyl esters, as a mixture ofC2 epimers (4:3, 3.1.28a:3.1.28b). 
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P P Q Q 
ZHN~~'OCH3 - ZHN~10Et - ZHNVOEt -:----ZHN~J'OEt 
o 0 0 OH 
3.1.25 3.1.26 3.1.27 3.1.28a (2R) 
3.1.28b (2S) 
Scheme 3.1.6. Preparation of N-Z-(2RS,3S)AHPBA ethyl esters by ozonolysis and 
reduction of a-ethoxy vinyl ketones. 
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Many other synthetic methods have been reported for the preparation of AHPBA, 
some of which include the cycloaddition of an imine and benzoylketene,17 and the 
ring opening of aziridine diols. 18 The examples above have been included to illustrate the 
range of synthetic methods that are available for the stereoselective and non-
stereoselective synthesis of AHPBA. Some of these published methods are synthetically 
challenging and in this current work we have investigated the synthesis of AHPBA, with 
the aim of developing a convenient preparation of this important ex-hydroxy acid. 
3 SYNTHESIS BY FUNCTIONALISATION OF N-Z-L-PHENYLALANINAL 
The most cited procedure for the preparation of and a procedure that we 
have investigated in this thesis, involves formation of cyanohydrins from an ex-amino 
aldehyde, followed by acidic hydrolysis. 19•2o We have prepared the key N-protected 
aldehyde 3.2.3 by two different synthetic routes (Scheme 3.2.1). In the first method, we 
prepared the aldehyde, from N-Z-L-phenylalanine, via a reduction with lithium 
aluminum hydride of either or . ABOP mediated coupling of Weinreb amine 
hydrochloride (Op-dimethylhydroxylamine hydrochlodde),21 gave Weinreb amide 
in 86% yield. Similarly, a mediated coupling of3,5-dimethylpyrazole to N-
Z-L-phenylalanine, gave 3.2.1, in 85% yield. Reduction with lithium aluminium 
hydride, at -50°C, for fifteen minutes gave the desired aldehyde, 3.2.3 in 77% yield. 
However, a similar reduction of gave a mixture of the aldehyde, 3.2.3, and the 
primary alcohol, 3.2.2, in 49% and 29% yields, respectively. The alcohol, 3.2.2 was 
formed by further reduction of the aldehyde, 3.2.3, in the presence of excess lithium 
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aluminium hydride. The alcohol was re-oxidised to the desired aldehyde with Dess-
Martin periodinane.22 
e e ZHN OH i. ZHN JOCH 
0 o 3 
3.1.25 
H. 
e ZIm -9 
0 
3.2.1 
P 
iii. 
----ZHN\rH 
iiL 
, 
o 
3.2.3 
liV 
o 
ZHN~OH 
3.2.2 
Scheme 3.2.1. Reagents and conditions: i. BOP, Et3N, O,N-
dimethylhydroxylaminc, rt; ii. 3,5-dimethylpyrazole, DCC, -10 
1 h, rt, 2d; ill. L~, -50°C, 15 min, -50-0 °C over 20 min; iv. 
Dess-Martin periodinane, rt, 1 h. 
The addition ofa nucleophile to 3.2.3 can occur with I,2-asymmetric induction to 
give an excess of one of the two possible epimeric cyanohydrin products (3.2.4a or 
3.2.4b) (Scheme 3.2.2).23 Two strategies have been developed to exert stereocontrol on 
the addition of a nucleophile to chiraI aldehydes such as 3.2.3 (Figure 3 1). The first of 
these methods occurs by the stereoselective attack of a bulky nucleophile according to 
electronic and steric factors in the presence of a non~chelating reagent, according to 
Cram's rules. 24 The second strategy proceeds with chelation control and requires the use 
of a Lewis acid to form an intermediate chelate, which reacts with a bulky nucleophile 
from the least hindered face. Generally the two methods lead to opposite diastereomeric 
products. 
Herranz et al. 25 investigated the chelation and non-chelation controlled attack of 
trimethylsilylcyanide (TMSCN) on N-Z-D-phenylalaninal «2R)-epimer of 3.2.3). They 
reported that under chelation control, in the presence of tin tetrachloride, the syn/anti-
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diastereoisomeric ratio (3.2.4a:3.2.4b) was unaffected. Under non-chelation control, a 
predominance of the syn- product was observed. The steric bulk of the amine protecting 
group is also important in effecting non-chelation control.26 The bulky N,N-
dibenzylamino aldehydes form almost exclusively the non-chelation controlled adducts.27 
We anticipated that non-chelation controlled addition ofTMSCN to 3.2.3 would 
give a (2R,3S)-cyanohydrin, 3.2.4a (Scheme 3.2.2) stereos electively. Treatment of the 
aldehyde, 3.2.3, with TMSCN according to the method of Herranz et al.25 gave low 
yields of both diastereomeric cyanohydrins, 3.2.4a and 3.2.4b. As an alternative the 
aldehyde 3.2.3 was reacted directly with potassium cyanide under non-chelation control 
in ethyl acetate-water to give the cyanohydrin C2-epimers, 3.2.4a and 3.2.4b (1: 1 mixture 
by IHNMR), in 74% combined yield (Scheme 3.2.2). 
Nucleophile -.......j .... 
H 
Figure 3.2.1. Non-chelation controlled attack (left), and 
chelation controlled attack (right) of3.2.3. 
The mixture of epimeric cyanohydrins, (3.2.4a and 3.2.4b), was directly 
transformed into the corresponding a-hydroxy amino esters, 3.2.5a and 3.2.5b by 
treatment with dry methanolic hydrogen chloride, followed by an in situ hydrolysis of the 
imidate hydrochloride intermediates (Scheme 3.2.2). The product methyl esters, 3.2.5a, 
and 3.2.5b, were separated by flash column chromatography, and further purified by a 
single recrystallisation. The less polar (2R,3S)-AHPBA methyl ester, 3.2.5a, (27% yield), 
eluted prior to (2S,3S)-AHPBA methyl ester, 3.2.5b (30% yield). The methyl esters were 
identified by comparison oftheir IH NMR spectra with that of the enantiomeric literature 
compounds,25 derived from N-Z-D-phenylalanine. 
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Alkaline hydrolysis of methyl ester 3.2.5a with sodium hydroxide in methanol-
water for 2 hours, to give the corresponding acid, in 88% yield (Scheme 3 
Similarly, methyl ester 3.2.5b was hydrolysed to give acid, in 88% yield. 
B B ZHN : ~OCH3 iii. ZHN : 0 OH 
e I. eN OH OH ii. 3.2.5a (2R) 3.1.1a (2R) ZHN H -ZHN + 
0 OH (l (l 3.2.3 3.2.411 (2R) 3.2.4b (2S) ZHN °OCH3 ZHN 0 OH ill. 
OH OH 
3.2.5b (2S) 3.1.1h (2S) 
Scheme 3.2.2. Reagents and conditions: i. KCN, EtOAc, water, rt; ii. MeOHlH20, 
HCI(g), 5°C, 24 h; iii. NaOH, MeOHlH20, rt, 2h. 
Overall we have found this procedure for the preparation of N-Z-AHPBA to be 
highly variable. Formation of the primary alcohol, was difficult to avoid in the 
preparation of the key aldehyde, 3.2.3, and required further purification and re-oxidation 
to produce the desired aldehyde (Scheme 3.2.1). Formation of the epimeric cyanohydrins 
did not occur reliably and in some instances no product cyanohydrin could be detected in 
the reaction mixture. With this in mind we thought it would be beneficial to develop a 
new synthetic route to that was synthetically reliable, made use of readily 
available intermediates and that lacked the complexity of some of the existing 
procedures. 
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3.3. SYNTHESIS BY AMINOHYDROXYLATION OF (E)-4-PHENYL-2-BUTENOIC 
ACID METHYL ESTER 
o¢0,A~k ~ I..<N 
OAlk 
(Alk),Phthalazine 
(PRAL) 
K,OsO,(OH), 
R ° 
XHNYOR' 
OH 
syn-
X sulfonamide. carbamate, or amide 
(DHQ),PHAL 
K,OsO,(OH), 
X sulfonamide, carbamate, or amide 
(DHQD),PHAL 
R ° XHN~OR' 
OH 
Qnti-
Dihydroquinyl (DRQ) Dihydroquinidyl (DRQD) 
Figure 3.3.1. Osmium catalysed asyrrtmetric aminohydroxylation (AA) of 
a,p-unsaturated esters. 
The Sharpless asymmetric aminohydroxylation (AA) reaction has received 
considerable attention as a method of synthesising chiral compounds with the 
aminohydroxy functionality,zs The utility of the AA reaction has been refined with the 
development of new ligands and reaction conditions to give improved regioselectivity, 
chemoselectivity and stereo selectivity. This reaction utilises the masked 1,2-functional 
group relationship of olefins to achieve a 1 ,2-functionalisation by face selective oxidation 
(Figure 3.3.1). The reaction employs osmium to catalyse the suprafacial addition of a 
nitrogen atom, from an appropriate nitrogen source (X) and an oxygen atom from water, 
to the double bond. The nitrogen atom is added preferentially to the center distal to the 
most electron withdrawing group. Three types of enantiomerically enriched N-protected 
hydroxyamines can be prepared depending on the choice of the stoichiometric nitrogen 
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source, X: N-sulphonamides, N-carbamates, and N-carboxamides. Enantioselectivity is 
induced by the cinchona alkaloid ligands, dihydroquinidine (DHQD), and dihydroquinine 
(DHQ), developed for the asymmetric dihydroxylation (AD) system?9 The cinchona 
ligands dictate enantiofacial selectivity, which can be predicted using the mnemonic 
device from the AD system (Figure 3.2.2). 
N-N 
AIl<'-0o-0-AIl<' 
Phthaia2ine <"HAL. ) 
Ligands 
Et~ ~N Oihydroquinidine Ligands, e.g. R-Q (OHQO) 2PHAL, (OHQO) 2AQN ~/~ H OMe 
Aik"-OXO-Aik" 
°0° 
Anthraquinone (AQN ) 
Ligands 
Top (p) Attack 
Figure 3.2.2. Mnemonic device for the prediction off ace selectivity. 
Sharpless et aI, have applied the AA reaction to the synthesis of N-protected 
(2R,3S)-3-amino-2-hydroxy-3-phenylbutanoic acid (3.3.2), which was further elaborated 
to give the Cl3 side chain of Taxo1.30 The commercially available methyl cinnamate, 
3.3.Jl., was subjected to the catalytic AA process using (DHQ):zPHAL ligand in the 
presence of Chloramine T hydrate (Scheme 3.3.1). The N-sulphamide protected (2R,3S)-
hydroxyamine methyl ester, 3.3.2, was obtained in 69% yield and 82% enantiomeric 
purity (ee). 
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o 
~OCHg 
3.3.1 
i. U TU 
' TsHN : OCHg 
OR 
3.3.2 
Scheme 3.3.1. Reagents and conditions: i. (DHQ)zPHAL, 
K20sOz(OH)4, TsNClNa.3H20, rt, l-BuOHlH20. 
Sudalai and Upadhya31 have applied the Sharpless AA reaction to the synthesis 
of cyclohexylnorstatine [(2R,3S)~3~amino-4-cyclohexyl-2-hydroxybutyric acid, 3.3.4], a 
key C-terminal moiety of potent renm inhibitors.32 Catalytic asymmetric 
aminohydroxylation of olefin, using OS04, (DHQ)2PHAL and Chloramine T 
hydrate, (Scheme 3.3.2) as the nitrogen source, gave theN-sulphonamide protected ester, 
in 60% yield and 96% ee. 
B 
----...,,. TsHN : OCR3 
i. 
Oil 
3.3.3 3.3.4 
Scheme 3.3.2. Reagents and conditions: i. (DHQ)2PHAL, 
K20s02(OH)4, TsNClNa'~20, rt, l-BuOHJH20. 
We have extended this work by preparing the aryl olefin, and subjecting it 
to the Sharpless AA reaction to prepare 3-amino-2-hydroxy methyl ester, 3.2.5a. The aryl 
olefin, (Scheme 3.3.3), substrate for the Sharpless aminohydroxylation, was 
prepared by standard Wittig-Horner chemistry.33 Phenylacetaldehyde was reacted with 
the stabilised ylide, methyl (triphenylphosphoranylidene) acetate, at room temperature, to 
gIve as a mixture of cis- and trans- olefins (1:9 by NMR). Flash column 
chromatography of the isomeric mixture gave the desired trans-3.3.5 in 54% yield. The 
aryl olefin, 3.3.5, was reacted in the presence of benzyl carbamate, as the nitrogen source, 
catalytic K20S04(OH)4 and the (DHQ)zPHAL ligand, according to the procedure of 
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Sharpless.30 Flash column chromatography of the reaction mixture gave N-Z-protected 
(2R,3S)-AHPBA methyl ester, in <5% yield, contaminated with benzyl 
carbamate. We were unable to optimise the reaction any further and considered a 
different strategy for the synthesis of AHPBA 
rP) 9 ~H i. ii. 
3.3.5 
B ZHN : OCH3 OH 
3.2.5a 
Scheme 3.3.3. Reagents and conditions: i. Ph]PCHCOOCH3• rt; ii. (DHQ)2PHAL, 
K:zOSOZ(OH)4, benzyl carbamate, rt, CH)CNIH20. 
3.4. SYNTHESIS BY ENOLATE HYDROXYLA nON OF 
HOMO PHENYLALANINE METHYL ESTER 
N-Z-L-
Introduction of the a-hydroxy functionality can be achieved by direct 
hydroxylation of an appropriate enolate by the oxodiperoxymolybdenum (pyridine) 
(hexamethyl phosphoric triamide) complex (MoOPH).34 The MoOPH complex has been 
employed in the synthesis ofthe C13 taxol side chain, (Scheme 3.3.1) [(2R,35)-3-
amino-2-hydroxyl-3-phenylpropanoic acid], by direct oxidation of an enolate derived 
from N-protected L-homophenylglycine methyl ester. 35 In consideration of this method, 
we concluded that a similar approach could be used for the synthesis of AHPBA, 3.1.1,36 
and turned our attention to the preparation of the required fJ-amino acid methyl ester, 
3.4.2. 
Diazoketone (Scheme 3.4.1) was obtained in high yield (75%) from 
phenylalanine by treatment of the mixed anhydride with diazomethane, according to the 
established procedure of Plucinska et al?7 Compound was subjected to a Wolff 
rearrangement, catalysed by silver benzoate, in the presence of methanol, to give N-Z-L-
homophenylalanine methyl ester, 3.4.2 in 83% yield?8 Similarly, the benzyl ester ofN-Z-
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L-homophenylalanine was synthesised by usmg benzyl alcohol as the trapping 
nucleophile during Wolff rearrangement of diazoketone 3.4,1, to gIve 
homophenylalanine benzyl ester in 83% yield. Wolffrearrangement of diazo ketones with 
a chiral centre adjacent to a carbonyl group is shown to proceed with retention of 
configuration (see Chapter 4.2)39 
B ZHN : OCR3 
OR 
3.2.53 
i. Q ~ z:r.IN~N2 
o 
3.4.1 
ii. 
... 0 Ill. 
P B
~ 
.. ZHN OCR3 
ZHNYOCR3 
OR 
3.2.Sb 
3.4.2 
Scheme 3.4.1. Reagents and conditions: i. 
EtOCOCI, NEt), THF/ether, CH2N2, -15°C, 
18h; it PhCOOAg, CH)OH, NEt), THF, rt, 
Ih; ill. KHMDS, THF, MoOPH, -78°C, 3h. 
Hydroxylation of 3.4.2 (Scheme 3.4.1) was examined in anticipation of delivery 
of oxygen by the MoOPH complex.40 Reaction of the potassium enolate derivative of 
(KHMDS,6 eq., -78 DC to -25 DC) with MoOPH (1.5 eq.) was carried out at -60 DC 
to give methyl esters, 3.2.5a and (53:47 syn/anti mixture by J\fMR) (Scheme 
3.4.1). Column chromatography ofthe crude reaction mixturegaveN-Z-(2R,3S)-AHPBA 
methyl ester (3.2.5a), and N-Z-(2S,3S)-AHPBA methyl ester (3.2.5b) in 35% and 32% 
yield respectively, based on recovered starting material. A single recrystallisation gave 
pure samples ofthe methyl esters, the diastereomeric purity of which was determined to 
be >95% by ]\fMR. 
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In the course of developing this method we investigated optimising the 
stereoselectivity and yield of the hydroxylation reaction. There was only slight variation 
in the syn/anti- selectivity and yield between the bases KHMDS, NaHMDS and 
LiHMDS. Best syn- selectivity was obtained with potassium as the counterion 
(KHMDS). This result can be rationalised according to Davies et al. 41 by considering the 
reacting potassium enolate existing as an equilibrium mixture of a chelated eight-
membered ring (1), or six-membered ring (II) (Figure 3.4.1), which are preferentially 
attacked by the electrophilic MoOPH complex at the Si and Re faces respectively. The 
eight-membered ring (I) is favoured when potassium acts as the counterion and is 
attacked at the less hindered face of the enolate, resulting in a predominance of the syn-
hydroxylated product, (2R,3S)-AHPBA methyl ester, 
I 
o 0 Sf; VuJl~ &:,OCH3 
3.2.Sb 
anli-p rod llct 
3.4.1. Rationalising the syn- stereoselectivity of the enolate hydroxylation. 
Variations in temperature, (-40°C, -60°C), and time of the reaction, (3-5 h), had 
little impact on the syn- selectivity or yield of the product methyl esters, and 
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N-Z-L-Homophenylalanine benzyl ester was untouched by the same reaction 
conditions (KHMDS, 6 eq., -78 to °c, MoOPH 1.5 eq., -60°C) presumably due 
to the steric constraints of the bulkier benzyl ester. 
Hydrolysis of the methyl esters, 3.2.5a, and with sodium hydroxide 
followed the established procedure (Scheme 3.2.2) to give the free acids, 3.1.la and 
Incorporation of the free acids into the appropriate substrate can be achieved 
simply through C-terminal elongation, N-Z-deprotection and N-terminal elongation, to 
furnish the desired ligand incorporating the hydroxyethylamide isostere. 
The method developed here provides a convenient synthesis of N-Z-(2R,3S)-
AHPBA (3.1.la) and N-Z-(2S,3S)-AHPBA (3.1.1b), in 36% overall yield from 
commercially available N-Z-L-phenylalanine. Standard synthetic methods were 
employed for the synthesis of an enolisable substrate to which the hydroxyl 
functionality could be directly introduced by the MoOPH complex. Practically this 
method was found superior in simplicity and efficiency to those methods already 
published. 
3.5. CONCLUSION 
The a-hydroxy amino acid, (2RS,3S)-AHPBA, (3.1.1) is an important component 
of many protease inhibitors, where it is used as a non-hydrolysable amide bond isostere. 
The importance of this compound is reflected in the variety of methods that exist in the 
literature for the preparation of (2R5',3S)-AHPBA. The available methods for forming the 
diastereomeric CZ and C3 centres vary in synthetic complexity and practicality. 
We have synthesised (2RS,3S)-AHPBA by functionalisation of 
phenylalaninal and found this method to be highly variable, with several steps being non-
reproducible. In an effort to develop new synthetic strategies for the synthesis of 
(2RS,3S)-AHPBA we have investigated the Sharpless reaction and enolate 
hydroxylation by the MoOPH complex. The Sharpless AA methodology proved to be 
low yielding and suffered from reagent contamination. Direct introduction of the a-
CHAPTER THREE-S)'NTHESIS OF 3 -AMINO-2-HYDROXY -4-PHENYLBUT ANOlC ACID 59 
hydroxy functionality by the MoOPH complex has been developed as a simple and 
reliable method for the synthesis of (2RS, 3S)-AHPBA, 
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4.1. INTRODUCTION 
Foulds et at. J prepared modestly potent mvp inhibitors, 4.1.1 and which 
incorporated the tetrazole-based amide bond mimic (see Chapter 2.5). Inhibitor 1 
incorporated the non-hydrolysable a-methylene tetrazole isostere, 2.5.1, while was 
based around the a-hydroxymethylene tetrazole isostere, (see Chapter 2.5). 
2.5.1 2.5.2 
4.1.2 
Inhibitor 4.1.1 was prepared by Foulds et al. I as a 1:1 (by IH NMR) mixture of 
C6 epimers, 4.1.1a and according to Scheme 4.1.1. The core a-methylene 
tetrazole-based dipeptide mimic 4.1.5, was synthesised from the corresponding dipeptide, 
4.1.4, by the method of Zabrocki et aZ? Following N-Z-deprotection, the N-terminal was 
elongated by a BOP mediated coupling of the amine hydrobromide, 4.1.6, and N-(2-
quinolinylcarbonyl)-L-asparagine to give the protected tripeptide, The free acid, 
was coupled to tert-butyl amine with BOP reagent in the presence of triethylamine. 
This final coupling step, in the preparation of resulted in epimerisation at C6, to 
give a mixture of diastereomers, 4.1.1a and (l: 1 by IH NMR). The epimeric C6 
inhibitors were separated by HPLC, and their C6 stereochemistry was assigned by IE 
NMR spectroscopy. Foulds et al. l based this stereochemical assignment on trends seen in 
the chemical shifts of the Ala-p-H3 resonance of the synthetic intermediates leading to 
the target inhibitors and 4.1.1b (Scheme 4.1.1). The Ala-p-H3 resonances of the 
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(6S)- intermediates (Scheme 4.1.1) 4,1.5, 4.1.6, 4.1.7, were 0 1.88, 1.89, 1.88, 1.91 
respectively. The C6 configuration of tetrazole was assigned as (6S)- (the same 
configuration as natural L-alanine) as the observed Ala-~-H3 resonance of 
similar shift to the (6S)- intermediates, 4.1.5-4.1.8, at 0 1. 92.1' Tetrazole 
gave a 
gave an 
Ala-p-H3 resonance at 0 1.74, and was according assigned as the (6R)-configuration (the 
same configuration as unnatural D-alanine). t 
8' 8' 8' - - -o L 0 .. N-N ZHN OH - ZHN N\roBn ~ ZHN I N:N 
H 0 ••.. ~O 
4.1.3 4.1.4 ' OBn 4.1.5 
j ill. 
8:-N I :N 
--- HBr.H2N N 0 
, .... '-1 
iv. 
4.1.6 OBn 
v. 
8' CC\r~ 0 N-N I H II .. ::".. '" N~ I.N N ,N N o : H .l ".0 I " .. , l' 
H2N~0 OH 
4.1.8 
8' ~~ HO N-N m N,Jl J:N ~N~,N N 
o i H , •. ··YO 
H2N~0 HN 
4.l.h (6S)- Y 
vL 
+ 
8' ~?' I H 0 N-lj ::""" NJ I .N N ,N N o j H ...;yo 
H2N~0 HN 
4 . .l.th (6R)- i< 
Scheme 4.1.1. Reagents and conditions: i, HCI-L-Ala-OBn, DCC, HOBt, EhN, rt 
IS h; it PCls, 1.5 h, HN3, rt, 2 d; iii. 30% HBr/acetic acid, rt; iv. QC-L-Asn-OH, 
BOP. EbN, rt; v. H2o 10% PdlC. 1 atm, rt; vi. t-buM amine, BOP, EhN, rt. 
t The Ala-IJ-H3 lH NMR shift of 4.1.1a was obtained in CDChITF A., while 4.1.1b was obtained in 
CDClfCD30DITF A l 
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The synthesis of inhibitor also resulted in epimerisation of the 
stereocentre and the configuration of the C6 epimers of 4.1.2 was also based on the above 
premise. The synthesis of inhibitor was further complicated by the additional 
stereo centre adjacent to the tetrazole ring at C3. Foulds et al.! showed that the basic 
coupling conditions used in the synthesis of 4.1.2 not only epimerised the C6 
stereo centre, but also epimerised the C3 stereocentre. A stereochemical assignment of the 
C3 centres of 4.1.2 were made using the a-hydroxy methyl esters, 3.2.Sa and 3.2.5b (see 
Chapter 3.2) as reference compounds. 
We have undertaken a systematic study of the stereochemistry of the C6 
stereocentre of these compounds in an effort to unambiguously assign the configuration 
of this stereo centre in inhibitors, 4.1.1a and 4.1.1b, and hence related compounds. We 
have synthesised a series of reference compounds with defined C6 stereochemistry to 
establish spectral trends, to aid in the assignment of the epimeric C6 tetrazole-based 
inhibitors. We have also been able to monitor epimerisation of the C6 stereocentre in 
intermediates in the synthesis of inhibitor 
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SYNTHESIS OF TETRAZOLE-BASED COMPOUNDS 
A. (6S)- -
N-N IN 8~ 
PgHN N~s 0 
4.1.5a , .. -
" OPg 
o 
P HN0N 168 OPg 
g H'I( 
o 
4.1.4a 
o~ 
U+ 
PgHN OR 
L-homo phenylalanine L-alanine 
B. (6R)· -8~ N-N I .' .N PgHN N 4.1.5b~O 
OPg 
B~ o = PgHN N~OPg 
H 0 
4.1.4h 
o~ 
0+ 
PgHN OR 
L-bomo pbenylalanine V-alanine 
Figure 4.2.1. Retrosynthetic analysis of the target tetrazole-based dipeptide mimics 
4.1.5a, and 4.I.SIl. 
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A retrosynthetic analysis of the core tetrazole-based dipeptide mimics, 4.1.5a and 
4.1.5b, with defined C6 stereochemistry is outlined in Figure 4.2.1. The stereochemistry 
of the C6 chiral centre was introduced from the corresponding alanine amino acid to give 
dipeptides, 4.1.4a [(6S)- derived from L-alanine] and 4.1.4b [(6R)- derived from 
alanine]. 
The tetrazole heterocycle (eg. 4.1.5 Figure 4.2.1) can be prepared from the 
corresponding amide (eg. 4.1.4 Figure 4.2.1) by reaction with phosphorous pentachloride 
(PCls), to give an imidoyl chloride intermediate, which is subsequently reacted in 
with hydrozoic acid (HN3), according to the method of Zabrocki et al? A protecting 
group strategy was chosen to reflect the requirements of the tetrazole forming reaction 
and be amenable to N- and C-terminal elongations, by standard peptide synthesis. 
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The inhibitors and 4.1.th (Scheme 4.1.1) have been synthesised to 
incorporate the non-hydrolysable a~methylene tetrazole isostere (2.5.1). This isostere is 
derived from the unnatural homologated amino acid, L-homophenylalanine, 4.1.3 (Figure 
4.2.2). Arndt-Eistert homologation of an N~protected a-amino acid, via an Cl-
diazoketone, is a widely used method for the preparation of enantiomerically pure ~-
amino acids such as from relatively cheap a-amino acid starting materials. Two 
routes can be employed for the synthesis of N-protected L-homophenylalanine containing 
dipeptides, either; Arndt-Einstert homologation utilising a silver (1) catalysed 
rearrangement in the presence of water as the trapping nucleophile (Figure 4.2.2 I), to 
generate ~-amino acids (eg. 4.1.3), which can subsequently be coupled; or a 
photochemical or silver (1) catalysed rearrangement in the presence of an amino acid, to 
generate the homologated L-amino acid, with comittant peptide coupling (eg. 4.1.4 
Figure 4.2.2 rll)?.4 Both methods require the synthesis of the a-diazoketone, 
(Figure 4.2.2). Ketene rearrangement in the presence of an alcohol (R20H) can also be 
=J)NJ 
o 
3.4.1 
(Z)-a.-DIAZOKETONE 
3.4.1 
(S)·a.-DIAZOKETONE 
Ag (I) 
or hI.) 
f:J zcm~~ B ZEN 0 OR 
~J o KETENE 
INTERMEDlATE I 
4.1.3 
p-AMINO ACiD 
B~ ~ 
m 
ZEN lOR2 
fJ-AMiNO AClD 
ESTER 
B: R, ZHN N~OBl1 
4.1.4 
H 0 
P-AMINO ACiD 
DIPEPTiDE 
Figure 4.2.2. Wolff rearrangement of an O'.-diazoketone mmno acid. Ag (I) catalysed 
Amdt-Einstert bomologation (1) in the presence of water; SYlltllesis of ~-amillO acid 
esters by Wolff rearrangement in the presence of an alcohol (R20H) (ll); 
pbotocbemically catalysed Wolff rearrangement with comittallt peptide coupling (Ill). 
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acid esters (Figure 4.2.2 II). 
The Wolff rearrangement of a.-diazoketones containing a chiral centre adjacent to 
the carbonyl occurs with retention of configuration. 5 The rearrangement of 0.-
diazoketones (Figure 4.2.2) proceeds via a ketene intermediate, with elimination of the 
nitrogen and alkyl group migration. Thermal initiation of the reaction is catalysed by 
metal ions such as silver (1), or the rearrangement can be photochemically catalysed. A 
concerted mechanism has been proposed for the ketene formation, 6 from the (Z) form of 
the a.-diazoketone (3.4.1 Figure 4.2.2), where the leaving group N2 and migrating group 
are in an ideal antiperiplanar geometry. The ketene intermediate can then be trapped by a 
variety ofnucleophiles (Figure 4.2.2 I-ill). 
The a.-diazoketone 3.4.1 (Scheme 4.2.1), can be prepared via the acid chloride of 
the L-amino acid,7 however, attempts to form the acid chloride of N-Z-L-phenylalanine 
usually results in formation of the undesired cyclic N-carboxyanhydride. 1 We have used 
an alternative procedure for the preparation of N-Z-protected L-amino acid u-
diazoketone, 3.4.1, via the corresponding mixed anhydride. 8 Treatment of N-Z-L-
phenylalanine with ethyl chloroformate and triethylamine (Scheme 4.2.1), followed by an 
in situ reaction of the mixed anhydride intermediate with diazomethane, gave the desired 
a.-diazoketone, 3.4.1, in 70% yield. 
The a.-diazo ketone, was then dissolved in dioxane/water and heated in the 
presence of silver (I) oxide to give N-Z-L-homophenylalanine, in 68% yield 
(Scheme 4.2.1). Foulds et al. 1 coupled the free acid, 4.1.3, to L-alanine benzyl ester to 
give the desired dipeptide intermediate, 4.1.4a (Scheme 4.1.1). We have used a more 
direct route to the dipeptide intermediates, by using a Wolff rearrangement of 3.4.1 with 
comittant peptide coupling (Figure 4.2.2 III), to furnish the dipeptides and 
A solution of a.-diazoketone, and L-alanine benzyl ester in acetonitrile, was 
irradiated at 300 nrn in the presence of triethylamine (Scheme 4.2.1 A). Following flash 
column chromatography, the dipeptide, 4.1.4a was isolated in 61 % yield as a cream solid. 
Similarly, was reacted photochemically with D-alanine benzyl ester (Scheme 4.2.1 
B) to dipeptide in 65% yield. 
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~ e B ZHN OH i. ii. 0 ZHN "N2 » ZHN -lOR 
° 
0 
3.4.1 4.1.3 A.)l B. 
B:I ill ~~, ZHN N' Ir°Bn ZHN0N~OBn 
R 0 H ° 
4. 1.4 a 4.1.4h 
Scheme 4.2.1. Reagents and conditions: i, EtCOCl, EhN, 
-20°C, 15 min, then, CHzN2, 5°C, 18 h; ii. Ag20, 
Na2C03, Na2SZ03, 78-85 °C, 2 h; iii. HCl.L-Ala-OBn, 
EhN, 300 run, ft, 24 11; iv. pTsOH.D-Ala-OBn, EhN, 300 
run, rt, 24 h. v. PCls, quinoline, HN3, ft. 
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Having synthesised the key dipeptide intermediates, 4.1.4a and 4.1.4lb, we 
focused on converting these protected dipeptides to the desired a-methylene tetrazole 
dipeptides, 4.1.5a and (Scheme 4.2.1). Several methods for the conversion of 
amides into 1,5-disubstituted tetrazoles have been published in the literature and are 
summarised in Figure . Thomas9 synthesised simple 1,5-dialkyl tetrazoles by 
reacting the corresponding amide with trifluoromethansulphonic anhydride, to form an 
imidoyl triflate, which was subsequently reacted in situ with sodium azide to furnish a 
1,5-disubstituted tetrazole (Figure 4.2.3 A). Dunda et al.to employed triphenylphosphine 
and diethyl azodicarboxylate to activate an amide toward reaction with trimethylsilyi 
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azide, to yield 1,5-disubstituted tetrazoles (Figure B). Yu and Johnson ll have 
studied the conversion of dipeptides to the corresponding 1,5-disubstituted tetrazoles. The 
reaction proceeded via an imidoyl chloride from reaction of the amide with phosphorous 
pentachloride. The imidoyl chloride was then reacted in situ with hydrazoic acid to give a 
1,5-disubstituted tetrazole (Figure 4.2.3 C). Zabrocki et al. 2 have further extended the 
methodology of Yu and Johnson by adapting the synthesis to exert stereocontrol over the 
product tetrazoles by the simply addition of quinoline to the reaction mixture. We have 
used the method of Zabrocki et al? for the synthesis of the tetrazoleqbased dipeptides, 
4.1.5a and 4.1.5b (Scheme 4.2.1). 
IMIDOYL 
AJvfiDE DERIVATiVE i.5-TETRAZOLE 
A. 0 [ 'Tf] N-N R)lN·R2 R(~~2 R/ :N 1 N 1 H 1 
R2 
B. [ 6~Pl"] 0 Ph3P N-N R)lN,Rz DEAD RAN TMSN3 R/ :N 1 N J H 1 I \ 
Rz R2 
C. 0 [ R~~,] N-N R)lNR2 HN3 I .' . R/ .N J N 1 H \ 
R2 
Figure 4.2.3. Methods for the preparation of 1,5-disubstituted tetrazoles from 
amides; .A. trimethylsulphonic anhydride (TfzO) , sodiwu azide;9 B. 
triphenylphosplUne diethyl azodicarboxy late (DEAD), 
trimethylsiiylazide (TMSN3); 10 C. phosphorous pentachloride (PCls), hydrazoic 
acid (HN3).11 
Both Yu and Johnsonll and Zabrocki et al. l reported that treatment of a protected 
dipeptide with phosphorous pentachloride and hydrazoic acid led to epimerisation of the 
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carbon centres adjacent to the tetrazole ring. The use of phosphorous pentachloride to 
convert the amide bond to the imidoyl chloride, leads to acid catalysed epimerisation at 
by the proposed mechanism shown in Figure 4.2.4. A reversible elimination of the 
H proton of 4.2.2 (Figure 4.2.4) to form the dipeptide ketene imine hydrochloride, 4.2.3, 
leads to scrambling of the C2 stereocentre. The 2-H proton is more acidic in the 
hydrochloride 4.2.2, than in 4.2.1, and therefore the simple addition of an organic base 
such as quinoline to the reaction when generating the imidoyl chloride, was shown to 
prevent the acid-catalysed epimerisation of the C2 stereocentre. 
~ H 0 ~ 0 J.:. ,N~ PCls J.:. _N~ 
PgHN 2" ~ OPg - PgHN2 Y ~ OPg 
o R2 CI R2 
4.2.1 
j 
4.2.511 
RJ H 0 pgHN~N00pg 
CI R2 
4.2.4 
It-
Hel 
H 
Rl I 0 
pgHN-Zr::00pg 
Cl R2 
4.2.2 
1t-HC1 
4.2.3 
Figure 4.2.4. Acid catalysed epimerisation during tetrazole formation. 2 
The resulting tetrazole dipeptides (eg. and 4.1.5b) are base sensitive and 
both the C3 and C6 stereocentres have been shown to epimerise in mildly basic 
conditions. Therefore the choice of acidolytic protecting groups is crucial to maintain the 
chiral integrity of these stereocentres. Zabrocki et al. 2 favoured the use of and N-
phthalyl protected dipeptides as the formation of the tetrazole was shown to favor 
aromatic N-terminal protection. Aromatic C-terminal protection was favoured over alkyl 
ester protection, with methyl ester protected dipeptides giving greatly reduced yields of 
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the corresponding tetrazoles. 12 Studies by Yu and Johnsonll suggested that the yield of 
tetrazole was dependent not only on the choice of N- and C-terminal protection, but also 
the nature of the amino acid residues of the dipeptide. Dipeptides with bulky amino acid 
side-chains gave low yields of the tetrazole, probably due to unfavorable cis-l,4 steric 
interactions in the transition intermediates leading to the tetrazole product. Glycine 
containing dipeptides also gave low yields of the corresponding 1,5-disubstituted 
tetrazoles. 
Boteju and Hrubyl2 used a modified procedure to prepare tetrazoles containing 
bulky tryptophan residues. The modifications involved longer reaction times and the use 
of an additional portion of phosphorous pentachloride in the formation of the imidoyl 
chloride intermediate. With the longer reaction times higher yields were reportedly 
obtained, while the shorter reaction times reported by Zabrocki et ai. 2 resulted in the 
recovery of a higher percentage of starting dipeptide. 
For the preparation of tetrazoles 4.1.5a and (Scheme 4.2.1) we have used 
N-Z-protection, and benzyl ester protection of the C-terminal, following the criteria 
outlined by Zabrocki et ai. 2 Selective removal of N-Z-protection by reaction with 
hydrobromic acid in the presence of the acid stable benzyl ester, is part of an orthogonal 
protecting group strategy that is amenable to the synthesis oftetrazole dipeptides. 
The conversion of the protected dipeptides and 4.1.4b into the 
corresponding tetrazole-based dipeptides, 4.1.5a and followed the modified 
method ofBoteju and Hruby. 12 Quinoline was added to the reaction mixture even though 
there was no stereocentre adjacent to the amide bond at C3 in or 4.1.4h. The 
addition of base in the synthesis oftetrazoles via imidoyl chlorides is known to accelerate 
the reaction.13 This is supported by the work of Zabrocki et ai. 2 which showed that the 
addition of quinoline to the reaction mixture not only prevented epimerisation of the C2 
stereocentre (4.2.1 Figure 4.2.4), but also increased the yield of the reaction. 
dipeptide, 4.L4a was added slowly to a stirred chloroform solution of phosphorous 
pentachloride and quinoline (Scheme 4.2.1 A). After 1 hour an additional portion of 
phosphorous pentachloride was added. A total reaction time of3.5 hours was allowed for 
conversion of the dipeptide to the imidoyl chloride. At this time a benzene or chloroform 
solution of hydrazoic acid was added and stirring continued for 48 hours. The tetrazole, 
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4.1.5a was purified, first by radial chromatography, then by reverse-phase to give 
4.1.5a in 10% yield, as a single stereoisomer by IH NMR. Similarly, the dipeptide 4.1.4b 
was converted to the protected tetrazole, 4.1.Sb (Scheme 4.2.1 B), and obtained in 15% 
yield following radial chromatography and reverse-phase 
Zabrocki et al. 2 reported that the C-terminal stereocentre adjacent to the tetrazole 
flng readily undergoes epimerisation in the presence of triethylamine. We have 
epimerised tetrazole 4.1.5a to confirm the structure of the C6 epimer, 4. (Scheme 
4.2.2)' A sample of tetrazole was dissolved in 10% triethylamine/CDCh, and 
epimerisation of the C6 stereocentre was monitored by IH NMR. After 48 hours at room 
temperature complete epimerisation of tetrazole had occurred to give a mixture of 
diastereomeric tetrazoles, 4.1.Sa and 4.1.Sb (1: 1 by IH NMR). The tetrazoles were 
separated by plate layer chromatography. Tetrazole 4.1.Sa was collected from a higher Rf 
band in 17% yield, while tetrazole 4.1.Sb ran as a lower Rf band and was obtained in 20% 
yield. The IH NMR and BC NMR of tetrazole were identical to that obtained by 
direct synthesis from dipeptide 4.1.4b (Scheme 4.2.1). 
8~-~ .N ZAN N6 0 
.. ~) 
.... ". \ 
i. 
4.1.5a OBn 
8~ N-N IN ZHN N' + 
, ..~,P 
" '\ 
4.1.5a OBn 
8:-N IN ZHN N 0 /1 
4.1.5b OBn 
Scheme 4.2.2. Reagents and conditions: i. Et3N, CDCI3, It, 48 h. 
Having synthesised the key tetrazole-based dipeptide mimics, and 4.1.Sb, 
we focused on elongating the N-terminal of the dipeptides to generate reference 
compounds for spectral comparison with the tetrazole-based inhibitors, 4.1.1 and 4.1.2. 
Firstly, the preferential removal of the N-Z-protection in the presence of the benzyl ester 
C-terminal protecting group, was necessary to enable extension ofthe tetrazole dipeptides 
through coupling of the free amines. Acidic cleavage of the N-Z-protection with 
hydrobromic acid to give the deprotected dipepddes followed a well established 
deprotection method (Scheme 4.2.3).14 Tetrazole dipeptide, 4.1.Sa, was dissolved in 
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concentrated acetic acid and the solution treated with a 50% hydrobromic acid/acetic acid 
solution (Scheme 4.2.3 A). The reaction was stirred at room temperature for 30 minutes, 
then triturated with ether/petroleum ether. The hydromide salt was dried in vacuo for 24 
hours to give the product dipeptide in 90% yield, as a mixture of C6 epimers, 4.1.6a and 
4.1.6b (9:1 by IH NMR). The same deprotection protocol was used for tetrazole 
dipeptide, and gave an epimeric mixture of 4.1.6b and (4:1 by IH NMR), 
in 89% yield (Scheme 4.2.3 B). In both cases the major isomer is assumed to have the 
same absolute C6 configuration as the starting material. The epimeric hydrobromides, 
4.1.6a. and 1.6b, were used without further purification. 
A. 8~ 
N-N 
I " 
.N 
ZHN ~'---bO 
\' \' 
OEn 4.1.58 
B. 8~ 
N-N IN 
ZHN HO 
OEn 4.1.Sb 
i. i. Statting Material 4.1.6a:4.1.6b 
+ 
4.1.68 (6,s) 4.1.6b (6R) 
4.1.58 
4.1.Sb 
Scheme 4.2.3. Reagents and conditions: i. CH3COOH, 
50% HBr/CH)COOH, rt, 30 min. 
To model the original tetrazole~based HIVp inhibitors, 
9:1 
1:4 
and 4.1.2, the amine 
hydrobromides, and 4.1.6b, were elongated from the N-terminal by coupling to N-
(2-quinolinylcarbonyl)-L-asparagine (QC-L-Asn-OH), (Scheme 4.2.4). This N-
protected L-amino acid was synthesised in a simple one-pot reaction of quinaldic acid 
chloride, using L-asparagine under modified Schotten-Baumann conditions,15 according 
to the procedure of Camp et al. 16 Quinaldic acid chloride, 4.2.6, was prepared from the 
reaction of thionyl chloride with quinaldic acid in the presence of triethylamine (Scheme 
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4.2.4). The crude acid chloride, was then reacted in situ with L-asparagine in the 
presence of potassium carbonate. Work-up and a single recrystallisation from ethanol 
gave the free acid, 4,2.7, in 40% yield. 
~ ~ ~Nlr°H~ ~NlrCI 
o 0 
4.2.6 
Scheme 4.2.4. Reagents and conditions: i. thionyl chloride, EiJN, rt, 3 h; ii. K2C03, rt, 4 h. 
The amine hydrobromide, 4.1.6a, as a mixture of C6 epimers (9: 1 4.1.6a:4.1.6b, 
by IH NMR) was coupled to 4.2.7 by a standard BOP mediated coupling procedure in the 
presence of triethylamine (Scheme 4.2.5 A). The crude reaction product was purified by 
plate layer chromatography to give the protected tripeptide, 4.1.7, as a mixture of C6 
epimers, 4.1.7a and 4.1.7b (7:3 by IH NMR). Similarly, hydrobromide 4.1.6b, as an 
epimeric mixture (4: 1 4.1.6b:4.1.6a), was coupled to N-(2-quinolinylcarbonyl)-L-
asparagme, (Scheme 4.2.5 B). Purification of the crude protected tripeptide by plate 
layer chromatography gave the epimeric tripeptides, 4.1.7b and 4.1.7a (5.5:4.5 by IH 
A. 
.N 8~
HBr.H2N N~o 
OBn 
4.1.63 (6S) 
L 
4.1.7a (6S) 
8:-N I " .N 
HBr.H2N N~o 
B. 
OBn 
4.1.6b (6R) 
i. 
4.1.7h (6R) 
4.1.7a:4.1.7b 
7:3 
4.5:5.5 
Scheme 4.2.5. Reagents and conditions: i. QC-L-Asn-OH (4.2.7), BOP, Et3N, rt, 18 h. 
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NMR). In both cases it was assumed that the major isomer of the product mixtures had 
the same absolute configuration as the major isomer ofthe starting material. 
Further elongation of the C-terminal was considered futile because of the known 
epimerisation at C6 that had occurred during the synthesis of inhibitors and 4.1.1b 
(Scheme 4.1.1).1 Based on these earlier results it would be expected, for example, that C-
terminal deprotection, and subsequent coupling of 
coupled products, 4.1.1a and 4.1.1b (Scheme 4.1.1). 
would give a 1: 1 mixture of the 
A spectral analysis of the epimeric reference compounds was undertaken to 
establish trends in the chemical shifts ofthe 6S and 6R compounds. 
4.3. NMR STUDIES ON THE TETRAZOLE-BASED REFERENCE COMPOUNDS 
The reference tetrazole compounds 4.1.4a-4.1.7a and 4.1.4b-4.1.7b were 
characterised by IH NMR and 13C NMR to establish differences in the NMR spectra 
between these epimeric references compounds. Epimerisation of the C6 stereocentre was 
also detected by IH NMR in the synthesis of intermediate tetrazoles, and 4.1.7. 
Studies by Yu and Johnson ll on the conversion of protected dipeptides to the 
corresponding tetrazole dipeptides showed characteristic differences between the IH and 
13C NlVIR spectra of the starting dipeptide and the 1,5-disubstituted tetrazole product. We 
have noted similar spectral distinctions in the formation of tetrazoles and 4.1.5b 
from the dipeptides, 4.1.4a and Typically the tetrazole products are less polar than 
the starting dipeptides and elute on silica at a higher Re. The formation of the tetrazole 
ring was evidenced by the disappearance of the amide carbonyl carbon resonance (hPhe-
CO) typically observed at 8 170 and the appearance of a new signal corresponding to the 
tetrazole (hPhe-CN4) carbon at 8 150-155. The signal of the tetrazole product 
was shifted downfield in the order of 8-10 ppm, to around 8 56, in comparison with the 
Ala-a-ClI signal of the dipeptide. Additionally, the Ala-a-ClI3 carbon resonance was 
shifted upfield ppm to 8 16-17 in the tetrazole product. The methylene carbon signal, 
hPhe-a-ClI2, was shifted upfield in the order of 8-13 ppm. An example of the observed 
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changes in the Be NMR spectra is shown in Figure 4.3.1, where the key changes in the 
De NMR resonances have been annotated by a broad arrow. 
8 Y 0 Ii ZHN Ii a. ~JyOBn 
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./ \ 
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Figure 4.3.1. Representative DC NMR spectrd for the dipeptide 4.1.4a, and the tetrazole 
dipeptide 4.1.5a, showing diagnostic shift differences between the two compounds. 
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The IH NMR spectrum of the dipeptide was also characteristically different to the 
NMR spectrum of the corresponding 1,5-disubstituted tetrazole, The Ala-J3-H3 and 
Ala-cx-H signals were shifted downfield, 0.4-0,5 ppm and 0.4-0,6 ppm, respectively 
relative to the starting dipeptide, Likewise, the hPhe-cx-Hz resonances were shifted 
downfield 0,5-1.0 ppm. An example of the observed IH NMR differences are anotated in 
Figure 4.3,2, as indicated by the broad arrows, 
The resonance shifts are presumably associated with differences in the electron 
density between the amide bond and the tetrazole heterocycle (Figure 4.3 .3). The N5 lone 
pair of electrons are delocalised throughout the heterocycle, thus it is relatively more 
electron deficient than the nitrogen of the amide bond. Correspondingly, the 6-CH carbon 
centre of the tetrazole shows IH and 13 C NMR signals that are shifted downfield relative 
to the starting dipeptide. The delocalisation of the N5 electrons also makes the hPhe-CN4 
carbon centre more electron rich relative to the carbonyl of the amide bond (hPhe-CO). 
The C3 carbon centre of the tetrazole shows IH and l3C NMR resonances (hPhe-a-CHz) 
that are shifted up-field relative to the starting dipeptide to reflect this increase in electron 
density. 
Delocalisation of the N5 electrons 
onto the tetrazole ring. 
B~ 8iN P~,:,,,~:!pJOPG --..... p/ ~ 
C3 centre is relatively C6 celltre is relatively 
electron rich electron defiCient 
Figm'c 4.3.3. Rationalising the observed changes in the chemical shifts 
between the starting dipeptide, and the tetrazole-based dipeptide. 
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Figure 4.3.2. Representative NMR spectra for the dipeptide 4.1.4a, and the tctrazole dipeptide 
4,1.5a, showing diagnostic shift differences between the two compounds. 
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We have synthesised two senes (A and B) of tetrazole-based reference 
compounds with defined C6 configuration (Table 4.3.1) to investigate whether there are 
any distinguishable trends in the IH and l3C NMR spectra of these compounds. It is 
thought that the observed trends in NMR spectra could be used to unambiguously assign 
the C6 configuration of other tetrazole-based peptidomimetics, (eg. and 4,1.2). 
Compounds of series A (4.1.4a-4.1.7a Table 4.3.1) have defined (6S)-configuration 
derived from natural L-alanine, while the compounds of series B (4,1.4b-4.1.7b Table 
4.3.1), have defined (6R)-configuration, derived from unnatural D-alanine. 
Foulds et aZ. 1 assigned the C6 configuration oftetrazole-based inhibitors 4.1.1 and 
4.1.2 on the assumption that the (6S) Ala-B-H3 IH NMR resonances were in a 
characteristic downfield position (1.86-1.92 ppm) relative to the corresponding (6R)-
configuration (see Chapter 4.1), At each stage of the synthesis of the reference tetrazole-
based compounds a NMR comparison has been made between the diastereomeric 
compounds of series A and series B.t We have compared the IH and l3C NMR 
resonances of Ala-~-CH3 and Ala-a-CH, and summarised these in Table 4.3.1. 
t For comparison between epimeric reference compounds (series A vs. series B) iH and I3C NMR spectra 
were obtained in identical deuterated solvents (see Chapter 9.3). 
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.T-T. Ala-p-.~ 
B ZHN 0 N~oBn 1.36 4.59 18.01 48.05 
H 0 
4.1.4a 
B o ~ 1.39 4.60 18.15 48.09 ZHN N~oBn 
H 0 
4.1.4b 
8~ 1.87 5.00 16.80 55.92 / N 
ZHN N6 0 
""'\!!...f 
4.1.5a OBn 
8~ 1/ N 
ZHN ~o 1.87 5.15 16.66 53 
4.I.Sb OBn 
& 1.89 5.67 16.81 I :N HBr.HzN N6 0 
•... ~ 
OBn 
4.1.6a 
& I :N 
HBr.H1N h O 1.91 5.69 16.96 55 
OBn 
4.1.6b 
8 ~H ° N-:t:1 1.92 5.21 16.25 55.49 ::".. '" N0 I .N 
N iN N~o o - H . H2N~ <,., OBn 
o 4.1.711 
8 ? I "'" H 0 N-N 1.97 5.37 16.33 54 ~N0N I~N 
o ~ H ~o H2N~ OBn 
o 4.1.7b 
Table 4,3,1. Comparison of the lH and 13C NMR resonances of the (6Sh and (6R)-diastereomers. 
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Significant differences do not appear in the chemical shifts of the IH NMR signals 
of diastereomeric compounds of series A and series Reference compounds from series 
B with (6R)-configuration gave Ala-p-H3 and Ala-a-H resonances that were typically 
downfield of the (65)-epimer in the order of 0.01-0.03 ppm and 0.01-0.15 ppm, 
respectively. Differences in the l3C NMR of related compounds were more diagnostic. 
Typically the compounds with (6R)-configuration (4.1.4b, 4.1.6b, 4.1.7b) gave Ala-p-
CflJ resonances downfield (0.10-0.15 ppm) compared to their (6,sj-epimers. However, 
this trend was reversed for the protected tetrazoles, and 4.1.5b, with the Ala-p-
CH3 resonance of 4.1.5a being downfield (0.15 ppm) of the corresponding resonance of 
4.1.5b. This reversal in the trend was also seen in the Ala-a-CH resonance of 4.1.53., 
being OA1 ppm downfield of its (6R)-epimer, 4.1.5b. The Ala-a-CH resonances of the 
series B compounds were typically 0.02-0.12 ppm downfield of the series A (65)-
eplmers. 
The difference in NMR shifts between the diastereomeric reference compounds 
was very subtle and in some cases the shift difference was negligible. However, a trend is 
seen in the NMR resonances of the reference compounds. Tetrazoles with the (6R)-
configuration (ie. 4.1.4b-4.1.7b), characteristically gave Ala-p-CH3 and Ala-a-CH NMR 
resonances eH and BC) that were downfield of the corresponding (65)-epimer (ie. 
4. 1.4a-4. 1. 7 a). 
During the synthesis of the reference tetrazole-based compounds we were able to 
monitor the extent of epimerisation of the C6 stereocentre under the reaction conditions 
used for the synthesis of inhibitor 4.1.1. Epimerisation of the C6 centre has been detected 
much earlier in this synthetic sequence than was reported by Foulds et al., 1 who observed 
epimerisation at C6 only in the final coupling step in the preparation of inhibitor, 4.1.1 
(Scheme 4.1.1). We have observed epimerisation of the C6 stereocentre during two key 
steps in the synthesis of the reference tetrazole-based compounds, as evidenced by the IH 
J\lMR spectra of the product mixtures (Figure 4.3.4). Detectable epimerisation of C6 
occurred during N-Z-deprotection of tetrazoles, and 4.1.5b. Treatment of 4.1.5a 
with 50% hydrobromic acid/acetic acid gave a 9: 1 mixture (by IH NMR) of C6 epimers, 
and 4.1.6b (Scheme 4.2.2). Similarly treatment of 4.1.5b under identical 
conditions resulted in a 1:4 mixture (by IH NMR) of 4.1.6a and "W.A"",IV, Coupling of the 
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hydrobromide salts (4,1.6a and 4.1.6b), in the presence of triethylamine resulted in 
further epimerisation of the C6 centre (Scheme 4.2.3). The coupling of hydrobromide, 
4.1.6a, with BOP reagent in the presence of triethylamine gave a 7:3 mixture (by IH 
NMR) of the diastereomeric protected tripeptides, and 4.1.7h. Coupling of 
hydrobromide, 1.6b to N-(2-quinolinylcarbonyl)-L-asparagine, under the same reaction 
conditions gave a 5.5:4.5 mixture (by IH NMR) ofdiastereomers, 4.1.7b and 4.1.7a. 
6(R)~ 6(R)~ 
i. ii. 
.. 
4.1.4b 4.1.5b 
6(R)~ 
6(8)-
4.1.6b:4.1.6a 
4:1 
iii. 
6(R)-
6(S)-
4.1. 7b:4.1. 7a 
5.5:4.5 
Figure 4.3.4. Ala-p-H3 IH NMR resonace showing epimerisation of the C6 stereocentre. 
Reagents and conditions: i. PCls, HN3, quinoline, rt, 2 d; ii. 50% HBr/acetic acid, rt, 30 min; m. 
BOP, Et3N, QC-L-Asn-OH, rt, 18 h. 
4.4. CONCLUSION 
The synthesis of the tetrazole-based reference compounds has allowed trends to 
be established in the relative and I3C NMR chemical shifts of the diastereomeric 
tetrazole-based reference compounds. Although differences between the epimeric 
tetrazole-based references compounds of series and B were only subtle it can be seen 
that the reference compounds with a (6R)-configuration (series B) gave AJa-a-CH and 
and l3C NMR resonances that are typically downfield of the corresponding 
(6S)-epimers. The results obtained here are in contrast to the steroechemical assignment 
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tentatively made by Foulds et al. l of the tetrazole-based inhibitors, 4.1.1a and 4,1.lb. On 
the basis of the trends observed here the inhibitor, 4.1.1a, with (6 .. S)-configuration, would 
give the observed A1a-~·H3 resonance at 0 1.74. The (6R)-configuration of 4.1.1b would 
give the observed A1a-~-H3 resonance downfield at 0 1,92. These trends will be useful in 
the stereochemical assignment of tetrazole-based peptidomimetics where the carbon 
centres adjacent to the tetrazole heterocycle are susceptible to epimerisation even under 
the conditions of peptide synthesis. 
These results suggest the C6 stereocentre is highly susceptible to epimerisation in 
both acidic and basic conditions. In any future synthesis of tetrazole-based 
peptidomimetics careful consideration of the reaction conditions is needed to insure the 
chiral integrity ofthe stereocentres adjacent to the heterocycle. 
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5.1. INTRODUCTION 
In the design of peptidomimetic inhibitors it is generally recognised that the 
potency of inhibitors is greatly increased by elongation of the central isostere from theN-
and C-terminals. It is possible to fill all the sub sites (8) of the binding cleft by increasing 
the number of terminal residues (P) of the inhibitor. This leads to improved inhibitor 
activity as the interactions between the ligand and the enzyme binding cleft are increased. 
Although this approach has been used to develop potent inhibitors they generally display 
poor pharmacological properties in vivo due to their largely peptidic character. Potent 
protease inhibitors have been generated by simply replacing the central amide bond of a 
natural substrate with a non-hydrolysable isostere (eg. JG-365 1.2.4.3). In doing so the 
inhibitor retains the potent interactions that occur between the substrate residues and the 
subsites of the binding cleft. We have been interested in probing the effects ofC-terminal 
elongations on the activity of HIVp inhibitors with a central tetrazole-based dipeptide 
mimIc. 
2.5.1 2.5.2 
4.1.2 
Foulds et al. 2 synthesised a series oftetrazole-based inhibitors (4.1.1 and 4.1.2) of 
HIVp which were capped on the C-terminal by tert-butylamine. HIVp inhibitors that 
incorporate a tert-butyl C-terminal (eg. 8aquinavil' 1.2.4.4) have been shown to bind to 
HIVp with a pseudo trans- conformation about the non-hydrolysable isostere (see 
Chapter 2.3).1 tetrazole-based inhibitors, and were synthesised to 
incorporate the a-methylene tetrazole (2.5.1) isostere and a-hydroxymethylene tetrazole 
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(2.5.2) isostere respectively,Z These isosteric replacements have been designed (see 
Chapter 2.3) to preorganise the inhibitor ligands into a pseudo cis~ conformation, as seen 
in the bioactive conformation of JG-365 (1.2.4.3), Due to the conflicting binding 
preferences of the C-terminal tert-butyl (pseudo trans-), and the tetrazole-based isostere 
(pseudo cis-), we postulated that the tert-butyl substituent of and has limited 
complimentarity to the tetrazole-based cis- amide bond mimics, and The 
modest inhibitory potency (J.1M level) of 4.1.1 and 4.1.2 may in part be due to this 
unfavourable combination of structural elements, 
We have been primarily concerned with investigating the trends in inhibition of 
HIVp associated with elongation of the C-terminal of the tetrazole-based dipeptide 
isostere, We have synthesised a series of modestly potentHIVp inhibitors based on the a-
methylene tetrazole isostere [CHzCN4] 2.5.1, which have incorporated extended C-
terminal substituents, 
SYNTHESIS OF THE a-METHYLENE TETRAZOLE-BASED DIPEPTIDE 
MIMIC 
We considered that N-Z-L-homophenylalanine-[CN4]-glycine benzyl ester, 
(Figure 1) which incorporated the a-methylene tetrazole isostere, would be an 
ideal tetrazole-based dipeptide mimic with which to probe the effects of C-terminal 
substitution, The problems associated with epimerisation of the carbon centres adjacent to 
the tetrazole ring (C3 and C6) (see Chapter 4.3) have been negated by the lack of 
substitution at these centres in 5.2.1 (Figure 5,2,1), The unnatural amino acid 
homophenylalanine (hPhe), 4.1.3, has been used to provide a non-hydrolysable a-
methylene amide bond isostere in the dipeptide mimic, A benzyl residue has been 
incorporated at as a mimic of phenylalanine for enzyme recognition and specificity. 
Incorporation of the glycine residue at Pl' (2.5.1 reduces the complexity of the 
synthesis as epimerisation of methylene carbon (C6) under the conditions of peptide 
synthesis will not lead to the epimeric mixtures observed in the synthesis of inhibitor 
and (see Chapter 4,1), 
A retrosynthetic analysis of the core a-methylene tetrazole dipeptide mimic, 
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5.2.1, is outlined in Figure 5.2.1. The tetrazole heterocycle was prepared from the 
corresponding amide, 5.2.2, by reaction with phosphorous pentachloride (PCIs) and 
hydrozoic acid (HN3), according to the modified method of Zabrocki et al. 3 (see Chapter 
4.2). A protecting group strategy was chosen to reflect the requirements of the tetrazole 
forming reaction and that is amenable to N- and C-terminal elongations by standard 
peptide synthesis. For this, N-Z-protection of the N-terminal amine and benzyl ester (Bn) 
protection of the C -terminal were chosen. 
wN 
3 I N 8~ ZHN N yO 
5.2.1 OBn 
,~ 
o 
ZHNUN"lr0Bn 
H ° 
5.2.2 
il 
3.4.1 
H2Nl(OBn 
° glycine benzyl ester 
Figure 5.2.1. Retrosynthetic analysis of 
the target tetrazole-based dipeptide mimic, 
5.2.1. 
A Wolff rearrangement of the a-diazoketone, 3.4.1, with comittant peptide 
coupling (see Chapter 4.2) to glycine benzyl ester, was used to furnish the dipeptide 
intermediate, 5.2.2.4 Glycine benzyl ester hydrochloride was photochemically reacted 
with a-diazoketone, 3.4.1, in the presence of triethylamine (Scheme 5.2.1). Flash column 
chromatography of the crude reaction product gave the dipeptide, 5.2.2, in 85% yield. 
The dipeptide, 5.2.2, was then reacted with phosphorous pentachloride in the presence of 
quinoline according to the method ofZabrocki et al. 3 After 3.5 hours at room temperature 
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the imidoyl chloride intermediate was reacted in situ with a benzene solution of 
hydrazoic acid. The crude tetrazole was separated from unreacted starting dipeptide, 
by flash column chromatography and a single recrystallisation which then gave the 
desired tetrazole dipeptide mimic, 
based dipeptide mimic, 
detelmination by X-ray analysis. 
in 62% yield. The structure of the teu'azole-
was confirmed by a crystallographic structure 
B:-N I N ZHN N' yO 
5.2.1 OBn 
Scheme 5.2.1. Reagents and conditions: i. HCI.Gly-OBn, 300 nm, Et3N, 
rt, 18 h; ii. PCI5, quinoline, HN3, rt, 2 d. 
5.3. SOLID-STATE STRUCTURE OF THE a-METHYLENE TETRAZOLE-BASED 
DIPEPTIDE MIMIc 
Single crystals of N-Z-L-homophenylalanine-[CN4]-glycine benzyl ester, 5.2.1, 
were grown from methanol by slow evaporation. The crystal structure of 5.2.1 (see 
Figure 5.3.1) was determined at 160(2) K and was satisfactorily refined. For a detailed 
discussion of the crystal structure of5.2.1, see Chapter 7.2. 
5.3.1. Solid state structure of a-methylene teu'azole 
dipeptide mimic, 5.2.1. 
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We have used the tetrazole-based dipeptide mimic, to preorganise inhibitor 
ligands synthesised in the current work into a conformation analogous to the bioactive 
conformation of JO-365 (1.2.4.3). The solid state structure of the a-methylene tetrazole 
dipeptide mimic, 5.2.1, allows comparisons to be made between the design of the a-
methylene tetrazole isostere, 2.5.1, and the observed bioactive conformation of JG-365 
(1.2.4.3). 
A. 
e:-N 1 3 / N ZHN 2 4 N5 
~o 
5.2.1 OBn 
Figure 5.3.2. A. The solid state structure of the tetrazole-based dipeptide mimic, 5.2.1; B. the solid state 
structure of JG-365 (1.2.4.3) bound to the active site ofHIVp. 
JG-365 binds to the active site ofHIVp with a pronounced 'kink' characterised by 
the cis- conformation of the central C4-N5 bond of the non-hydrolysable isostere 
(indicated by the broad all'OW, Figure 5.3.2 B). The tetrazole-based dipeptide mimic, 
is folded at the homophenylalanine-[CN4]-glycine sequence. The solid state 
structure of shows the tetrazole heterocycle furces a cis- confOlmation about the 
equivalent C4-N5 bond in the dipeptide mimic, 5.2.1 (shown by the broad arrow, Figure 
5.3.2 A). The m torsion angle, [C3-C4-NS-C6], at the homophenylalanine-glycine 
junction of 5.2.1 is forced by the tetrazole annular structure to be cis-, 13.1°.5 This is a 
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good approximation of the w torsion angle observed in the bound conformation of 
where the w torsion angle, [C3-C4-N5-C6], is essentially planar at 11.6°. 
The correct positioning of the side chain residues, PI and PI', of the a-methylene 
tetrazole isostere is important for favourable interactions to occur with the binding 
subsites, 81 and 8 1', of IDVp. The inter-residue distance, C2-C6 (shown by the solid 
arrow, Figure 5.3.2) of both JG-365 and 5.2.1 are similar being 4.31 A and 3.88 
respectively. The distance between the PI' residue (C6), and the central non-hydrolysable 
isostere (C3) in (shown by the dotted arrow, Figure 5.3.2 A) is 3.19 A, only slightly 
longer than in JG-365, being 2.96 A. The increase in the C2-C6 and C3-C6 distances, 
may in part be due to the increased steric bulk of the tetrazole ring, which is reflected in 
an increased C4-N5-C6 bond angle (Figure 5.3.3) in 5.2.1. 
5.2.1 
Figure 5.3.3. Bond angles, C3-C4-NS and C4-NS-C6 for the 
tetrazole-based dipeptide mimic, 5.2.1, and JG-365, 1.2.4.3. 
ELONGATION OF THE a-METHYLENE TETRAZOLE-BASED DIPEPTIDE 
MIMIC 
Traditionally the activity of dipeptide isosteres has been enhanced by extension of 
the N- and C-terminals by incorporation of amino acid residues. Generally the vitro 
potency of peptidomimetic inhibitors is increased as more subsites (S) of the binding cleft 
are filled by residues (P) of the inhibitor. Suitable residues have been chosen for 
this current series ofIDVp inhibitors based on the optimisation of the known inhibitor 
JG-365 and the tetrazole based inhibitors, 4.1.1 and (Table 1). 
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P4 PJ PI-PI' Pz' PJ ' P/ I C3 I ICso 
A. The hydroxyethylamine isostere (eg. JG-365, 2.3.1). 
1. Z e OtBu R 6500nM 2. QC Asn OtBu R 23nM IN ' :? 3. Ac Leu Asn H OH ne OCH3 RS Ki 4520nM 
Ac Leu o I Ile Val OCH3 RS Ki 2lnM 
B. The a-hydroxymethylene tetrazole isostere (eg. 4.1.2). 
~ a z OCHJ R no 11M N-N :IN 3 I N.l-I 
6. QC Asn H OH ,:llyo NRtBu R 60JlM 
I 
C. The a-methylene tetrazole isostere (eg. 4.1.1). 
7. Z Asn 8 NHtBu N/A 700JlM N-N I . :IN N·N 
8, QC Asn H \" ... ly0 NHtBu N/A 170 11M 
I 
Table 5.4.1. HIVp activity with different N- and C-tenninal substitutions of; A. the hydrox)'ethylamine 
isostere; B. the a-hydroxyrnethylene tetrazole isostere; C. the a-methylene tetrazole isostere. 
The phenylalanine side chain is incorporated at Pi in most, if not all, 
peptidomimetic HIVp inhibitors for selectivity and binding affinity with the hydrophobic 
81 sub site (see Chapter 2.3). Though the 82 and 82' subsites are mostly hydrophobic, both 
hydrophilic and hydrophobic residues can occupy these sites. Asparagine (Asn) has been 
shown to occupy the 81 subsite and gives a dramatic improvement in activity when 
incorporated into the N-terminal of inhibitors that span (compare entries 1 and 2 
Table 5.4.1).6 The 83 subsite is large and less well defined than the S2 and S1 subsites. 
There is a clear preference for large aromatic residues at (entry 8 Table 5.4.1) over the 
smaller aromatic residues (entry 7 Table 5.4.1). The subsite will also accommodate a 
variety of natural amino acid residues (eg. entry 3 Table 5.4.1). Elongations of the c-
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terminal fills the S2' and S3' subsites. Inhibitors that span the S4-S2' (eg. entry 3 Table 
5.4.1) display reduced activity overP4-P3' inhibitors (eg. entry 4 Table 5.4.1). The S4 and 
S4' subsites are poorly defined and do not form an actual binding pocket. 
The dipeptide mimic, 5.2.1, was designed to incorporate a phenylalanine residue 
at PI, and a glycine residue at the PI' binding site. The HIVp Sl' sub site binds 
hydrophobic PI' residues of inhibitor ligands. A slight reduction in inhibitor potency has 
been noted when the Sl' subsite is left unfilled by inhibitors with a Pl'glycine residue.7 
We have chosen the remaining P3-P/ residues of our a-methylene tetrazole inhibitors 
based on the observed activity of known inhibitors (Table 5.4.1). Three inhibitors were 
targeted to investigate the effects of elongation of the C-terminal of 5.2.1 (Table 5.4.2). 
Each compound represents a step-wise increase in the C-terminal substitution. 
P3 P2 PI-PI' P2 ' P3 ' P/ 
5.4.1. QC Asn 8 NHtBu 5.4.2. QC Asn N-N Ile OCH3 • I N IN N' 
H lyo 5.4.3. QC Asn Ile Val OCH3 
oAAN 
I 
Table 5.4.2. a-Methylene tetrazole based inhibitors. 
The N-Z-protection of the dipeptide mimic, 5.2.1, was selectively removed in the 
presence of the benzyl ester C-terminal protection to give free amine, 5.4.4 (Scheme 
5.4.1). Coupling of the N-terminal and subsequent C-terminal deprotection and 
elongation, gave the inhibitors, 5.4.1, 5.4.2 and 5.4.3. We have also investigated an 
alternative deprotection and coupling strategy, starting with deprotection and coupling of 
the C-terminal and subsequent elongation of theN-terminal. 
The tetrazole, 5.2.1, was deprotected by treatment with 50% hydrobromic 
acid/acetic acid to yield the amine hydrobromide, 5.4.4, in 99% yield (Scheme 5.4.1). 
The free amine, 5.4.4, was coupled to N-(2-quinolinylcarbonyl)-L-asparagine, 4.2.7, with 
BOP reagent in the presence of triethylamine. The crude protected tripeptide was purified 
by flash column chromatography to give 5.4.5, in 51 % yield. 
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8~~· 8:-~·· CC)y"'" 0 8:-N 'NI. IN 11·1 HII 'N ZHN N - HBr.H2N N' - ~ N NV'N N 
yO yO 0 .= H l ~O 
5.2.1 OB 5.4.4 OB H N-{ 5.4.5 T 
n n 2 0 OBn 
Scheme 5.4.1. Reagents and conditions; i. 50% HBr/acetic acid, rt, 30 min; ii BOP, EtJN, 
QC-L-Asn-OH (4.2.7), rt, 18 h. 
Catalytic hydrogenation of 5.4.5, with 10% palladium on carbon, gave the free 
acid, 5.4.6, in 70% yield (Scheme 5.4.2). Several coupling reagents were investigated to 
maximise coupling of the free acid, 5.4.6, to tert-butylamine to give the target inhibitor 
5.4.1 (Scheme 5.4.2 ii.). The coupling reagents BOP, O-benzotriazol-1-yl-N,N,N,N-
tetramethyluronium hexafluorophosphate (HBTU), and EDCI were tria led under 
appropriate conditions,S and the reagents compared based on the yield and purity of 5.4.1 
(Table 5.4.3). Under these criteria, EDCI, used in conjunction with the trapping agent N-
hydroxybenzotriazole (HOBt), was used in subsequent coupling reactions of the free 
acid, 5.4.6. 
Coupling Reagent Yield 
BOP,Et3N 11% 
EDCI,HOBt 17% 
TBTU,DIPEA 5% 
.. Table 5.4.3. The percentage Yield of coupled product, 5.4.1, under vanous couplmg condItions 
Inhibitor 5.4.1 was synthesised in low yield (17%) by coupling the free acid, 
5.4.6, to tert-butylamine with EDeI in the presence ofHOBt (Scheme 5.4.2). The crude 
product was purified by flash column chromatography and reverse-phase high pressure 
liquid chromatography (HPLC). Coupling of the free acid, 5.4.6, to commercially 
available L-isoleucine methyl ester, using EDCI, gave inhibitor 5.4.2. The inhibitor was 
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purified by flash column chromatography and HPLC and obtained in 18% yield. The 
commercially available dipeptide N-(L-isoleucine)-L-valine was methylated with 2,2-
dimethoxypropane in the presence of aqueous hydrogen chloride according to the general 
procedure ofRachele.9 The resulting dipeptide methyl ester hydrochloride (L-Ile-L-Val-
OCH3) was coupled to using EDC! in the presence ofHOBt. The crude protected 
pentapeptide, 5.4.3, was purified by flash column chromatography and reverse-phase 
HPLC, and finally precipitated from ether as a white solid, in 11 % yield. 
Scheme 5.4.2. Reagents and conditions; i. H2, 10% FdiC, I atm, rt, 24 h. 
ii, t-BuNH, EDCl, HOBt, rt, 18 h; iii. L-Ile-OCH), EDCl, HOBt, rt, 18 h; 
iv.L-Ile-L-Val-OCH3, EDC!, HOBt, rt, 18 h. 
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We have also synthesised inhibitor 5.4.3 by an alternative deprotection and 
coupling strategy using the N-tert-butyloxycarbonyl (N-Boc) amine protecting group. The 
N-Boc protecting group is not a viable N-terminal protecting group for the synthesis of 
1,5-disubstituted tetrazoles by the method of Zabrocki et al} where formation of the 
tetrazole heterocycle is favoured by aromatic N-terminal protection (see Chapter 4.2). 
However, we have transformed the dipeptide mimic, to the N-Boc protected free 
acid, 5.4.7, which allowed coupling of the C-terminal prior to extension of the N-terminal 
(Scheme 5.4.3). This strategy is more in keeping with established peptide synthesis 
procedures where the peptide is elongated from the N-terminal. The transformation was 
made possible by the procedure of Ohfune et al. lo whereby the N-Z-protected tetrazole, 
5.2.1, underwent a simultaneous deprotection of both the C-terminal benzyl ester and the 
amine N-Z-protection, with an in situ conversion to the N-Boc-protected amine. A 
palladium catalysed hydrogenation of5.2.1 at atmospheric pressure was carried out in the 
presence of di-tert-butyl dicarbonate (Boc20) (Scheme 5.4.3). After 5 h at room 
temperature, the palladium catalyst was removed by filtration and the free acid, 5.4.7, 
was obtained as a white solid, in 76% yield. 
The free acid, 5.4.7, was elongated via the C-terminal by EDCI coupling to N-(L-
isoleucine)-L-valine methyl ester hydrochloride, in the presence of HOBt and Hunigs 
base (DIPEA, N,N-diisopropylethylamine). The N-Boc-protected tetrapeptide, 5.4.8, was 
obtained as a white solid in 75% yield following flash column chromatography. 
Deprotection of the N-Boc protecting group was achieved by treatment of5.4.8 with 95% 
aqueous trifluoroacetic acid (TF A) for 30 min, at room temperature. After drying over 
potassium hydroxide in vacuo for 24 hours the amine trifluoroacetate, was obtained 
quantitatively and used without further purification. This was then coupled to N-(2-
quinolinylcarbonyl)-L-asparagine, 4.2.7, with HOBt and DIPEA and the crude 
product was purified by plate layer chromatography, to give 5.4.3 in 40% yield. 
THE LIBRARY 
UNIVERSITY OF CANTERBURY 
CHmSTCHURCH, N.Z. 
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Scheme 5.4.3. Reagents and conditions: i. H2, 10% Pd/C 1 atm, BOC20, rt, 5 h; 
Ii. EDCI, HOBt, DIPEA, L-Ile-L-Val-OCH3, rt, 18 h; iii. 95% TFAlwater, rt, 30 
min; iv. EDCI, HOBt, DIPEA, QC-L-Asn-OH (4.2.7), rt, 18 h. 
This later deprotection and coupling strategy (Scheme 5.4.3) represents an 
improvement in yield over the former strategy (Scheme 5.4.2). The overall yield of 
inhibitor 5.4.3 by the N-Boc amine protecting group strategy was 23% from the tetrazole 
dipeptide mimic, 5.1.1. This can be compared with an overall yield of 3% of inhibitor 
5.4.3 via the former method, which required initial elongation of the N-terminal and 
subsequent substitution of the C-terminal. 
BIOLOGICAL ACTIVITY OF THE 
INHIBITORS 
The a-methylene tetrazole based inhibitors, 
TETRAZOLE-BASED 
and 5.4.3 were tested for 
in vitro activity against HlVp.ll The activity of the inhibitors is expressed as an 
value, where the lower the ICso value the more potent the inhibitor. The assay was run at 
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in 0.2 M aqueous sodium chloride and 0.1 M MES buffer at 37°C. The results 
are detailed in Table 5.5.1, along side the activity of the a~hydroxymethylene, and a~ 
methylene tetrazole based inhibitors, 4.1.h and 4.1.22, reported by Foulds et al,z 
Inhibitor M) 
B '" '" H 0 N-N 5.4.1 CCN~NylN 'NN 94(±50) 
o "H ~o HLN~O HN 
X 
B ~H 0 N-N 5.4.2 '-" N~ NyAN 'NN 47(±20) o "H ~o 
H,W.{o HN~ 
o OCH, 
8 '" '" 0 N-N ~l!'y/Jl 'N N N N 
5.4.3 o "H ~o 18(±10) H2N~O HN~ 
o NH 
'rYo OCH, 
13 ?' ?' i H 0 N-l'[ 4.1.h ~N~N INN 170(±20) 
o : H "'ly-0 
H2N.-{o ", HNy 
Q 4.1.22 ?'?' H 0 N-N ~NJ )IN 60(±10) N ,N N (3S) o : H OH ---It° H2N~O " HN'( 
• 
Table 5.S.1. Inhibitor potency against HlVp. 
The a-methylene tetrazole inhibitors have provided insight into the preferred C-
terminal substituents and also the binding mode of the tetrazole~based inhibitors. We 
were interested in establishing trends in the activity of the tetrazole~based inhibitors with 
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increasing C=terminal substitution. The assay results show that inhibitor potency of 
and increases as the C~terminal is elongated. We propose that the 
relative potency of inhibitor (ICso=18 11M) results from filling all the available 
subsites (83=S3') of the enzyme binding cleft with the corresponding P3=P4'residues of 
the inhibitor. A decrease in potency is seen when the 83' subsite is left unfilled by 
inhibitor 5.4.2 (ICso=47 !iM). This result suggests that for maximum binding interaction 
to occur between the tetrazole-based inhibitor and the enzyme binding cleft, all available 
subsites of the binding cleft should be accommodated by inhibitor residues. 
The inhibitors show reasonable activity with ICso values in the low micromolar 
(1-lM) range. The most active HIVp inhibitors are significantly more potent with ICso 
values in the low nanomolar (nM) range. The HIVp inhibitor, JG-365 (1.2.4.3), upon 
which the design of the tetrazole dipeptide mimic was based exhibits an ICso of6.0 nM. 
The most potent inhibitor of the a-methylene tetrazole series, 5.4.3 (IC50=18 )..1M), is 
approximately 3000 fold less potent than JG-365. t This is to be expected, as the core 
dipeptide isostere, 5.2.1, lacks specific functionality required for potent activity, namely 
a central hydroxyl and a large S1' residue. 
Comparison of the activity of inhibitor 5.4.2 (IC50=47 11M) and (ICso=94 
I!M) suggests that the binding mode ofthe latter inhibitor is unfavourably influenced by 
the tert-butylamine C-terminal substitution (see Chapter 5.1). The solid state structure of 
inhibitor-HIVp complexes where the inhibitor has the tert-butyl C-terminal shows the 
tert-butyl group fills the S2' subsite and in doing so, orientates the ligand backbone into 
a pseudo trans- conformation about the central isostere. 1 We have designed the tetrazole 
dipeptide isosteres as mimics of the alternative cis- binding mode seen in the bound 
conformation of JG-365 (1.2.4.3), where the ligand backbone adopts an extended 
conformation. The above results suggest that the C-terminal tert-butyl group of inhibitor 
is incompatible with the cis- conformation of the tetrazole-based mimic. We 
propose that the tert-butyl P2' residue of inhibitor twists the ligand backbone so as 
to maximise interaction with the S2' subsite. The backbone twist that occurs would be 
conformationally at odds with the tetrazole-based cis- mimic. In contrast, the isoleucine 
t IC so values of 1.2.4.3 and 5.4.3 were obtained under different assay conditions. 
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residue of inhibitor 5.4.2 can £ill the 82' subsite, with the ligand backbone still remaining 
in an extended conformation that is compatible with the cis- conformation of the 
tetrazole-based isostere. This would give an inhibitor-enzyme complex [5.4.2-IDVp] of 
lower energy, relative to the 5.4.1-HIVp complex. 
The inhibitors (ICso=94 ~ and 4.1.1a (ICso=170 )lM),2 show similar 
activity against HIVp, suggesting that the Pt' glycine residue of is tolerated. t This 
is supported by literature observations,12 which have shown that there is only a moderate 
increase in activity by replacing a glycine residue at PI' with an alanine residue. Real 
gains in potency are only seen when large aromatic residues are placed in the SI' 
binding subsite. 
A suprising result from this work was the potency of the a-methylene tetrazole-
based dipeptide inhibitor, (ICso=18 )lM), relative to the a-hydroxymethylene 
tetrazole-based inhibitor, (ICso=60 )lM). It has been well established that 
inhibitors containing the central hydroxyl functionality are more potent than analogous 
inhibitors with the a-methylene isostere. 13 Hydroxyethylamine, and a-hydroxy isosteres 
(eg 4.1.2) give rise to potent IDVp inhibitors, due to the fuvourable interaction of the 
central hydroxyl with the catalytic aspartate residues ofHIVp. In the absence of any (X.-
hydroxy functionality in our tetrazole-based inhibitors we would not expect potent HIVp 
inhibition, due to the lack of a-functionality which prohibits this favourable binding 
interaction. The increased potency of 5.4.3 relative to must in part be due to the 
complimentarity between the tetrazole-based isostere (2.5.1) and the C-terminal 
substituents of 5.4.3, and that the inhibitor spans all available subsites of the enzyme 
binding cleft. The dipeptide mimic, 5.2.1, is similar in structure to the reduced amide 
isostere, [CH2NH], which also lacks an a-hydroxy functionality. The reduced amide 
isostere has been incorporated into the HIVp inhibitor 14 an analogue of the potent 
inhibitor JG-365 (1.2.4.3). Inhibitor 5.5.1 (ICso=3.5 ttM) was shown to be less potent 
than JG-365 (ICso=6 nM), due to the lack of the central hydroxyl functionality, 
Subsequent studies that compared various isosteres with identical flanking peptide 
residues, indicated that the reduced amide isostere is the least effective of the isosteric 
t IC50 values of 5.4.1 and 4.1.h. were obtained under different assay conditions, 
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replacements specifically due to a lack of a-functionality. is Therefore, we would expect 
the potency of inhibitor would increase dramatically with the addition of the 
central a.-hydroxy functionality. 
Incorporation of the 1,5-disubstituted tetrazole ring as a cis- amide bond mimic 
into biologically active peptide substrates often results in reduced activity with respect to 
~he parent peptide (see Introduction 3.0). This has been attributed, in part, to the 
increased steric bulk of the tetrazole heterocycle, which may cause undue steric 
congestion within the active site and hence reduce ligand-receptor interactions. 
Additionally, the tetrazole ring lacks the adjacent hydrogen-donor, hydrogen-acceptor 
arrangement of the amide bond. This may preclude the tight binding of tetrazole 
containing peptidomimetics, due to the lack of specific hydrogen-bonding interactions 
between the central tetrazole isostere and the receptor site. The modest potency of the a-
methylene tetrazole-based inhibitors, may also be attributed to 
structural factors, which would limit interactions between the tetrazole-based inhibitors 
and the active site ofHIVp. 
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5.6. CONCLUSION 
We have synthesised tetrazole-based dipeptide mimic, 5.2,1, which incorporated 
the a-methylene tetrazole isostere [CHzCN4] The solid state structure of the 
dipeptide mimic, 5.2.1, closely resembles the bioactive conformation of the non-
hydrolysable isostere of the potent inhibitor JG-365, which was the design basis of the 
tetrazole-based isostere. 
Elongation ofthe tetrazole-based dipeptide mimic, 5.2.1, via the C-terminal has 
been used to establish trends in activity against HIVp with increasing ligand-enzyme 
interactions. This has shown that HIVp activity can be greatly improved by 
incorporating the tetrazole-based dipeptide mimic into HIVp substrates that span the 83-
84 ' subsites. 
The investigation has also enabled us to account for the reduced activity of the C-
terminal tert-butyl tetrazole-based inhibitors, and 4.1.2. We propose that the 
reduced activity is due to the non-complimentarity of the tert-butyl substitution, and the 
tetrazole-based cis- amide mimic. 
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6.1. INTRODUCTION 
The a-keto amide functionality (eg. 6.1.1) has found widespread application as 
an isosteric replacement in reversible inhibitors of the proteinase family of enzymes. 
Amino acid derived a-keto ami des have been incorporated into inhibitors of el-
chymotrypsin,1 calpain,2 cathepsin B,3 and the aspartyl proteinase, pepsin.4 The a-keto 
amide isostere, has been incorporated into potent inhibitors of HIVp.5 A 
comparison of the biological activity ofHIVp inhibitors which were based on the a-keto 
amide (6.1.2), the hydroxyethylamine,6 (6.1.3), and phosphinic acid7 (6.1.4) isosteres, has 
shown that the a-keto amide isostere is the most potent of the isosteric replacements used 
in this series of inhibitors. 5 
p 8 0 yO Bo"lN~ 0'2 BO'HNJ:1~2 IlRl 0 R2 BooHN ° '2 /N~(lNA/ OH O' 
H 0 H H3CO 0 H3CO 0 H)CO 0 
6.1.1 6.1.2 6.1.3 6.1.4 
K;6!-1M K;>50 !-1M K;230 !-1M 
It is proposed that the a-keto amide isostere inhibits protease enzymes via the 
formation of a stabilised tetrahedral adduct between the electrophilic carbonyl of the 
isostere and catalytic residues of the proteolytic enzyme. 8 For example, it is proposed that 
the a-keto amide based inhibitors ofHIVp (eg. 6.1.2) are hydrated within the active site 
to from a stabilised hydrate (Figure 6.1.1), which is a good mimic of the tetrahedral 
intermediate formed during normal amide bond hydrolysis (Figure 2.2.2). 
Figure 6.1.1. The proposed stabilised 
hydrate of the a-keto amide isostere, 
6.1.1, in the active site ofHIVp. 
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A related isostere, the aminoketone [COCH2NH] (6.1.5), has been incorporated 
into an ACE inhibitor, 9 and shown to be more potent than the hydroxyethylamine 
based analogue, The ketomethylene isostere [COCH2] is found in the naturally 
occurring aminopeptidase inhibitor arphmenine and has been incorporated into 
aminopeptidase,10 renin,lI and calpain inhibitors. 12 The mode of action of the 
aminoketone isostere is thought to be similar to a.-keto amide isostere, where 
nucleophilic attack on the ketone within the active site leads to a hem i-ketal, a mimic of 
the tetrahedral intermediate (Figure 6.1.1). 
R\ R2 
INYNJ.:/-
H 0 H 
6.1.5 6.1.7 
We have designed the a.-keto tetrazole isostere [COCN4], as part of the 
novel tetrazole-based isosteric replacements. The a.-keto tetrazole isostere (2.5.3) 
combines structural elements of a non-hydrolysable a.-keto methylene isostere, with the 
conformational restriction of the 1 ,5-disubstituted tetrazole. This novel class of isosteric 
replacement is an important addition to the structural analogues available to 
peptidomimetic chemists for incorporation into enzyme inhibitors and conformational 
probes. We have been interested in developing synthetic routes to the a.-keto tetrazole 
isostere. 
P N-N XAN 
,IN If N' 0 
H 0 }-{ 
p{ ;.r 
2.5.) 
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6.2. FUNCTIONALISATION OF TETRAZOLEMBASED DIPEPTIDE MIMICS 
By far the most common route to the a-keto amide isostere, 6.1.1, has been by 
oxidation of N-protected j3-amino-a-hydroxy amides (eg Scheme 6.2.1) prepared by 
elaboration of the NMprotected a-amino acids. Foulds et al. B synthesised the tetrazole-
based dipeptide mimic, 6.2.3 (Scheme 6.2.1), containing the a-keto tetrazole isostere by 
this strategy. The synthesis of the dipeptide mimic, 6.2.3 (Scheme 6.2.1), required the 
synthesis of the a-hydroxy acid, N-Z-L-AHPBA 3.1.1 (see Chapter 2.0), incorporation of 
the protected acid into the dipeptide, 6.2.1, and conversion of the dipeptide to the 
corresponding tetrazole, 6.2.2. The synthesis was completed by a Dess-Martin 
periodinane14 oxidation of the a-hydroxymethylene tetrazole, 6.2.2, to the a-keto 
tetrazole, 6.2.3. The ten step synthetic sequence was low yielding, giving a 2% overall 
yield from commercially available NMZ-L-phenylalanine. We have been interested in 
developing a more expedient route to the a-keto tetrazole isostere, 
by Foulds et al. 13 
Q 
ZHNVOH 
OH 
3.1.1a (2R) 
3.1.1b (28) 
6.2.3 
Q 
_i.,_iI_·. _ ZHN~JlN~OCH3 
OAc H 0 
6.2.1 
iii., iv. 
v. Q~ N-N I • ZHN OH ~~O 
-$ OCH3 
6.2.2 
Scheme 6.2.1. Reagents and conditions; i. L-Ala-OCH3.HCI, 
DCC, HOBt, EtJN, rt; ii. A~O, pyridine, rt; m. PCI" 
quinoline, HNJ, rt; iv. K2COJ , rt; v. Dess-Martin periodinane, 
rt, 18 h. 
from that used 
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Darkins et al. IS have developed a synthetic route to a~keto esters by direct 
introduction of the a-ketone functionality to homologated amino acid esters (Scheme 
6.2.2). A homologated amino acid ester, 6.2.4, was prepared via Wolff rearrangement of 
the corresponding a-diazoketone in the presence of methanol (see Chapter 4.2). A diazo 
group was introduced at the a-position of 6.2.4 by acylation with 2,2,2-trifluoroethyl 
trifluoroacetate, prior to azide transfer from mesityl azide (MsN3), in the presence of 
triethylamine, according to the method ofDansheiser et al. 16 To complete the synthesis, 
the diazo function of 6.2.5 was oxidatively cleaved by exposure to dimethyldioxarane 
(DMD),17 which furnished the a-keto esters, 6.2.6, in high yield. No detectable 
epimerisation was observed by BC NMR in the preparation of diastereomeric a-keto 
esters by this method. 
R] 0 R] 0 
f NVoCH3 _i_i. _0 'INVOCH3 H Nz H 0 
6.2.4 6.2.5 6.2.6 
Scbeme 6.2.2. Reagents and conditions: i. CF 3COzCHzCF 3, 
LiHMDS, -78°C 10 min, then M"N3, Et3N, rt, 2.5 h; ii. DMD. 
We considered that the a-keto functionality of the a-keto tetrazole isostere, 2.5.3, 
could be introduced directly to the tetrazole dipeptide, according to the method developed 
by Darkins et al. is for the synthesis of the a-keto esters, 6.2.6. A retrosynthetic analysis 
R N-N ~)!.N 
PgHN '8 ~\;-f ===:;, 
Rz OPg 
6.2.7 
6.2.10 
R N-N 
Y;3)!. N 
PgHN If N6 0 
N2 M Rz OPg 
6.2.8 
]J 
R N-N ~N 
PgHN NJLZO 
R2 OPg 
6.2.9 
Figure 6.2.1. Retrosynthetic analysis of the a-keto 
tetrazole dipeptide mimic, 6.1.8, via direct introduction of 
the a-keto functionality. 
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of the proposed method is outlined in Figure 6.2.1. 
The proposed synthesis required an a-methylene tetrazole dipeptide, 6.2.9, to 
which the a-keto functionality could be introduced, to give the desired a-keto tetrazole-
based dipeptide mimic, 6.2.7. We have had experience in the synthesis of dipeptide 
mimics containing the a-methylene tetrazole isostere [CH2CN4] such as 6.2.9 (see 
Chapters 4.2, 5.2). The key step in the transformation of the a.-methylene tetrazole 
isostere, 6.2.9, to the a-keto tetrazole isostere, 6.2.7, is the formation of the a-diazo 
intermediate, by alkylation of the a-carbon of 6.2.9 in the presence of lithium 
hexamethyldisilazide (LiHMDS). We have established that the carbon centres adjacent to 
the tetrazole ring (C3 and C6), are susceptible to base catalysed epimerisation. The a-
protons adjacent to the tetrazole ring are removed under the basic conditions of peptide 
coupling leading to the observed epimerisation of these carbon centres (see Chapter 4.3). 
Alkylation of a tetrazole dipeptide (eg. 6.2.9) to give the key diazo intermediate could 
occur at either of the carbon centres (C3 or C6) adjacent to the tetrazole heterocycle 
(broad arrows, Figure 6.2.2). We have undertaken a study on the alkylation oftetrazole-
based dipeptides and have shown that there is a preferential addition of electrophiles to 
the tetrazole dipeptides. 
N-N 
I~·N !or!~t-
E+ 
E+ 
6.2.:2. Possible electrophilic addition 
to the tetrazole dipeptide at either the C3, or 
C6 carbon centres. 
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We considered that a simple protected glycine-[CN4]-glycine tetrazole-based 
dipeptide (eg. or 6.2.13 Scheme 6.2.3) would be an ideal substrate with which to 
study alkylation of the unsubstituted C3 and C6 carbon centres (Figure 6.2.2)' The 
dipeptides, and 6.2.13 (Scheme 6.2.3), were synthesised by coupling the 
appropriate N-protected glycine, to glycine benzyl ester with EDCI. The N-Z-protected 
dipeptide, was obtained in 96% yield, and the N-Fmoc-protected dipeptide, 
was obtained in 85% yield. We attempted to convert the dipeptides, 6.2.11 and 
to the corresponding tetrazole-based dipeptides, 6.2.12 and however both 
reactions returned unreacted starting dipeptide. The reason for the lack of reactivity of the 
N-protected glycine-gylcine dipeptides is unknown. Yu and JohnsonlS have observed that 
conversion of dipeptides to 1,5-disubstituted tetrazoles is unfavoured with a glycine 
residue at the N-terminal. 
H 0 . ~ II I ZHNlTN~oBn ::xc ' 
o 
6.2.11 
N-N 
;--<!''N 
ZHN N 0 l.f 
6.2.12 OBn 
N-N 
H 0 . FmOCHNlTN~OBn :>< 
o 
;--<!''N 
, FmocHN N 0 l.f 
OBn 
6.2.13 6.2.14 
Scheme 6.2.3. Reagents and conditions: i. 
HN:h Ii, 48 h 
quinoline, 
As an alternative to the glycine-[CN4]-glycine tetrazole-based dipeptides, we have 
investigated the alkylation of a simplified tetrazole system, We have synthesised 
the model tetrazole from the corresponding amide, according to the method of 
Zabrocki et al. 19 N-Z-L-Homophenylalanine, was prepared by a silver (I) catalysed 
Wolff rearrangement of the corresponding N-Z-protected ot-diazoketone (see Chapter 
4.2). The homologated amino acid, 4.1.3, was coupled to benzyl amine with the coupling 
reagent in the presence of DIPEA. The crude product was purified by flash 
column chromatography to give the amide, in 91% yield. The amide was 
converted to the tetrazole, 6,2.16, by treatment with phosphorous pentachloride in the 
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presence of quinoline, followed by an in situ reaction of the imidoyl chloride with 
hydrazoic acid. 19 The crude product was purified by flash column chromatography and 
the tetrazole, 6.2.16, was obtained in 71 % yield, as a white crystalline solid. 
q i q ~ 8-NN 
ZHNVOH---' ZHNVjjl)--- ZHN N~ 
4.1.3 6.2.15 6.2.16 
Scheme 6.2.4. Reagents and conditions: i. BnNH, EDCI, HOBt, DIPEA, rt, 18 h; ii. 
PCls, quinoline, HN), rt, 48 h. 
To investigate alkylation of the tetrazole, 6.2.16, we deprotonated with the 
LiHMDS, and then methylated with methyl iodide (Mel) (Scheme 6.2.4). A solution of 
tetrazole, 6.2.16, was added dropwise to a solution ofLiHMDS at -78°C. After 30 min a 
solution of methyl iodide was added dropwise and the reaction was stirred at -78°C for 
30 minutes. The reaction was then allowed to slowly warm the room temperature over a 
period of 30 minutes. The crude reaction mixture was purified by plate layer 
chromatography to give two fractions, one containing the mono-methylated products, 
6.2.17a and 6.2.17b, (86%) and the other fraction containing the di-methylated product, 
6.2.18 (14%) (Scheme 6.2.4). The mono-methylated products, which resulted from 
alkylation of the C6 carbon, were obtained as an epimeric mixture of6.2.17a and 6.2.17b 
(1: 1 by IH NMR). The di-methylated product, 6.2.18, resulted from alkylation at both the 
C6 and C3 carbon centres in the presence of excess methyl iodide and was obtained as a 
single C6 epimer. The configuration of the C6 stereo centre of6.2.18 was assigned on the 
basis of trends observed during the stereochemical assignment of the tetrazole-based 
inhibitors, 4.1.1a and 4.1.1b (see Chapter 4.3). This investigation established that 
tetrazole-based dipeptides with the (6R)-conflguration (4.Llb) gave Ala-I3-H3 IH 
resonances downfield of the corresponding (6S)- epimer (4.1.1a). On this basis we 
propose that the C6 stereo centre of 6.2.17 has a (6R)- configuration. 
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8:-N I • . N 
ZHN ~ 
i. 
6.2.16 
8' N-N I N ZHN N~ 
/ V 
6.2.17a (6S)-
6.2.17b (6R)-
6.2.18 (6R)-
Scheme 6.2.5. Reagents and conditions: i. LiHMDS, -78"C, 30 min, then Mel -
78"C, 30 min, rt. 
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The relative yields of the methylated products, 6.2.17 (86%), and 6.2.18 (14%) 
indicated that the C6 carbon is more acidic than the C3 centre, leading to the 
predominance of the mono-methylated products, 6.2.17a and 6.2.17h. The observed 
alkylation of the C3 carbon to give the di-methylated product, 6.2.18, suggested that the 
C3 carbon could be functionalised. The problem was the relative reactivity ofthe C6 and 
C3 centres. For the introduction of the a-keto functionality to the C3 centre exclusively 
we required a tetrazole substrate that was block at the C6 carbon centre. It was thought 
that in blocking the C6 centre we would direct the functionalisation to the C3 carbon. 
The a-methylene tetrazole-based dipeptide mimic, 6.2.20 (Scheme 6.2.5), was 
designed with a disubstituted amino acid incorporated at the C-terminal to direct 
functionalisation to the C3 carbon. The dipeptide, 6.2.19 (Scheme 6.2.5), was synthesised 
from 2-amino-2-cyclopentane carboxylic acid benzyl ester (H2NCpCOOBn) and the a-
diazoketone, 3.4.1. The cyclopentane benzyl ester was prepared by refluxing the 
corresponding acid in benzyl alcohol, in the presence of para-toluene sui phonic acid, in a 
Dean-Stark apparatus for 4 hours. The addition of 4 A molecular sieves to the collector of 
the Dean-Stark apparatus greatly improved the yield of the cyclopentane benzyl ester 
over previously published methods.zo The crude product was triturated with pre-cooled 
ether and the cyciopentane benzyl ester was removed by filtration as a white solid (50% 
yield). A mixture of the a-diazoketone, 3.4.1, and the cyclopentane benzyl ester were 
reacted photochemically in the presence of triethylamine, according to the established 
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procedure (see Chapter 4.2).21 The crude product was purified by flash column 
chromatography to give the dipeptide, 6.2019, as a white solid, in 25% yield. 
B~ R 8:-~ o 3 I .N i. 'ZHN N OBn ~~ ..... ZHN ~O 
H 0 U OBn 
6.2.19 6.2.20 
Scheme 6.2.5. Reagents and conditions: i. pTsOHH2NCpCOOBn, 300 nrn, Et~, rt, 18 
h; ii. PCb, quinoline, HN3• rt, 48 h, 
The dipeptide, 6.2.19, was treated with phosphorous pentachloride and a solution 
of hydrazoic acid, according to the modified procedure of Hruby et a1. 22 These 
modifications to the original procedure of Zabrocki et aT.19 were found to be necessary 
for the conversion of the sterically constrained N-Z-L-tryptophan-L-norleucine dipeptide 
(see Chapter 1.31.3.11), to the corresponding tetrazole-based dipeptide (see Chapter 1.3 
1.3.12). The procedure employs longer reaction times and additional phosphorous 
pentachloride to ensure formation of the imidoyl chloride prior to the addition of 
hydrazoic acid. Analysis of the crude reaction product, by IHNMR, showed the presence 
of unreacted started dipeptide, 6.2.19, following reaction of the dipeptide, according to 
the procedure of Hruby et aT.22 An increase in the reaction time prior to the addition of 
hydrazoic acid (up to 4 hours) and an increase in the amount of phosphorous 
pentachloride, did not yield the desired tetrazole, 6.2.20. We propose that the steric bulk 
of the cyclopentane C-terminal substituent limits formation of the tetrazole ring, due to 
unfavourable steric interaction in the tetrazole intermediates. 
The attempted functionalisation ofthe tetrazole dipeptides provided some insight 
into the relative reactivity of the C3 and C6 centres, as well as highlighting the difficulty 
in synthesising sterically congested tetrazole-based dipeptides by the method ofZabrocki 
et al. 19 An alternative synthesis of the a-keto tetrazole isostere was pursued, via direct 
alkylation of the tetrazole heterocycle. 
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6.3. SYNTHESIS OF THE (lmKETO TETRAZOLE ISOSTERE BY DIRECT 
ALKYLATION OF THE TETRAZOLE HETEROCYCLE 
We have synthesised the a-methylene tetrazole isostere [CH2CN4] (2.5.1) by a 
functional group interconversion of the amide bond ofa protected dipeptide (eg 6.2.15), 
to a tetrazole heterocycle (eg. 6.2.16), according to the modified method of Zabrocki et 
al. 19 This method has several drawbacks: i. The synthesis of the tetrazole-based 
dipeptides often suffers from low yields, (eg. see Chapter 4.1.5); ii. The reaction 
conditions place rigid requirements for aromatic N- and C-terminal protecting groups of 
the dipeptide substrate (eg. see Chapter 4.2); iii. Some amino acid residues (eg. glycine) 
limit formation of the tetrazole (eg. see Chapter 6.26.2.11); iv. It is difficult to transform 
sterically demanding dipeptides into the corresponding tetrazoles (eg. see Chapter 6.2 
6.2.20); v. The reaction can be highly variable, with repeatability often being a problem. 
With this in mind, we have investigated an alternative synthesis of tetrazole-based 
dipeptide mimics and used this approach to synthesise the a-keto tetrazole isostere 
[COCN4], 2.S.3. 
It is possible to directly alkylate (lH)-tetrazoles (eg 6.3.1 Scheme 6.3.1) to yield 
1,5-disubstituted and 2,5-disubstituted tetrazoles. This approach has been used by 
Bavetsias et al?3 for the synthesis of thymidylate synthase (TS) inhibitors that 
incorporated a 1,5-disubstituted tetrazole (Scheme 6.3.l). Alkylation of the known (1H)-
tetrazole, 6.3.1,24 with methyl bromoacetate in the presence of triethylamine, gave a 
mixture ofregiomeric tetrazoles, 6.3.2, and 6.3.3. The 1,5-disubstituted tetrazole (6.3.2), 
and 2,5-disubstituted tetrazole (6.3.3), obtained in a ratio (by IH NMR), were 
separated by flash column chromatography and subsequently elongated via the N-
terminal to give the desired TS inhibitors. 
0yOCH3 0"'Y0CH3 
ZHN~'fNN ~ ZHN~NN 
HN-N N-N 
>=0 
H3CO 
6.3.1 
6.3.2 
0yOCH3 
+ ZHN~N~ 
N-tJ~O 
OCH3 
6.3.3 
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Using a similar approach, Valle et al.25 prepared a conformationally restricted 
tripeptide analogue which incorporated a 1,5-disubstituted tetrazole ring, 6.3.5. 
Alkylation of the known tetrazole, 6.3.4,26 with methyl bromoacetate in the presence of 
triethylamine gave a mixture of 1- and 2-tetrazoylacetic acid methyl esters, 6.3.5, and 
6.3.6, in a 1:1 ratio (by NMR) (Scheme 6.3.2). 
~, ZHN~l' .~ ~, + ZHN~i',f'T 
N-N 
<yo N-N 0 Y 6.3.4 OCH3 
H3CO 
6.3.5 6.3.6 
Scheme 6.3.2. Reagents and conditions: i. EhN, JJ"~J.J.7'-V'7'-J. rt,3h. 
In consideration of the above examples, we postulated that direct alkylation of a 
suitable (lH)-tetrazole could be used for the preparation of the a-keto tetrazole isostere, 
2.5.3. For the proposed synthesis we required a suitable (1H)-tetrazole substrate to which 
the C-terminal residue could be added by direct alkylation. We have used the procedure 
of Satoh et a/?7 for the synthesis of an a-hydroxy (IH)-tetrazole, 6.3.13 (Scheme 6.3.5) 
to which the C-terminal residue was added by direct alkylation of the tetrazole ring. 
The requisite protected tetrazole, 6.3.8, was prepared by condensation of 
commercially available (lH)-tetrazole, 6.3.7, with benzyl chloromethylether (Scheme 
6.3.3). The regiomeric products, 6.3.8 and 6.3.9, were separated by flash column 
chromatography. The desired tetrazole, 6.3.8, eluted first and was obtained in 20% yield 
as a clear oiL Further elution gave the N-2 regiomer, 6.3.9. 
6.3.9 
Scheme 6.3.3, Reagents and conditions: i. 
NaHMDS, BnOCH2CI, 0 °C, 30 min, rt, 2 h. 
CHAPTER SIX ~S YNTIIESIS OF THE (1-KETO TETRAZOLE ISOSTERE 120 
Lithiation was successfully effected by treatment with n-butyllithium at-
78 °e, to yield a deep purple solution typical of the 5-lithiotetrazoles. An in situ 
electrophilic condensation of the 5-lithiotetrazole with an N-protected Weinreb amide, 
3.1.25 or 6.3.10, gave the corresponding N-protected 1,5-disubstituted tetrazoles, 6.3.11 
and 6.3.12. Flash column chromatography of the crude reaction products gave the N-Z-
protected tetrazole, 1, or the N-Boc-protected tetrazole, both in 60% yield 
(Scheme 6.3.4). 
3.1.25Pg=Z 
6.3.10 Pg=Boc 
R-N 
pgIIN¥Nl.:N 
o OBn 
6.3.11Pg=Z 
6.3.11Pg=Boc 
Scheme 6.3.4. Reagents and conditions: i. n-BuLi, -78 5 min, 
-78 °C-25 °C over 30 min. 
Removal of the N-l benzyl methyl ether tetrazole protection can be achieved 
either under acidic conditions (6 MHCl/dioxane), or by hydrogenation in the presence of 
10% palladium on carbon, following established procedures.27 However, the success of 
the deprotection step was found to be dependant on theN-terminal protection ofthe 1,5-
disubstituted tetrazole. A catalytic hydrogenation of the N-Z-protected tetrazole, 6.3.11, 
resulted in comittant N-Z-deprotection and removal of the benzyl methylether tetrazole 
protecting group. Similarly, under acidic conditions the N-Z-protection of 6.3.11 was 
removed along with the benzyl methyl eth er tetrazole protection. A catalytic 
hydrogenation of the N-Boc-protected tetrazole, resulted in removal of the 
tetrazole protecting group, as expected, but also a reduction of the a-ketone to the a-
hydroxy (Scheme 6.3.5). Upon work-up, the reaction gave the epimeric a-hydroxy (1H)-
tetrazoles, and 6.3.13b, in 90% yield, which were used without further 
purification. 
Having synthesised the desired (lH)-tetrazole substrate we turned our attention to 
alkylation of the tetrazole heterocycle (Scheme 6.3.5). Alkylation of the a-hydroxy (1H)-
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tetrazoles, and with benzyl bromoacetate In the presence of 
triethylamine gave the 1,5-disubstituted tetrazole products, and and also 
the 2,5-disubstituted tetrazole products, 6.3.15a and The products were purified, 
but not separated, by flash column chromatography to give the regiomeric tetrazoles, 
6.3.14 and 6.3.15, as a mixture in 60% yield. The alkylation was also carried out using 
DIPEA as the base, which gave an improved yield (75%) over the use of triethylamine. 
Q~-~ 
.N I. 
Bocllli ~-
o ....... OBn 
6.3.ll 
8~ WN I .' 3 N BooRN OIl ~O 
6.3.14a (3R)_OBn 
6.3.14b (3S)-Q~ N-N 3 I 'N Bocl-fN N ~ + 
OH H 
6.3.13a (3R)-
6.3.13b (3S)- Q:~~ 3'" N\ BooRN N ,;-OBn 
OH 0 
6.3.158 (3R)-
6.3.1Sb (3S)-
Scheme 6.3.5. Reagents and conditions: i. Hz, 10% Pd/C, 1 atm, rt, 24 h; ii. 
DIPEA, BrCH2C02Bn, rt, 24 h. 
The a-hydroxy tetrazoles, 6.3.14 and 6.3.15 were oxidised, as a mixture, with a 
solution ofTEMPO,28 to give a mixture ofthe regiomer tetrazoles 6.3.16 and 6.3.17 (3:4 
by IH NMR) (Scheme 6.3.6). 
The regiomeric tetrazoles, 6.3.16 and were separated by flash column 
chromatography, the less polar 1,5-disubstituted tetrazole, 6.3.16, eluted prior to the 
disubstituted tetrazole, 6.3.17. The tetrazoles were obtained in 30% and 40% yield, 
respectively. The structures of the regiomeric tetrazoles were assigned on the basis of 
and Be NMR, and an X-ray structure determination of 6.3.17. In previous NMR 
studies of regiomeric tetrazoles,z9 it has been shown that the Gly-a-H2 IH resonance for 
the 1,5-disuhstituted tetrazole appears further upfield than the Gly-a-Hz signal of the 
disubstituted tetrazole. Be NMR studies of 1- and 2-methyltetrazoles have shown that the 
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methyl and CN4 carbon atoms of the 1,5-disubstituted tetrazole are more shielded than 
the conesponding carbon atoms of the 2,5-disubstituted tetrazoles?O on the above 
observations the tetrazole that was eluted first was designated the 1,5-disubstituted 
tetrazole, 6.3.16, since it showed a Gly-a-H2 IH resonance at 85.47, and Gly-a-CH2 and 
CN4 13C resonances at 8 50.11 and 8 148.09, respectively. The more polar tetrazole, 
6.3.17, had a Gly-a-H2 IH resonance at 8 5.53, and Gly-a-CH2 and CN4 13C resonances 
at (5 53.76, and 8 161.15, respectively. The IH NMR and l3C NMR spectra of the 
regiomeric tetrazoles, and 6.3.17, are compared in Figures 6.3.1 and 6.3.2, where 
the diagnostic shift differences between the regiomeric tetrazoles are annotated by a 
broad arrow. 
8~ N-N 3 I :N BoeHN OH ~o 
6.3.14a (3R)- OBn 
6.3.14b (3S)-
i. 
8~ N-N BoeHN I tNj 
° TO 
6.3.16 OBn 
+ 
-
+ 
Q:~ 3 " N\ BoeHN N _rOBn 
OH ° 
J3:=N " .N\ BoeHN N .rOBn 
° 0 
6.3.15a (3R)- 6.3.17 
6.3.1Sb (3S)-
Scheme 6.3.6. Reagents and conditions: i. TEMPO, KBr, 
sodium hypochlorite, 0 °C, 10 min. 
More evidence for the stereochemical assignment of the tetrazole regiomers, 
6.3.16 and was obtained by a heteronuc1ear multiple bond correlation (HMBC) 
experiment. The NMR experiment shows connectivity between carbon and 
hydrogen atoms at a two to three bond distance. The observed correlations for the 
tetrazole, and are shown in Figure 6.3.3. Both compounds show similar 
HMBC correlations, however only the 1,5-disubstituted tetrazole, 6.3.16, shows a 
correlation between the Gly-a-H2 protons and the CN4 carbon centre (indicated by a 
CHAPTER SIX-SYNTHESIS OF THE !X-KETO TETRAZOLE ISOSTERE 123 
-------------------------------------------
broad arrow, Figure 6.3.3), The ring substitution of places the CN4 carbon centre 
three bonds from the Gly-a-H2 protons, such that a weak correlation is observed. This 
correlation is not seen in the HMBC spectrum of 6.3.17, as the Gly-a-H2 protons and 
CN4 carbon are separated by four bonds, and as such, are out of range for an observable 
HMBC correlation. 
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Figure 6.3.1 A. IH NMR spectrum of the J ,S-disubstituted tetrazoJe, 6.3.16; B. lH NMR spectrum of the 
2,5·disubstituted tetrazote, 6.3.17. 
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6.3.2, A,BC NMR spectrum of I,5-disubstituted tetrazoIe, 6.3.16; B. BC NMR spectrum of 
2,5-disubstituted tetrazole, 6.3.17. 
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6.3.16 6.3.17 
Figure 6.3.3. Observed HMBC correlations of the 1,5- and 2,5-disubstituted tetrazoles. 
Single crystals of the 2,5-disubstituted tetrazole, 6.3.17, were grown from 
methanol by slow evaporation. The structure of 6.3.17 was confirmed by an X-ray 
structure determination at 173(2) K and was satisfactorily refined (Figure 6.3.4) For a 
detailed discussion ofthe crystal structure of6.3.17 see Chapter 7.3. 
Figure 6.3.4. The solid state structure ofthe 2,5-disubstituted tetrazoJe, 6.3.17. 
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6.4. CONCLUSION 
Although our investigation into the direct functionalisation of tetrazole-based 
dipeptides could not be used as a synthetic route to the a-keto tetrazole isostere (see 
Discussion 6.2), the work gave some insight into the relative reactivity of the C3 and C6 
carbon centres adjacent to the tetrazole. We have established that alkylation of the 
tetrazole-based dipeptides will occur at the more acidic C6 carbon centre in preference to 
the C3 centre. This preliminary investigation into the synthesis of the a-keto tetrazole 
isostere also highlighted deficiencies in the synthesis oftetrazole-based dipeptides by the 
method ofZabrocki et al. 19 
An alternative synthesis of tetrazole-based dipeptides has been investigated and 
this method has been used as a nove.l route to the a-keto tetrazole isostere, A direct 
alkylation of the a-hydroxy (lH)-tetrazole, 6.3.13, was used to introduce the C-terminal 
, glycine residue and gave a mixture of readily separable regioisomers. The method 
developed here is more succinct than the method employed by Foulds et al. B involving 
only five synthetic steps from N-protected L-phenylalanine, to yield the desired isostere, 
in 10% overall yield. 
The synthetic method than we have investigated would also provide an expedient 
route to the a-hydroxy tetrazole isostere, 2.5.2, through reduction of the a-keto tetrazole 
isostere, 2.5.3. This new method has more scope than the previous method employed, 13 as 
it allows for the introduction of a variety of PI and PI' residues into the tetrazole-based 
dipeptide mimic. This increases the utility of the a-keto tetrazole isostere for 
incorporation into substrate sequences as potential inhibitors or confonnational probes. 
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7,1. INTRODUCTION 
During the course of this investigation into the synthesis of tetrazole-based 
isosteres we have been able to detennine the solid structures of three tetrazole-based 
dipeptide mimics. What follows is a brief discussion of some of the features of the solid 
state structures of the tetrazole-based dipeptide mimics. 
SOLID STATE STRUCTURES OF 1,5-DISUBSTITUTED TETRAZOLE-BASED 
DIPEPTIDE MIMICS 
The solid state structures of three 1,5-disubstituted tetrazole-based dipeptide 
mimics have been presented in the literature to date (Figure 7.2.1 1.3.5-1.3.7). The 
structures all show a remarkable resemblance to the cis- amide bond, in their orientation 
the peptide backbone and adjacent amino acid side chains (see Chapter 1.3). The 
tetrazole ring and its 1,5-substituents adopt an essentially planar arrangement, such that 
the torsion angle, w, approximates zero in all three examples presented to date (1.3.51 
, 1.3.62 w=4.8°, 1.3.73w=2.9°). The tetrazole ring represents a good geometrical 
mimic, with bond angles and lengths reasonably close to the cis- amide conformer. 2 
1.3.5 1.3.6 
~: N-N ro I \\ ,.,N HN~ 
o 
1.3.7 
Figure 7.2.1, Tetrazole-based peptides of which the solid state 
structure is known. 
We have observed the solid state structures of two tetrazole-based dipeptide 
mimics, 5.4.1 and 7.2.1, where the tetrazole heterocycle has been incorporated to lock the 
non-hydrolysable isostere of the ligand into a cis- conformation. We have designed and 
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synthesised an a-methylene tetrazole isostere, 2.5.1, and incorporated this into a 
tetrazole-based dipeptide mimic, N-Z-L-homophenylalanine-[CN4]-glycine benzyl 
(see Chapter 5.2 for a comparison of the solid state structure of the a-methylene 
tetrazole isostere, 2.5.1 and JG-365, 1.2.4.3). Single crystals of the tetrazole-based 
dipeptide, 5.4.1 were obtained by slow evaporation from methanol and the structure 
confirmed by an X-ray structure determination (Table 7.2.1, Figure 7.2.2) 
B:-N I .. . N 
ZHN ~O 
OBn 
2.5.1 5.4.1 7.2.1 
The structural data obtained for the tetrazole heterocycle of 5.4.1 compares well 
with other reported 1 ,5-disubstituted tetrazoyl groups.4 The tetrazole ring was found to be 
essentially planar with the torsion angles C3-N2-N3-N4, N2-N3-N4-N5, N4-N5-C3-N2, 
N3-N2-C3-N5, C3-N5-N4-N3, being 0.04 (0.40)°, -0.02 (0.41)°, 0.03 (O.4ot, -0.04 
(0.41)°, -0.01 (0.42)°, respectively and the ring atoms show a mean deviation from the 
plane of 0.00 A. Bond lengths of the tetrazole heterocycle are all similar, with the bonds 
N5-N4, N4-N3, N3-N2, N2-C3 being, 1.317 (5) A, 1.364 (5) A, 1.302 (5) 
A,1.356 (4) A, 1.334 (5) A, respectively. The C3-N5 and N4-N3 bonds are slightly 
shorter than the other ring bonds, indicative of their double bond character. The N5-N4-
N3 endocyclic bond angle, 110.5 (3)°, is wider than the C3-NS-N4 and N4-N3-N2 bond 
angles, 106.1 (3)° and 105.9 (3)°. The dipeptide mimic is folded at the 
homophenylalanine-[CN4]-glycine sequence with the torsion angles, C3-C2-Cl 
"--'.J-"--,,,,,-''L- , C3-N2-C4-C5, and N2-C4-C5-04, being, 66.26 (0.36)°, -97.14 (0.40)°,98.23 
(0.43)°, and -172.34 (0.24)° respectively. The 'OJ torsion angle at the homophenylalanine-
glycine junction, C2-C3-N2-C4, is forced by the tetrazole heterocycle into a cis-
conformation, where 'OJ=13.05 (0.59)°. The phenyl ring of the homophenylalanine side 
chain is disordered in the crystal structure (Figure 
conformations, related by rotation about the C2 axis. 
1). The ring can be seen in two 
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Data collection device 
Empirical formula 
Formula weight 
Temperature 
Crystal system 
Space group 
Unit cell dimensions 
Volume 
Z 
Density (calculated) 
Absorption coefficient 
F(OOO) 
Crystal size 
Theta range for data collection 
Index ranges 
Reflections collected 
Independent reflections 
Data I restraints I parameters 
Goodness-of-fit on F2 
Final R indices [1>2sigma(l)] 
R indices (all data) 
CCD 
C27 H27 N5 04 
485.54 
160(2) K 
Triclinic 
PI 
a = 5.0379(3) A 
b = 10.1066(7) A 
c = 12.7865(9) A . 
624.55(7)A3 
I 
1.291 Mg/m3 
0.089 mm- I 
256 
0.8 x 0.4 x 0.02 mm3 
3.23 to 25.61°. 
a = 83.577(2)°. 
f3= 81.897(2)°. 
Y = 76.475(2)°. 
-I <=h<=5, -IO<=k<=II, -12<=1<= 15 
2198 
1867 [R(int) = 0.1 010] 
1867 I 3 1365 
1.064 
RI = 0.0359, wR2 = 0.0898 
RI = 0.0427, wR2 = 0.0957 
Table 7.2.1. Crystal data and X -ray experimental details for 5.4.1. 
Figure 7.2.2. The solid state structure of N-Z-L-homophenylalanine-[CN4J-glycine 
benzyl ester, 5.4.1. 
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We have also been able to determine the solid state structure of the cyclic 
tetrazole-based dipeptide mimic, cyclo-{L-homophenylalanine-[CN4]-glycine} 7.2.1, a 
seven-membered ring analogue of 1.3.7 (Figure 7.2.1). Compound IS a 
tetrazolodiazepines derivative of which very few exist in the literature. 5 A great deal of 
synthetic work has been presented in the literature describing the preparation of nitrogen-
containing five membered rings fused to the diazepine nucleus. Pyrrolodiazepines, 
imidazodiazepines, and triazolodiazepines are of great interest due to their interesting 
pharmacological activity on the central nervous system. The tetrazolodiazepine, 7.2.1, 
was formed during the attempted EDCI mediated coupling of the N-Boc-protected 
tetrazole-based dipeptide, to amine hydro bromide, (Scheme 7.2.1). The 
attempted coupling in the presence of DIPEA gave the cyclic product 7.2.1, in 93% 
yield." The target coupled tetrapeptide was not observed by III NMR or mass 
spectrometry. Single crystals of 7.2.1 were obtained by slow evaporation from methanol. 
The structure of was solved at 163 (2) K, and was satisfactorily refined (see Figure 
7.2.3). 
o S:-N S:-N C-BocHN INN + HBr.H2N I NyN __ i. -, rn( '!=N l ,0 yO O~N, .~ Y N' 5.4.7 OH 5.4.4 OBo 
7.2.1 
Scheme 7.2.1. Reagents and conditions: i. EDCI, HOBt, DIPEA, rt, ISh. 
The solid state structure of the cyclic tetrazole-based peptide mimic, (Table 
Figure 7.2.3), shows the tetrazole ring as essentially planar with a mean deviation 
from the plane of 0.003 A. The ring torsion angles, N2-C5-N5-N4, C5-N5-N4-N3, 
N4-N3-N2, N4-N3-N2-C5, and N3-N2-CS-N5 being -0.55 (15)°,0.17 (16)°, 0.27 (16)°,-
0.62 (15)° and 0.74 (15)°, respectively. The N3-N4 bond [1.2887 (18) A) possesses the 
most double bond character of the heterocyclic bonds. The N2-N3 and N4-N5 bonds are 
the longest being 1.3537 (16) A and 1.3650 (18) A, respectively. The N2-C5 bond 
Yield based on starting benzyl ester, 5.4.4. 
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[1 (18) A] is shorter than the amide bond, N1-C2 [1.3508 (19) A]. The diazepine 
is puckered with a deviation from the plane of 0.317 A. The phenylalanine ring is 
essentially planar and adopts a flagpole orientation over the diazepine ring. The m torsion 
angle at the homophenylalanine-glycine junction is forced to adopt a planar 
conformation, where m=3.3 (2)°. This torsion angle is more than that observed for the 
six-membered analogue, 1.3.' (rn=2.2°), possibly due to the increased flexibility of the 
seven-membered ring of7.2.1, compared to the six-membered ring of 
Data collection device 
Empirical fonnula 
Fonnula weight 
Temperature 
Crystal system 
Space group 
Unit cell dimensions 
Volume 
Z 
Density (calculated) 
Absorption coefficient 
F(OOO) 
Crystal size 
Theta range for data collection 
Index ranges 
Reflections collected 
Independent reflections 
Completeness to theta = 26.42° 
Absorption conection 
Max. and min. transmission 
Refinement method 
Data 1 restraints I parameters 
Goodness-of-fit on F2 
Final R indices [I>2sigma(l)] 
R indices (all data) 
CCD 
Cl2 Hl3 N5 0 
243.27 
163(2) K 
Orthorhombic 
P2(1 )2(1 )2(1) 
a = 6.374(2) A 
b = 8.621(3) A 
c = 20.890(7) A 
II 47.8(7) A3 
4 
1.408 Mglm3 
0.096 rom-I 
512 
0.63 x 0.24 x 0.21 mm3 
2.56 to 26.42°. 
a= 90". 
b= 90". 
g 90° 
-4<=h<=7, -I O<=k<= 10, -26<=1<=25 
14344 
2338 [R(int) == 0.0271] 
99.4% 
Semi-empirical from equivalents 
0.9800 and 0.9418 
Full-matrix least-squares on F2 
2338/01163 
1.036 
RI = 0.0323, wR2 0.0827 
RI = 0.0374, wR2 0.0853 
Table 7.2.1. Crystal data and X-ray experimental details for 7.2.1. 
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Figure 7.2.3. The solid state structure of cyclo-Lhomophenylalanine-[CN4h,'Ylcinel, 
7.2.1 . 
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Figure 7.2.4 compares the geometric properties of the cis- amide bond obtained 
from a statistical analysis of published peptide X-ray diffraction structures,6 with 
geometric properties of the tetrazole-based dipeptides, 5.4.1 and 7.2.1. The tetrazole-
based dipeptide, 7.2.1 , is an excellent candidate for comparison with known structures of 
cyclic dipeptides in which the amide bonds must assume a cis- conformation to allow 
ring closure. In the tetrazole-based dipeptides, 5.4.1 and 7.2.1, the critical Cu ___ Cu 
separation (Figure 7.2.4) between adjacent amino acid residues is only 0.3 angstrom 
greater than that typical of a cis- amide bond. The Cu ___ Cu separation is shorter in the 
cyclic tetrazole-based dipeptide, 7.2.1 (3.190 A), than its linear analogue, 5.4.1 (3.229 A) 
and the former cyclic dipeptide makes a closer approximation to the Cu __ Cu distance in 
the cis- amide bond (2.9 A). The small variation between the tetrazole-based dipeptide 
mimics, 5.4.1 and 7.2.1 , and the cis- amide bond is mainly due to the wider bond angles 
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at the Cl.-C=N bond of the tetrazole (see Figure 7.2.4), as a consequence of the increased 
steric bulk of the tetrazole moiety. 
N 
N/ ""'N 
126.5° \ / 130.9° ~h1.33 ~(..,,/ ~ Co......... . CU 
3.19 
5.4.1 
/N"", 
N N 
127.2° \ / 132.0° 
~1.34~.." ~~.", :;t IT' 
C ....... _. _. CU 
3.22 
7.2.1 
o H 
118.40 \ / 126.5° ~ CU ---···-co. 2.9 
cis- amide 
bond 
Figure 7.2.4. A comparison of the bond lengths (A), angles and C"'-··C'" distances of the 
tetr6Zole-based amide bond surrogates, 5.4.1 and 7.2.1, and a generic cis- amide bond 
The results ofthese structural determinations illustrate the rigidity of the tetrazole 
ring when it is incorporated into a peptide backbone. In addition, these results confirm the 
high degree of geometric similarity with linear peptides containing the cis- amide bond. 
7.3. SOLID STATE STRUCTURE OF 2,5-N-Z-L-PHENYLALANINE-[COCN4]-
GL YCINE BENZYL ESTER 
We have synthesised the a-keto tetrazole isostere [COCN4] 2.5.3, and 
incorporated this into 1,5-disubstituted tetrazole-based dipeptide, 6.3.16, and 2,5-
disubstituted tetrazole-based dipeptide, 6.3.17 (see Chapter 6.3). The solid state structure 
of2,5-disubstituted, was solved by a single crystal X-ray determination at 173 (2) 
K and was satisfactorily refined (Table 7.3.1). The solid state structure of 6.3.17 (Figure 
7.3.1) was used to confirm the structural assignment of the regiomeric tetrazoles, 6.3.16 
and 6.3.17 (see Chapter 6.3) and this unique structure represents the first a-keto 
tetrazole-based dipeptide mimic to be reported. 
2.5.3 
Q~ WN BoeHN I tN~ 
° yO 
OBn 
6.3.16 
~~YB" 
BOeHN¥N 0 
o 
6.3.17 
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The tetrazole ring of 6.3.17 is essentially planar with the ring torsion angles, C5-
NI-N2-N3, Nl -N2-N3-N4, N2-N3-N4-C5, N3-N4-C5-NI, N4-C5-NI-N2 being -0.3 
(4)°, 0.0 (4)°, 0.3 (4)°, -0.6 (4)° and 0.5 (4), respectively. The tetrazole ring of 6.3.17 
showed a mean deviation from the plane of 0.002 A. This indicates that the 2,5-tetrazole 
ring has similar planarity to the 1,5-tetrazole rings of 5.4.1 , and 7.2.1 (see Chapter 7.2) 
where the mean deviations from the plane were 0.00 A, and 0.003 A, respectively. The 
bond lengths ofthe tetrazole ring are all similar, with the C5-N I, N I-N2, N2-N3, N3-N4, 
N4-C5, being, 1.345 (4) A, 1.325 (4) A, 1.351 (3) A" 1.327 (3) A, and 1.352 (4) A, 
respectively. The a-keto carbonyl bond sits in the same plane as the tetrazole ring, with 
the 018-CI7-C5-N4, and 018-CI7-C5-N4 torsion angles being -178.1 (3)° and - 0.1 
(5)°, respectively. The core isostere [C 17 ---C6] is essentiaIly planar, with a mean 
deviation from the plane of 0.013 A. The Cl7-C5 and N2-C6 bonds are offset by -10°. 
The phenylalanine ring is essentially planar and sits in a flagpole position over the 
tetrazole heterocycle. 
Figure 7.3.1. The solid state structure of the 2,5-disubstituted tetrazole-based dipeptide mimic, 
6.3.17. 
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Data collection device 
Empirical fonnula 
Fonnula weight 
Temperature 
Crystal system 
Space group 
Unit cell dimensions 
Volume 
Z 
Density (calculated) 
Absorption coefficient 
FeOOO) 
Crystal size 
Theta range for data collection 
Index ranges 
Reflections collected 
Independent reflections 
Completeness to theta = 26.45° 
Absorption correction 
Max. and min. transmission 
Refinement method 
Data / restraints / parameters 
Goodness-of-fit on F2 
Final R indices [I>2sigma(I)] 
R indices (all data) 
CCD 
C24H27 N5 05 
465.51 
173(2) K 
Orthorhombic 
P2(1 )2(1 )2(1) 
a = 6.140(3) A a= 90°. 
b = 16.264(7) A b= 90°. 
c.= 23.523(10) A g = 90°. 
2349.0(\7) A3 
4 
1.316 Mg/m3 
0.094mm- 1 
984 
0.55 x 0.26 x 0,02 mm3 
2.14 to 26.45°. 
-7<=h<=7, -20<=k<=IS, -29<=1<=29 
30663 
4837 [R(int) = 0.1593] 
99.7% 
Semi-empirical from equivalents 
1.0000 and 0.8407 
Full-matrix least-squares on F2 
4837/0/307 
0.794 
Rl = 0.0448, wR2 = 0,0714 
Rl = 0.1525, wR2 = 0,0904 
Table 7.3.1. Craystal data and X-ray experimental details for 6.3.17. 
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The solid state structures of the a-methylene tetrazole isostere [CH2CN4] 
incorporated into the tetrazole-based dipeptide mimics, 5.4.1 and 7.2.1, have provided a 
useful insight into the structural properties of the tetrazole-based isostere. The tetrazole 
ring was shown to be essentially planar and compared well to the published structural 
data of known tetrazole-based dipeptides. We have used the tetrazole heterocycle as a 
amide bond mimic to conformationally constrain ligands into the cis- conformation. The 
solid state structures of and 7.2.1 illustrate the conformational restriction imparted 
by the tetrazole heterocycle forcing a pronounced 'kink' in the tetrazole-based dipeptide 
mimics. The solid state structure of the a-methylene tetrazole isostere, IS an 
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invaluable resource for the rational-based design of inhibitors and conformational probes 
that contain this tetrazole-based isosteres. 
The cyclic tetrazole-based dipeptide, is part of a rare class of medicinally 
important compounds the tetrazolodiazepines. To date no solid state structure of a 
tetrazolodiazepine has been reported in the literature. 
The solid state structure ofthe a-keto tetrazole-based dipeptide mimic, 6,3,17, is 
unique in the literature and has aided in the unequivocable assignment of the regiomeric 
a-keto tetrazoles, 6.3.16 and 6.3.17. 
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8.1. HIVp INHIBITORS 
We have developed synthetic routes to the a-methylene tetrazole (2.5.1), a-
hydroxymethylene tetrazole (2.5.2), and a-keto tetrazole (2.5.3) isosteres. The potent 
HIVp inhibitor JG-365 (1.2.4.3) formed the design basis of the tetrazole-based isosteres, 
2.5.1-2.5.3, and of these the a-methylene tetrazole isostere (2.5.1) was incorporated into 
the modestly potent HIVp inhibitors, 5.4.1-5.4.3 (see Chapter 5.4). Computationally 
based studies should be undertaken to compare the bioactive conformation of JG-365 
(1.2.4.3) and the more potent of the a-methylene tetrazole-based inhibitors, compound 
5.4.3. It is thought that computational studies may support the effectiveness of the 
tetrazole-based isostere in its ability to orient the inhibitor backbone and side chain 
residue of the inhibitor, 5.4.3, into an equivalent conformation to that seen in the 
bioactive conformation of JG-365. 
P N-N 
-Z/l.1 I" " N IN N 
H P ",.1 D J+ 
2.S.1 2.5.2 2.5.3 
Future work directed at the inhibition of HIVp should also focus on the 
incorporation of the a-hydroxymethylene tetrazole (2.5.2) and a-keto tetrazole (2.5.3) 
isosteres into substrate sequences of HIVp which span the subsites. We propose, 
based on the observed potency of a-hydroxy and a-keto based isosteric replacements, 
that the tetrazole-based equivalents, and 2.5.3, could be used to generate HIVp 
inhibitors of improved potency over the a-methylene tetrazole-based inhibitors 
5.4.3 Chapter 5.4) presented in this current work. Additionally, research should 
directed at incorporating larger PI' substituents into the tetrazole-based IllVp inhibitors 
5.4.1-5.4.3, 
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8.2. TARGETING MEDICINALLY IMPORTANT RECEPTORS 
The Brookhaven Protein Database (PDB) should be screened in compuo to 
identifY target enzymes or receptors that bind ligands with a cis- conformation, as 
identified though the conformation of bound ligands in available receptor-ligand 
complexes. Having identified target receptors in this manner, ligands could be designed 
making use of the tetrazole-based isosteres to mimic the cis- confonnation observed in 
these solid-state structures of ligand-receptor complexes. For this, the structural and 
electronic features of the a-methylene tetrazoJe isostere (2.5.1) obtained from the solid 
state structures of the tetrazole-based dipeptide mimics, 5.4.1 and 7.2.1 (Chapter 7.2) 
should be utilised in the rational design oftetrazole-based peptidomimetic ligands. 
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CHAPTER NINE 
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9.1. GENERAL METHODS AND EXPERIMENTAL PROCEDURES 
Magnetic Resonance 
Proton detected NMR spectra were obtained on a Varian Unity 300 spectrometer 
operating at 300 MHz. Carbon detected NMR spectra were obtained on a Varian XL 300 
spectrometer operating at 75 MHz. Unless otherwise indicated, spectra were obtained at 
23 cc. Other NMR experiments described in this thesis viz, reverse-detected HMQC, 
HSQC and HMBC were all obtained on the Unity 300 spectrometer at 300 lVIHz. At 
various stages this instrument was fitted with either a Nalorac Z.spec 1\100300 3 mm 
Indirect Detection Probe or a Pulsed Field Gradient MLD driver with a 5 mm Indirect 
Detection Probe. Chemical shifts are reported in palts per million (ppm), on the 8 scale 
and are referenced to the appropriate solvent peaks; CDCb referenced to (CH3)4Si at 
8H=0 ppm (1H) and CDCb at 8c=77.0 ppm (l3C); CD30D referenced to CHD20D at 
DH=3.30 ppm CH) and CD30D at 8c=49.3 ppm (DC); DMSO-d6 referenced to 
(CD3)(CHD2)CO at 8H=2.l7 ppm (1H) and (CD3)2CO Dc=29.2 ppm (DC). IH NMR 
spectra were obtained using an acquisition time (At) of2 s. De NMR were obtained with 
an At of 0.878 and typically at delay (D!) of 0.5 s. HMQC experiments with the pulsed 
field gradient system were run with an At of 0.137 s, a Dl of 1.0 s, and !JcH=140 Hz. 
HMBC experiments were obtained with an At of 0.21 s (0.137 s with the pulsed field 
gradient system), a relaxation delay of 0.3 s, IJCH=140 Hz, and flJcH=8.3 Hz, unless 
otherwise stated. 
Spectroscopy 
Mass spectroscopy was preformed on a Kratos MS80 Mass Spectrometer 
operating at 4 kV. Various ionisation techniques were used including Electron Impact (EI 
MS) at 70 eVand chemical ionisation (el; C~IO). The softer ionisation technique of Fast 
Atom Bombardment (FAB MS) was used where necessary and was preformed with an 
Ion Tech ZNIIFN ion gun using Xe as the reagent gas, operating at 8 kV and 2 rnA with 
either NOBA (m-nitrobenzyl alcohol), m-b (magic bullet, 50% 
dithioerythritolldithiothreitol), or glycerol as the matrix. Alternatively, compounds were 
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analysed by Electrospray (ES MS) by a Micromass LCT probe at 150 DC, operating at 
3200 V, with an acetonitrile/water (1: 1) carrier, from a source at 80 DC, 
Infra-Red Spectroscopy 
Infra-red (IR) spectra were obtained usmg a Shimadzu 820lPC series FTIR 
interfaced with a Intel 486 PC running Shimadzu's HyperIR® software. Spectra were run 
in a solution of CHCb, or as plates. 
Melting Points 
Melting points were taken on an Electrothermal apparatus, and are uncorrected. 
Optical Rotations 
Optical rotations were measured on a JASCO J-20C recording spectropolarimeter 
or a Perkin Elmer polarimeter Model 341, both with a 10 mm path length. The [U]D20 
values are given in units ono·1 deg cmz gOt, with the concentration given in gcm-3. 
Reagents and Solvents 
Unless otherwise indicated, all reactions were conducted in flame-dried 
glassware, under an atmosphere of dry Nz or Ar. Solvents and reagents used in reactions 
were purified according to well established procedures. l Tetrahydrofuran (THF), ether 
and benzene were distilled from sodium benzophenone ketyl immediately prior to use. 
Dichloromethane (CHzClz), chloroform (CHCb) were distilled from calcium hydride. 
Triethylamine (Et3N), Hunig's base (N,N-diisopropyl-N-ethylamine, DIPEA), were 
distilled fresh from potassium hydroxide. Methanol and ethanol were distilled from 
iodine-magnesium turnings and stored over 4 A molecular sieves under N2 or N. N,N-
Dimethylformamide (DMF) and acetonitrile (CH3CN), were dried over 4 A molecular 
sieves under Nz or Organolithium reagents were titrated before use by the method of 
Watson and Eastham? 
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Chromatography 
Analytical thin layer chromatography (TLC) was conducted on aluminium-backed 
Merck Kieselgel KG60Fz54 silica plates. Visualisation was by short-wave ultraviolet 
light. Flash chromatography was perfomed on Merck Silica 60 following the guidelines 
of Still et a/.3 Plate layer chromatography (PLC) was performed on aluminium~backed 
Merck Kieselgel KG60Fz54 silica plates, visualised by short~wave ultraviolet light. 
Preparative high pressure liquid chromatography (HPLC) was perfomed on a Philips 
PU41 00 HPLC, fitted with a PU4120 diode alTaY detector. Inj ections were made to either 
a Rainin RP-ClS analytical or RP-C18 preparative column. 
General Procedure Preparation of esters and amides via Wolf rearrangement4 
To a solution of diazoketone (1.0 eq.) in dry THF (0.15 M), in a flame-dried flask 
under Nz, was added the appropriate nucleophile (eg. benzyl alcohol, or methanol) (1.3 
eq.) at rt. A solution of silver benzoate (catalytic, 0.3 eq.) in triethylamine (6.6 eg.) was 
added dropwise to the stirred solution and the reaction was stirred for a further 2 h at rt. 
Volatiles were removed under reduced pressure and the resulting residue was taken up in 
ethyl acetate, washed with 10% aqueous HCI (2 x 10 mL), saturated aqueous NaRC03 (2 
x 10 mL), saturated aqueous NaCI (2 x 10 mL), dried (MgS04), filtered and evaporated. 
See experimental for details. 
General Procedure B: Amino acid homologation with comittant peptide coupling5 
A solution of amino acid ester hydrochloride or para~toluenesulphonate salt (1.5 
eq.) and triethylamine (2.0 eq.) in dry acetonitrile (0.07 M) was prepared in a flame-dried 
quartz reaction vessel (100 mL capacity) under Nz. A solution of a~diazoketone (1.0 eq.) 
in dry acetonitrile (0.15 M) was prepared in a flame-dried flask under Nz and then 
transferred, via syringe, to the quartz reaction vessel. The reaction vessel was irradiated at 
300 nm under N2 for h or until the evolution ofNz had ceased. Solvent was removed to 
114 ofthe original volume, diluted with ethyl acetate and washed with 1 M aqueous citric 
acid (2 x 100 mL), saturated aqueous NaCI (2 x 100 mL), dried (MgS04), filtered and 
evaporated. See experimental for details. 
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Procedure Tetrazole formation6,7 
A solution of phosphorous pentachloride (1.2 eq.) in dry CHCh (0.12 M) was 
prepared in a flame-dried flask under Nz. Freshly distilled quinoline (2.4 eq.) was added 
dropwise to the stirred solution at rt. The white precipitate that formed was stirred for 20 
min at rt, while a solution of dipeptide (1.0 eq.) in dry CHCh (0.08 M) was prepared in a 
flame-dried flask under N2. The reaction was cooled in an ice-water bath, prior to the 
dropwise addition of the dipeptide over 30 min. After 30 min at <10 DC the ice-water bath 
was removed and a further portion of phosphorous pentachloride (0.2 eq.) was added. 
The reaction was stirred at rt for 2.5 h then a dry (Na2S04) CHCb or benzene solution of 
hydrazoic acid (30-50 eq.) was added. The reaction was stirred at rt for 48 h, then 
evaporated and redissolved in ethyl acetate (20-50 mL). The organic phase was washed 
with aqueous 2 M HCl (2 x 50 mL), water (2 x 50 mL) and saturated aqueous NaCI (2 x 
50 mL), dried (MgS04), filtered and evaporated. See experimental for detail. 
General Procedure D: Acidic cleavage of N-benzyloxycal'bonyI (Z) pl'otecting 
groupS 
The peptide (1.0 eq.) was dissolved in concentrated acetic acid (2.0 M) and the 
solution treated with 50% hydrobromic acid/acetic acid (0.4 M). The reaction was stirred 
at rt for 30 min, then ether (45 mL), precooled at DO C was added with vigorous stirring. 
Petroleum ether (20 mL) was added and the reaction stood at 0 DC for 30 min. The 
solvent was decanted off and the brown residue washed with ether/petroleum ether (1: 1,3 
x 30 mL). Solvent was removed under vacuum and the brown residue dried in vacuo, 
over KOH for 24 h. The hydromide salts were used without further purification. 
experimental for detail. 
E: Catalytic hydrogenation benzyl ester (OBn) protecting 
A stirred solution of the benzyl ester (1.0 eq.) and acetic acid (6.2 M) in ethyl 
acetate/ethanol (4:1, 50 mL) was hydrogenated at rt in the presence of 10% palladium on 
carbon (390 mgmmor1). The mixture was filtered through a plug of celite, evaporated 
and redissolved in aqueous 1 M NaHC03. The aqueous phase was washed with ethyl 
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acetate (20 mL) and then acidified to pH=2 with solid sodium bisulphite. The free acid 
was extracted with ethyl acetate (4 x 50 mL), dried (MgS04), evaporated and the solid 
dried in vacuo over for 24 h. The free acids were used without further purification. 
See experimental for detail. 
General Procedure Acidic cleavage of N-tert-butyloxycarbonyl (Boc) protecting 
grm.rplO 
The protected peptide (1.0 eq.) was dissolved in 95% aqueous trifluoroacetic acid 
(1-5 mL) and stirred slowly at rt for 30 min. Solvent was removed by rotary evaporation 
and the brown residue washed with petroleum ether (3 x 50 mL). The residue was dried 
in vacuo for 24 hover KOH and used without further purification. 
General G: Peptide coupling benzotriozo-l-
yloxytris( dimethylamino )phosphonium hexafluorophosphate reagant!! 
A solution of the amine hydrobromide or hydrochloride (1.0 eq.), carboxylic acid 
(1.1 eq.), BOP reagant (1.1 eq.) and dry DMF (100 ~L), in dry CH2Ch (0.15 M) was 
prepared in a flame-dried flask under N2. The solution was stirred at rt and triethylamine 
(3.0 eq.) was added dropwise. The reaction was stirred for 1 h, prior to the addition of a 
further portion of triethylamine (1.0 eq.). The reaction stirred at rt for 18 h and was 
quenched with saturated aqueous NaCl (5 mL). The reaction was diluted with ethyl 
acetate (100 mL), separated and washed with 2 M aqueous HCl (3 x 100 mL), 2 M 
aqueous NaHC03 (3 x 100 mL) and saturated aqueous NaCl (2 x 100 mL). The solution 
was dried (MgS04), filtered and evaporated. See experimental for detail. 
General pl'ocedure Peptide coupling 1-(3-dimethylaminopropyl)-3-
ethylcarbodiimide hydnH!hlodde (EDCI)12 
To a solution of carboxylic acid (1.0 eq.) and (1.5 eq.) in dry DMF (0.2 M) 
in a flame~dried flask under N2, was added amine hydrochloride or hydrobromide (1.1 
eq.) as a solution in dry DMF (0.2 M). The reaction was cooled to 0 °C with stirring and 
EDCI (1.5 eq.), as a solution in dry DMF (0.5 M) was added dropwise. The reaction was 
stirred at 0 for 1 h, then for 24 h at rt. The reaction mixture was diluted with ethyl 
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acetate (20 mL), and washed with saturated aqueous NaHC03 (3 x 20 mL), 1 M aqueous 
Hel (3x 20 mL) and saturated aqueous NaCl (2 x 25 mL). The organic phase was dried 
(MgS04), filtered and evaporated. See experimental for detail. 
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SYl\TTHESIS OF 3-AMINO-2-HYDROXY-4-PHENYLBUTANOIC ACID 
9.2.1. SYNTHESIS BY FUNCTIONALISATION OF N-Z-L-PHENYLALANINAL 
3.2.3, -Method A 
(2S)-N-(N,O-dimethylhydroxyl)-2-(N-benzyloxycarbonylamin0 )-3-
en)'lp.'opanl:amlide, 3.1.2513 
llrnf;H --_. J~LH' 
o 0 
3.1.25 
N-Z-L-Phenylalanine (500 mg, 1.6 mmol) was coupled to Weinreb amme 
hydrochloride14 (N,O-dimethylhydroxylamine hydrochloride, 180 mg, 1.84 mmol) with 
BOP reagant (739 mg, 1.67 mmol), in dry CH2Ch (5 mL), according to general procedure 
G. Purification of the crude reaction mixture by flash column chromatography (50% ethyl 
acetate/petroleum ether) gave amide, 3.1.25 (495 mg, 86%). 
IH NMR (300 MHz, CDCb) 02.91-3.08 (2H, m, Phe-p-H2), 3.18 (3H, s, NCH3), 
3.68 (3H, s, OCH3), 5.02 (IH, m, Phe-a-H), 5.06 (2H, AB system, oA=5.03, 08=5.09, d, 
Z-H2)' 5.41 (IH, d, J=7.8 Hz, NH), 7.15-7.37 (lOH, m, ArH). 
Preparation of (2S)-2-(N-benzyloxycarbonylamino )-3-phenylpropanal, 
o 0 ZIINL~-j"ocH,---' ZHN( H 
o 0 
3.1.25 3.2.3 
solution of amide, 3.1.25 (760 mg, 2.23 mmol) in dry (15 mL) was added 
dropwise to a solution oflithium aluminum hydride (100 mg, 2.67 mmo) in dry (5 
mL) at -50°C, over 5 min. After stirring at -50 °C for 10 min the mixture was allowed to 
warm to 0 °C over 20 min, before recooling to -50°c' Ethyl acetate (2 mL) was slowly 
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added to decompose remaining lithium aluminum hydride and the mixture was stirred at 
o DC for 20 min. The mixture was filtered and evaporated. The residue was re-dissolved 
in ethyl acetate (10 mL) washed with ice-cooled aqueous 1 M HCI (5 mL), aqueous 10% 
NaHC03 (5 mL) and water (5 mL), dried (MgS04), filtered and evaporated to give 
aldehyde, (484 mg, 77%). 
NMR (300 MHz, CDCh) 0 3.14 (2H, d, J=6.4 Hz, Phe-fl-H2), 5.51 (1H, m, 
Phe-a-H), 5.11 (2R, s, Z-R2), 5.33 (lR, d, J=6.3 NH), 7.14-7.37 (lOR, m, ArH), 9.64 
(lR, s, CRO). 
Synthesis of N-Z-L-Phenylalaninal, -Method B 
Preparation of (2S)-N-(3,5-dimethylpyrazole )-2-(N-benzyloxycaz'bonylamino )-3-
phenylpropanamide, 3.2.1 15 
3.2.1 
To a solution of N-Z-L-phenylalanine (5.06 g, 16.9 mmol) and 3,5-
dimethylpyrazole (1.93 g, 20.3 mmol) in CHCh (250 mL) at -10°C, was added 
dicyclohexylcarbodiimide (DCC, 3.59 g, 20.3 mmol) and the mixture was stirred for 1 h 
before warming to rt and stirring for a further 48 h. The insoluble urea was removed by 
filtration and solvent removed by evaporation. The residue was redissolved in ethyl 
acetate (50 mL), washed with aqueous 2 M HCI (10 mL) and water (10 mL), dried 
(MgS04), filtered and evaporated. A single recrystallisation from ethyl acetate/petroleum 
ether gave amide, as fine white needles (5.44 g, 85%). 
IR NMR (300 MHz, CDCh) 02.77 (3R, s, CH3), 2.48 (3R, s, CH3), 3.21 AB 
system, oA=3.09, 08=3.33, dd, 
88 =5.10, d, J=12.2 Hz, 
7.33 (lOR, m, ArR). 
1, 13.8 Phe-fl-Hz), 5.07 (2R, AB system, 8A=5.05, 
5.47 (IR, d, J=8.8 Hz, NH), 5.99 (lR, s, PyA-H), 7.06-
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Prepanation of (2S)~2-(N-benzyloxycal'bonylamino )-3-phenylpl'opanal, 3.2.3, and 
(2S)-2-(N-benzyloxycal'bonylamino )d3-phenylpl'opanol, 
e 'ZHN ~H 
0 
3.2.1 . 3.2.3 3.2.2 
A solution of amide, 3.2.1 (5.44 g, 14.4 mmol) in dIY THF (150 mL) was added 
dropwise to a solution of lithium aluminum hydride (5.08 mg, 17.0 mmol) in dry THF 
(100 mL) at -50°C over 5 min. After stirring at -50 °C for 10 min the mixture was 
allowed to warm to 0 °C over 20 min, before recooling to -50°C. Ethyl acetate (80 mL) 
was slowly added to decompose remaining lithium aluminum hydride and the mixture 
was stirred at 0 °C for 20 min. The mixture was filtered and evaporated. The residue was 
redissolved in ethyl acetate (150 mL), washed with ice-cooled aqueous 1 M HCI (150 
mL), aqueous 10% NaHC03 (150 mL) and water (150 mL), dried (MgS04), filtered and 
evaporated. Purification of the crude reaction mixture by flash column chromatography 
(30% ethyl acetate/petroleum ether) gave aldehyde, (1.99 g, 49%). 
Spectral data for aldehyde, 3.2.3, was identical to that already reported (see 
Method A). 
Further elution gave alcohol, 3.2.2 (1.19 g, 29%). 
IH NMR (300 MHz, CDCh) 02.86 (2H, d, Phe-y-Hz), 3.63 (2H, AB 
system, oA=3.58, o[l=3.68, dd, J=4.9, 1l.2 Hz, Phe-a-Hz), 3.94 (lH, m, Phe-j3-H), 5.00 
(lH, d, J=7.3 Hz, NH), 5.07 (2H, s, Z-Hz), 7.18-7.93 (lOH, m, ArH). 
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lPrepal'ation of (2S)-2-(N-benzyloxyc~U'bony]amino )-3-phenylpropanal, 
c ZHN =--OH e • ZHN ~H 
0 
3.2.2 3.2.3 
To a stirred solution of Dess-Martin periodinane16•17 (774 mg, 1.83 mmol) in 
CHzCh (5 mL) was added a solution of alcohol, 3.2.2 (476 mg, 1.67 mmol) in CHzCh (5 
mL) and the mixture was stirred at rt for 1 h. Ether (25 mL) and a solution of 
NaZSZ03.5HzO (2 g, 8 mmol) in saturated aqueous NaHC03 (20 mL) were added and the 
mixture was stirred at rt for a further 15 min. The organic layer was separated and 
washed with saturated aqueous NaHC03 (5 mL), water (5 mL) and saturated aqueous 
NaCI (5 mL), dried (MgS04), filtered and evaporated to give aldehyde, (468 mg, 
98%). 
Spectral data was identical to that already reported for this compound (see 
Method A). 
Preparation of (2RS,3S)-3-(N-benzyloxycarbonylamino)-2-hydroxy-4-
phellylbutanonitl'ile, 3.2.4a and 3.2.4b18 
ZHNe ---.... ZHNeN 
o OH 
3.2.3 3.2.4a (2R) 
3.2.4b (2S) 
a solution of aldehyde, 3.2.3 (484 mg, 1 mmol) in ethyl acetate (10 mL) 
was added a solution of potassium cyanide (143 mg, 1 mmol) in water (10 mL) and 
the mixture was stirred vigorously at rt for 18 h. organic layer was separated and 
washed with water (5 mL), dried (MgS04), filter and evaporated to yield a mixture of 
epimeric cyanohydrins, 3.2.4a and 3.2.4b (1:1 by NMR, 408 mg, 76%). 
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(2R,3S)-3.2.4a; NMR (300 CDCb) 8 2.85 d, J=7.8 Hz, hPhe-y-H2), 
4.17 (lH, m, hPhe-f3-H), 4.42 (1H, d, .0 Hz, hPhe-a-H), 5.00 (2H, s, 5.08 (lH, 
d, J=8.8 NH), 7.1 0-7.31 (1 m, ArH). 
(2S,3S)-3.2.4b; NMR(300 MHz, CDC h) 8 2.95 (2H, m, hPhe-y-H2), 3.96 
m, hPhe-f3-H), 4.49 (IH, d, J=3.9 Hz, hPhe-a-H), 5.01 (2H, s, Z-H2), 5.18 (IH, d, J=7.9, 
NH), 7.10-7.31 (lOH, m, ArH). 
Preparation of (2R,3S) and (2S,3S)-3-(N-benzyloxyc31'bonylamino )-2-hyda'oxy-4-
phenylbutanoic acid methyl esters [N-Z-(2R,3S)-AHPBA methyl ester, 
Z-(2S,3S)-AHPBA methyl ester, 3.2.5b]1l 
nme ----. nm80CH' + ZHNQocH, 
OH OH Oll 
3.2.4a(2R) 
3.2.4b (28) 
3.2.Sa (2R) 3.2.Sb (28) 
andN-
The cyanohydrins, 3.2.4, as an epimeric mixture (3.2.4a and 1:1 by IH 
NMR, 1.78 g, 5.7 mmol) were dissolved in pre-cooled (0 DC) dry ether/methanol (3: 1, 80 
mL), previously saturated with gaseous HCI. The reaction was stirred at 5 DC for 24 h, 
prior to the addition of ice-cooled water (15 mL), added at such a rate that the 
temperature was maintained below 10 DC, The mixture was stirred at 5 DC for a further 48 
h. Solvent was removed to 1/3 of the volume and extracted with CH2CIz (3 x 10 mL). 
Combined organic extracts were washed with water (5 mL) and saturated aqueous NaCl. 
(5 mL), dried (MgS04), filtered and evaporated. The crude reaction products were 
separated by flash column chromatography (30% ethyl acetate/petroleum ether) to give 
methyl 3.2.5a and 
N-Z-(2R,3S)-AHPBA methyl ester, (567 mg, 29%); mp 95-96 DC (lit. 19 mp 
94-95 0C); [o,]D20-68° (c=0.0036, methanol) (lit. 19 [a]D20 -82° c=0.83, methanol). 
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iR NMR (300 CDCh) 6 2.93 (2R, m, hPhe-y-R2), 3.69 (3R, 5, OCR3), 4.08 
(IR, bs, hPhe-a-H), (IR, m, hPhe-13-R), 5.03 (2R, s, 5.16 (lR, d, J=9.9 Rz, 
NH), 7.20-7.36 (lOR, m, ArR), 
I3C NMR (75 CDCb) 6 38.22 (hPhe-y-CRz), 52.83 (OCR3), 54.69 (hPhe-13-
CH), 66.72 (Z-CHz), 70,09 (hPhe-a-CH), 126.69,127.88,128.03,128.44,128.58,129.34 
(ArCH), 136.34,137.24 (ArC), 155.67 (Z-CO), 174.08 (COOCH3). 
TLC (analytical, 30% ethyl acetate/petroleum ether) RFO.20; IR (CDCh, em-i) 
3529, 3435, 3033, 2956, 2252, 1732, 1508, 1456, 1442, 1220; MS 254.1189 
CUJl16N02 (M-C3H503l requires mlz 254.1181, 252.0879 C12HI4N05 (M-C7H/) 
requires mlz 252.0872; MS (reI. intensity) 91(100), 108(70), 143(15),203(20). 
N-Z-(2S,3S)-AHPBA methyl ester, 3.2.5b; (584 mg, 30%); mp 121-122 °C (lit. 19 
mp 121-122 °C); [a]Dzo (c=O.013, methanol) (lit. I9 [a]D20 _6° c=0.85, methanol). 
iH NMR (300 MHz, CDCh) 6 2.80 (2H, m, hPhe-y-H2), 3.55 (3H, s, OCH3), 4.34 
(IH, bs, hPhe-a-H), 4.37 (IR, m, hPhe-13-H), 5.03 (2H,5, 5.13 (IR, d, J=9.0 Hz, 
NH), 7.17-7.32 (lOR, m, ArR). 
l3C NMR (75 MHz, CDCb) 635.58 (hPhe-y-CH2), 52.54 (OCH3), 54.61 (hPhe-13-
eH), 66.76 (Z-CRz), 7 (hPhe-ct-CR), 126.64, 127.96, 128.04, 128.35, 128.43, 129.40 
(ArCH), 136.27, 136.80 (ArC), 155.87 (Z-CO), 172.95 (COOCH3). 
TLC (analytical, 30% ethyl acetate/petroleum ether) RF0.12; IR (CDCb, em-I) 
3531, 3436, 3031,2956,2252, 1720, 1510, 1456, 1440, 1220; EI MS 254.1189 
CHiH16N02 (M-C3R503l requires mlz 254.1181, 252.0876 C12H14N05 (M-C7R7l 
requires mlz 252.0872; MS mlz (reI. intensity) 91(100),108(60), 143(5),203(25)' 
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9.2.2. PREPARAIlON OF (2R,3S) AND (2S,3S)-3-(N-BENZYLOXYCARBONYLAMINO)-2-
HYDROXY -4-PHENYLBUTANOIC ACID [N-Z-(2R,3S)-AHPBA, 3.1.1 A AND N-Z-(2S,3S)-
AHPBA,3.1.lB]l1 
8' ZHN ~~OH 
OR 
3.1.1a (2R) 
Q ZJm~OH 
OR 
3.1.1b (2S) 
The methyl esters, (N-Z-(2R,3S)-AHPBA methyl ester "' .......... or N-Z-(2S,3S)-
AHPBA methyl ester (1.0 eq.) and sodium hydroxide (1.4 eq.) were dissolved in 
methanol/water (80%, 5 mL) and the mixture stirred at rt for 2 h. The methanol was 
evaporated under reduced pressure and the aqueous layer acidified to pH=2 with 2 M 
aqueous HCI. The white precipitate was extracted with ethyl acetate (3 x 10 mL), dried 
(MgS04), filtered and evaporated. The white solid was dried in vacuo over KOH for 24 h, 
to give acids, 3.1.1a or 3.l.lh. 
N-Z-(2R,3S)-AHPBA, 3.1.1a (88%); IH NMR (300 MHz, DMSO-d6) 02.92 (2R, 
m, hPhe-y-Hz), 3.93 (lH, bs, hPhe-a-H), 4.08 (lH, m, hPhe-p-H), 4.95 (2H, AB system, 
oA=4.92, oB=4.98, d, J=12.6 Hz, Z-Hz), 7.12-7.36 (lOR, m, ArH). 
DC NMR (75 MHz, DMSO-d6) 037.44 (hPhe-y-CHz), .44 (hPhe-p-CH), 65.17 
(Z-CH2), 70.74 (hPhe-a-CH), 126.31, 127.46, 127.75, 128.36, 128.41,129.30 (ArCH), 
137.26, 139.70 (ArC), 155.67 (Z-CO), 174.09 (hPhe-COOH). 
EI MS 1182 C16H16N02 (M-GJI303"1 requires mlz 1181; MS mlz(rel. 
intensity) 1 (20), 108 (50), 91 (100),51 (50). 
N-Z-(2S,3S)-AHPBA, 3.1.1b; (88%); IH NMR (300 DMSO-d6) 02.68 (2H, 
m, hPhe-y-H2), 3.99 (1 m, hPhe-p-H), 4.02 (lH, s, hPhe-a-H), 4.87 (2H, AB system, 
0A=4.88, d, J=6.9 Hz, Z-H2) 7.l8-7.34 (10H, m, ArH). 
DC NMR (DMSO-d6) 0 38.75 (hPhe-y-CHz), 55.38 (hPhe-p-CH), 64.92 (Z-CHz), 
72.77 (hPhe-a-CH), 126.02, 127.35, 127.64, 128.12,128.33,129.13 (ArCH), 139.13 (d, 
ArCH), 155.63 (Z-CO), 174.05 (hPhe-COOH). 
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ElMS 254.1187 C16H16N02 (M-C2H30 3+) requires mlz 1181; ElMS mlz (reI. 
intensity) 143 (20), 108 (50),91 (100),51 (30). 
9.2.3. SYNTHESIS BY AMINOHYDROXYLATION OF (E)-4-PHENYL-2-BUTENOIC ACID 
METHYL ESTER 
Preparation of (E)-4-phenyl-2-butenoic acid methyl ester, 
~H V6 + Ph3P-9](OCH3 ____ '" ~OCH3 o V 
3.3.5 
To a solution of methyl(triphenylphosphoranylidene)acetate (1.1 eq., 9.41 g,28.2 
mmol) in dry CH2Ch (50 mL), was added phenylacetaldehyde (3.08 g, 25.6 mmol, 3.0 
rnL) and the reaction stirred at rt for 16 h. The mixture was diluted with saturated 
aqueous ~CI (50 rnL) and the layers were separated. The organic layer was washed 
with saturated aqueous NaCI (3 x 50 mL), dried (MgS04), filtered and evaporated. The 
resulting white solid was triturated with ether/petroleum ether (1 :10, 10 rnL) and filtered 
to remove the white solid. Solvent was removed from the filtrate to give crude methyl 
esters, E-3.3.5 and (9: 1). The methyl esters were separated by flash column 
chromatography (5% ethyl acetate/petroleum ether) to give the desired product, 
as a yellow oil (2.42 54%). 
IH NMR (300 IvIHz, CDCh) b 3.51 (2R, AB system, bA=3.50, bB=3.52, d, J=0.09 
Hz, y-R2), 3.71 (3H, s, OCH3), 5.81 (IH, dt, J=1.5, 15.6 Hz, P-H), 7.11 (lR, dt, J=6.9, 
15.6 Hz, a-H), 7.15-7.33 (5R, m, ArH). 
TLC (analytical, 5% ethyl acetate/petroleum ether) RFO.32; MS 176.0837 
(M+) CllH1 20 2 requires mlz 176.0837; EI MS (reI. intensity) 176.1 (50), 144 (30), 
117 (100), 91 (35). 
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Prepan'ation of (2R,3S)~3-(N-bei!lzyloxyca .. bonylamino )-2-hydl'oxy-4-phenylbutanoic 
acid methyl [N-Z-(2R,3S)-AlWBA methyl ester, 3.2.5a]21 
0~~OCH3 
~~ 0 
:3.3.5 
o 
-----. ZHN1)OCH, 
OH 
3.2.5a 
A solution of sodium hydroxide (122 mg, 3.05 mmol) in water (8.5 mL), was 
prepared in a single-necked round bottom flask. Potassium osmate dihydrate (14.7 mg, 
0.04 mmol) was dissolved in a vial with a portion of the aqueous sodium hydroxide 
solution (0.5 mL). Benzyl carbamate (469 mg, 3.1 mmol) was dissolved in acetonitrile (4 
mL) and cooled to 0 °C in an ice-bath. The fume hood was darkened and freshly prepared 
ten-butyl hypochlorite (346 ~, 3.05 mmol) was added dropwise over 2 min. In another 
flask hydroquinidine l,4-phthalazinediyl diether [(DHQ2)(PHAL), 39 mg, 0.05 mmol), 
and aryl olefin, (E)-3.3.5 (190 mg, 1.0 mmol), were dissolved in acetonitrile (4.5 mL). 
This mixture was transferred to the aqueous sodium hydroxide solution. The pink osmate 
solution was transferred to the mixture and the reaction was stirred vigorously at rt for 2 
h. The reaction was quenched with sodium sulphite (2.0 g) and the reaction mixture 
separated. The aqueous layer was extracted with ethyl acetate (3 x 10 mL). The combined 
organic phases were washed with saturated aqueous NaCI (3 x mL), dried (MgS04), 
filtered and evaporated. Purification of the crude reaction mixture by flash column 
chromatography (30% ethyl acetate/petroleum ether) gave methyl ester 3.2.5a «5%), 
contaminated with benzyl carbamate. 
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9.2.4. SYNTHESIS BY ENOLATE HYDROXYLATION OF N-Z'£-HoMOPHENYLALANINE 
METHYL ESTER 
Preparation of diazokeione, 
A) A) Z>rn~~H ---' Z>rn~' 
o 0 
3.4.1 
To a stirred solution ofN-Z-L-phenylalanine (2.92 9.7 mmol) in dry THF/ether 
(1:1, 50 mL) was added triethylamine (1.0 eq., 0.98 g, 9.7 mmot, 1.36 mL) and ethyl 
chloroformate (1.0 eq., 1.06 g, 9.7 mmol, 0.93 mL) at -20°C. After 15 min at -20 °C the 
mixed anhydride was added to a dried (Na2S04) ethereal solution of diazomethane23 (5.0 
eq.). The mixture was stirred at -15°C for 1 h, then left to stand at 5 °C overnight. 
Excess diazomethane was destroyed by the dropwise addition of acetic acid [caution] 
until the evolution of N2 ceased. The mixture was washed with saturated aqueous 
NaHC03 (2 x 30 mL), saturated aqueous NaCI (2 x 30 mL), dried (MgS04), filtered and 
evaporated. Flash column chromatography (30% ethyl acetate/petroleum ether) of the 
crude product and a single recrystallisation (ethyl acetate/petroleum ether) gave a-
diazoketone, 3.4.1 (2.24 g, 71 %). mp 85-86 °C (lit.22 mp 84-85 °C); [a]D20 -28 0 (c=0.005, 
methanol). 
IH NMR (300 MHz, CDCb) () 3.28 (2H, d, J=6.9 Hz, Phe-13-H2), 4.48 (lH, m, 
Pheca-H), 5.06 (IH, s, Z-H2), 5.20 (IH, s, CHN2), 5.47 (d, J=7.5 Hz, NH), 7.16-7.39 
(10H, ill, ArR). 
l3C NMR (75 MHz, CDC b) 8 38.30 (Phe-13-CH2), 54.53 (CHN2), 58.76 (Phe-a-
CH), 66.91 (Z-CH2), 126.97, 127.93, 128.12, 128.44, 128.57, 129.21 (ArCH), 1 .94, 
136.05 (ArC), 155.66 (Z-CO), 192.78 (Phe-CO). 
TLC (analytical, 30% ethyl acetate/petroleum ether) RF0.44; IR (CDCb, em-I) 
2124, 1730, 1635; MS 324.1355 CaH17N303 (.MIt) requires mlz 324.1348. 
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PI'eparation of 
4 ester, 3.4.2 
Z~eN' o 
3.4.1 
B ___ " Z~ ~D DCH, 
3.4.2 
162 
methyl 
A solution of diazoketone, 3.4.1 (1.0 eq., 3.0 g, 9.6 mmol) was reacted with dry 
methanol (1.3 eq., 0.4 g, 13.0 mmol, 0.5 mL) in dry THF (100 mL) in the presence of 
silver benzoate (0.1 eq., 0.25 g, 1.0 mmol) and triethylamine (2.9 eq., 2.9 g, 29.0 mmol, 
4.0 mL) according to general procedure A. The crude reaction mixture was purified by 
flash column chromatography (10% ethyl acetate/petroleum ether) and a single 
recrystallisation (ethyl acetate/petroleum ether) to give methyl ester, 3.4.2 as a pale solid 
(2.7 g, 84%). mp °c (1it.4 mp, 56-57°C). 
IH NMR (300 MHz, CDCh) & 2.44 (2H, m, hPhe-y-Hz), 2.83 (2H, m, hPhe-a,-
H2), 3.60 (3H, s, OCH3), 4.16 (IH, m, hPhe-j3-H), 5.00 (2H, s, Z-H2), 5.23 (1H, d, J=9.0, 
NH), 7.08-7.31 (lOH, m, ArR). 
DC NMR (75 MHz, CDCb) & 37.29 (hPhe-a.-CH2), 40.19 (hPhe-y-CH2), 66.60 
(Z-CH2), 126.69, 127.99, 128.05, 128.47, 128.55, 129.30 (ArCH), 136.48, 137.48 (ArC), 
155.58 (Z-CO), 171.92 (hPhe-COOCH3). 
TLC (analytical, 40% ethyl acetate/petroleum ether) RFO.65; IR (CDCh, em-I) 
3435,2962, 1724, 1508, 1438, 1220; EI MS 296.1285 CliHlSN03 (M-OCH/) 
requires mlz 296.1 236.0922 C12Hl~04 (M-PhCH/) requires mlz 236.0926; EI MS 
mlz (reI. intensity) 176 (50), 145 (20), 117 (30) 91 (l00). 
PreparatilOn IOf oXlOdipel'OxymlOlybdenum(pyridine)(hexamethylphosphol'ic triamide) 
(MOOPH)24 
MoOPH was freshly prepared according to the procedure of Vedejs et a1. 24 
Molybdenum oxide (30 g, 0.2 mmol) and 30% aqueous hydrogen peroxide (150 mL) 
were stirred by a mechanical paddle in a 500 mL three-necked flask equipped with an 
internal thermometer. The mixture was heated in a 40°C oil bath, until the internal 
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temperature reached At this time an exothernlic reaction was initiated. The oil bath 
was removed and replaced with a water bath to maintain the internal temperature below 
40 0e,25 The mixture was then stirred at 40°C for 3.5 h to give a yellow solution, with a 
small amount of white particulate. The solution was cooled to rt and filtered through a 
plug of celite. The resulting yellow filtrate was cooled in an ice bath to 10°C and 
hexamethylphosphoric triamide (HMPA) (37.3 g, 0.21 mmol) was added dropwise to the 
stirred filtrate over 5 min. Stirring was continued for 15 min at 10 to give a yellow 
crystalline precipitate which was filtered and air dried using a vacuum aspirator for 30 
min. The yellow solid was recrystallised from methanol and the resulting yellow needles 
were filtered and washed with cold methanol to gIve 
oxodiperoxymolybdenum(aqua)(hexamethylphosphoric triamide). The crystalline 
product was dried in vacuo over phosphorous pentoxide for 24 h to give 
oxodiperoxymolybdenum(hexamethylphosphoric triamide) as a hygroscopic yellow 
solid. A sample of this material, (36 g, 0.10 mol) was dissolved in dry THF (150 mL), 
and the solution filtered through a celite plug to remove any particulate. The filtrate, 
collected in a Buchner funnel equipped with a magnetic stirrer, was placed in a 20°C 
water bath. Dry pyridine (8.0 g, 0.10 mol) was added portion-wise to the stirred solution 
over 10 min to give a yellow crystalline precipitate. The product was filtered off, washed 
with dry (25 mL), dry ether (200 mL) and finally dried in vacuo. 
Oxodiperoxymolybdenum(pyridine )(hexamethylphosphoric triamide) was thus obtained 
as a finely divided crystalline yellow solid (35 g); mp Ill-112°C (lit. 24 mp 103-105 Qe). 
Prepal'ation of (2R,3S) and (2S,3S)-3-(N-benzyloxycarbonylamino )-2-hydroxy-4-
phenylbutanoic acid methyl esters [N-Z-(lR,3S)-AHPBA methyl ester, 3.2.5a and N-
methyl ester, 3.2.5b]26 
B B (1 ZHN -OOCH, • ZHN ~O OCH, + ZHN -'lOCH' 
em OR 
3.4.2 3.2.5n (2R) 3.2.5b (2S) 
CHAPTER NINE-SYNTHESIS OF 3 -AMINO-2-HYDROXY-4-PHENYLBUT A.."IOIC ACID 164 
A solution ofKHMDS (6.0 eq., 0.5 M in toluene, mmol, mL) in dry THF 
(2 mL) was stirred and cooled to -78°C. A solution of methyl (140 mg, 0.43 
mmol) in dry THF (4 mL) was prepared and added dropwise to the solution ofKHMDS. 
The reaction mixture was warmed to -25°C, then cooled back down to -78 °C prior to 
the addition of MoOPH (1.5 eq., 360 mg, 0.64 mmol) as a single portion. The reaction 
mixture was warmed to -60°C and stirred for 3 h. The reaction was quenched with 
saturated aqueous Na2S03 (1 mL) and saturated aqueous NatCI (1 mL), wanned to rtand 
stirred until dissolution of the white solids. The aqueous layer was extracted with THF (3 
x 10 mL) and the combined organic layers were washed with 10% aqueous HCI/saturated 
aqueous NaCl (1:1, 2 x 10 mL), 2% aqueous Na2C03 (2 x 10 mL), saturated aqueous 
NaCl (2 x 10 mL) and dried (MgS04)' After filtration, solvent was removed under 
reduced pressure to a yellow oil. The crude reaction mixture was purified by flash 
column chromatography (30% ethyl acetate/petroleum ether) to give unreacted starting 
material methyl ester, 3.4.2 (52 mg, 33%) and product methyl esters, N-Z-(2R,3S)-
AHPBA methyl ester 3.2.5a (34 mg, 35%) and N-Z-(2S,3S)-AHPBA methyl ester 3,2.5b 
(32%, 31 mg). 
Spectral data was identical to that already reported for these compounds. 
Preparation of (3S)-3-(N-benzyloxycal'bonylamino )-4-phenylbntanoic acid benzyl 
ester 
Diazoketone 
P ZJll<~N' 
o 
3.4.1 
(100 mg, 0.31 mmol) in dry (2 mL) was reacted with 
benzyl alcohol (1.3 eq., 43 mg, 0.40 mmol, 42 ilL) in the presence of silver benzoate (0.3 
eq., 21mg, 0.09 mmol) and triethylamine (6.6 eq., 206 mg, 2.04 mmol, 285 ilL) 
according to general procedure A The crude reaction mixture was purified by flash 
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column chromatography (10% ethyl acetate/petroleum ether) and a single 
recrystallisation (ethyl acetate/petroleum ether) to give the benzyl ester as a pale solid 
(104 mg, 83%). 
IH NMR (300 CDCh) 0 2.55 (2H, m, hPhe-y-H2), 2.88 (2H, m, hPhe-a-
H2), 4.24 (lH, m, hPhe-p-H), 5.06 (2H, s, Z-H2), 5.11 (2H, AB system, oA=5.08, 
oB=5.14, d, J=12.3 Hz, Bn-H2), 5.29 (1H, d, J=7.5 NH), 7.10-7.35 (I5H, m, ArH). 
l3C NMR (75 MHz, CDCb) 0 37.50 (hPhe-a-CH2), 40.15 (hPhe-y-CH2), 49.53 
(hPhe-p-CH), 66.50 (Z-CH2), 66.62 (Bn-CH2), 126.69, 128.00, 128.07, 128.35, 128.37, 
128.48,128.55,128.59,129.31 (ArCH), 135.59, 136.48, 137.36 (ArC), 155.56 (Z-CO), 
171.33 (hPhe-COOBn). 
IR (CDCb, em-I) 3433,3033,2252, 1720, 1508, 1456, 1222; F AB MS 404.1872 
C2sH26N04 (MH) requires mlz 404.1 861. 
Attempted preparation of (2R,3S) and (lS,3S)-3-(N-benzyloxycarbonylamino)-2-
hydroxy-4-phenylbutanoic acid benzyl esters [N-Z-(2R,3S)-AHPBA benzyl estel' 
N-Z-(2S,3S)-AHPBA benzyl ester] 
50 
+ Z!!NIlOB" 
OH 
A solution ofKHMDS (6.0 eq., 0.5 M in toluene, 0.21 mmot, 0.35 mL) in dry 
(0.3 mL) was stirred and cooled to -78°C. A solution of the benzyl ester (14 mg, 0.03 
mmol) in dry TEF (0.02 mL) was prepared and added dropwise to the solution of 
KHMDS. The reaction mixture was warmed to -25°C then cooled back down to °C, 
prior to the addition of MoOPH (1.5 eq., 45 mg, 0.1 0 mmol) as a single portion. The 
reaction mixture was warmed to -60°C and stirred for 3 h. The reaction was quenched 
with saturated aqueous (1 mL) and saturated aqueous NHtCI (1 mL), warmed to 
rt and stirred until dissolution of the white solids. The aqueous layer was extracted with 
THF (3 x 10 mL) and the combined organic layers were washed with 10% aqueous 
HCI/saturated aqueous NaCI (1:1, 2 x 10 mL), 2% aqueous Na2C03 (2 )( 10 mL), 
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saturated aqueous NaCI (2 x 10mL) and dried (MgSO,,). After filtration, the solvent was 
removed under reduced pressure to give a pale solid. The crude reaction mixture was 
purified by flash column chromatography (30% ethyl acetate/petroleum ether) to yield 
unreacted starting benzyl ester. 
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9.3. STEREOCHEMICAL ASSIGNMENT OF TETRAZOLE-BASED INHIBITORS 
9.3.1. SYNTHESIS OF L~ALANINEDERIVATIVES 
Preparation of (3S)-N-[3m (N-benzyloxycarbonylamino )m4m phenylbutanoic acid]-L-
alanine benzyl estel', 4.1.4a11 }) 8\ ZHN~:N' + HCI.H,N~(OB" ---" ZHN -0 N~OB" 
o 0 H 0 
3.4.1 4.1AIl 
N-Z-L-Phenylalanine diazoketone, 3.4.1 (1.0 eq., 370 mg, 1.14 mmol) was reacted 
with L-alanine benzyl ester hydrochloride (1.2 eq., 372 mg, 1 mmol) in the presence 
of triethylamine (2.0 eq., 232 mg, 2.28 mmol, 0.4 mL) according to general procedure B. 
The crude reaction product was purified by flash column chromatography (30% ethyl 
acetate/petroleum ether) and a single recl)'stallisation (ethyl acetate/petroleum ether), to 
give dipeptide, 4.1.4a (330 mg, 61 %), as a white solid. 
iH NMR (300 MHz, CDCh) 0 l.36 (3H, d, J=7.2 Ala-j3-H3), 2.39 (2H, m, 
hPhe-y-H2), 2.88 (2H, m, hPhe-a-H2), 4.14 (lH, m, hPhe-j3-H), 4.59 (lH, q, J=7.2 Hz, 
Ala-a-H), 5.05 (2H, s, Z-H2), 5.17 (2H, AB system, oA=5.l4, , d, J=12.0 Hz, Bn-
Hz), 5.79 (lH, d, 5 Hz, NH), 6.21 (IH, d, J=6.3 Hz, NH), 7.17-7.34 (ISH, m, ArH). 
BC NMR (75 MHz, CDC h) 0 18.01 (Ala-j3-CH3), 38.51 (hPhe-a-CH2),40.13 
(hPhe-y-CHz). 48.0S (Ala-a-CH), 50.10 (hPhe-J3-CH), 66.44 (Z-CHz), 67.12 (Bn-CH2), 
126.52, 127.85,127.93,128.12,128.41,128.51,128.58,129.27 (ArCH), 135.24,136,54, 
137.86 (ArC), 155.81 (Z-CO), 170.40 (Ala-CO), 172.57 (hPhe-CO). 
TLC (analytical, 30% ethyl acetate/petroleum ether) 
CZsil31NzOs (MHI-) requires mlz 475.2233. 
MS 475.2228 
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Preparation (lS,2' ~1-1-(benzyl 
benzyloxycm'bonylamino )-3-phenylpropane] tetrazole, 4.1.5a II 
8,,-\ 8~:-N ° I I :N ZHN IN' j(0Bn --____ I> ZHN ,X ~O 
H 0 " T 
OBn 
4.1.40 4.1.5a 
Dipeptide, (100 mg, 0.21 mmol) was reacted according to general 
procedure C. Purification of the crude reaction mixture by radial chromatography (20%-
50% ethyl acetate/petroleum ether) and HPLC (RP-C18 preparative column, 30% 
H20/methanol, retention time 10.5 min) gave tetrazole, 4.1.5a (10 mg, 10%). 
lR NMR (300 MHz, CDCh) () 1.87 (3R, d, J=6.9 Hz, Ala-~-H3), 2.88 (2H, m, 
hPhe-y-H2), 2.89 (2H, d, J=6.0 Hz, hPhe-a-H2), 4.25 (lH, m, hPhe-~-H), 5.00 (tH, q, 
J=6.9 Hz, Ala-a-H), 5.03 (2H, s, Z-H2), 5.11 (2H, AB system .07, oB=5.14, d, 
J=12.3 Hz, Bn-H2), 5.50 (IH, d, J=8.4 Hz, NH), 7.05-7.36 (I5H, m, ArH). 
BC NMR (75 MHz, CDCb) () 16.80 (Ala-~-CH3), 26.77 (hPhe-a-CH2), 39.08 
(hPhe-y-CH2), 55.92 (Ala-a-CH), 66.75 (Z-CH2), 68.26 (Bn-CH2), 126.84, 127.06, 
127.33,127.91,128.14,128.51,128.70,128.81,129.30 (ArCH), 134.35, 136.16, 137.10 
(ArC), 1 (CN4), 155.78 (Z-CO), 167.59 (Ala-CO). 
TLC (analytical, 50% ethyl acetate/petroleum ether) RF0,46; ESMS 500.2292 
C2sli30NS04 (MH+) requires mlz 500.2298. 
of (lS,2' S)-5-(2-amino-3-phenylpropane )-l-(benzyl 
ethanoate)tetl'azole hydrobromide, 4.1.6all 
4.1.5a 4.1.68 
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The tetrazo Ie (11 mg, 0.02 mmol) was deprotected according to general 
procedure D to give the amine hydrobromide salt 4.1.631 (8 mg, 90%), as a mixture ofC-6 
epimers (9: 1 4.1.631:4.1.6b). 
IH NMR (major product 4.1.6a, 300 MHz, CD30D) 0 1.89 d, J=6.6 Hz, Ala-
P-H3), 3.01-3.45 (4H, m, hPhe-a.-H2 & hPhe-y-H2), 4.10 (lH, m, hPhe-p-H), 5.13 (2H, s, 
Bn-H2), 5.67 (IH, q, J=6.6 Hz, Ala-a.-H), 7.21-7.34 (10H, m, ArH). 
l3C NMR (major product 4.1.6a, 75 MHz, CD30D) 0 16.81 (Ala-CH3), 27.14 
(hPhe-a.-CH2), 39.55 (hPhe-y-CH2), 52.35 (hPhe-f3-CH), 57.43 (Ala-a.-CH), 69.50 (Bn-
CH2), 127.95, 128.97, 129.95, 129.80, 129.90, 129.94, 130.44, (ArCH), 136.59 (ArC), 
154.17 (CN4), 169.67 (Ala-CO). 
Preparation of N-(2-quinolinylcarbonyl)-L-asparagine, 
Quinaldic acid (1.0 eq., 2.0 g, 11.5 mmot) was dissolved in dry CH2Clz (60 mL) in 
a flame dried flask under N2. Thionyl chloride (2.0 eq., 1.75 mL, 23 mmol) was added 
and the white precipitate redissolved with the addition of triethylamine (1.0 eq., 1.6 mL, 
11.5 mmol). The reaction was stirred at It for 3 h then the solvent was removed under 
reduced pressure to give the acid chloride as a brown solid. A solution of L-asparagine 
(1.0 eq., 1.53 g, 11.5 mmot) and K2C03 (1.0 eq., 3.45 g, 11.5 mmol) was prepared in 
water (20 mL) and the acid chloride, as a solution in toluene (80 mL) was added at rt. The 
reaction was stirred vigorously for 4 h, then the layers separated. The aqueous layer was 
acidified to with 6 M aqueous HCI to precipitate a white solid. The solid product 
was filtered off and redissolved in ethanol, decolourised, filtered and evaporated in 
vacuo. The crude product was recrystallised from ethanol, to give acid, 4.2.7 (1.33 g, 
40%). 
IH NMR (300 MHz, DMSO-d6) 0 2.79 (2H, system, 17, oB=2.85, dd, 
J=4.8,16.2 Asn-p-H2), 4.81 (Ill, m, Asn-a.-H), 7.73 (Ill, t, J=7.8 Hz, QC-6-ll), 7.88 
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(1H, t, J=7.8 Hz, QC-7-H), 8.08-8.19 (3H, m, QC-3-H & QC-5-H & QC-8-H), 8.59 (1H, 
d, J=8.4, QC-4-H), 9.16 (lH, d, J=8.7 Hz, QC-NH). 
DC NMR (75 MHz, DMSO-d6) 8 36.48 (Asn-p-CH2), 48.97 (Asn-a-CH), 118.65 
(QC-3-CH), 128.25, 128.34, 129.04,129.28,130.79 (ArCH), 138.19 (QC-4-CH), 146.02 
(QC-9-C), 149.53 (QC-2-C), 163.49 (QC-CO), 171.91 (Asn-CONH2), 172.60 (Asn-
COOH). 
FAB MS 288.0983 C14H14N304 (MW) requires mlz 288.0984. 
Preparation of (lS,2'S)-1-(benzyl 1-methyl-2-ethanoate)-5-{ 2-[N-«2-
quinolinylcarbonyl)-L-aspaa'aginyl)arnino ]-3-phenylpropane} tetrazole, 4.1.7 a 11 
4.1.711 
The amine hydrobromide (1.0 eq., 8 mg, 0.02 mmol, as a mixture ofC6 epimers 
9:1 4.1.6a:4.1.6b) was coupled to N-(2-quinolinylcarbonyl)-L-asparagine 4.2.7 (2.5 eq., 
17 mg, 0.05 mmol) according to general procedure G. The crude reaction product was 
purified by plate layer chromatography (ethyl acetate) to give protected tripeptide 4.1.7a 
(3 mg, 25%) as a mixture ofC-6 epimers (7:3 4.1.7a:4.1.7b). 
IH NMR (major product 4.1.7a, 300 MHz, CDCh) 8 1.92 (3H, d, J=6.6 Hz, Ala-
P-H3), 2.72 (2H, m, Asn-p-H2), 2.89-3.06 (4H, m, hPhe-a-H2 & hPhe-y-H2), 4.49 (lH, m, 
hPhe-p-H), 4.91 (lH, m, Asn-a-H), 5.16 (2H, s, Bn-H2), 5.21 (lH, q, J=7.5 Hz, Ala-a-
H), 5.50 (lH, bs, NH), 5.98 (lH, bs, NH), 6.98-7.33 (lOH, m, ArH), 7.63 (lH, t, J=6.3 
Hz, QC-6-H), 7.77 (lH, t, J=7.8 Hz, QC-7-H), 7.87 (1H, d, J=6.0 Hz, QC-3-H), 8.19 (lH, 
q, J=9.3 Hz, QC-5-H), 8.29 (lH, t, J=11.7 Hz, QC-4-H), 9.25 (1H, d, J=8.1 Hz, NH). 
13C NMR (major product 4.1.7a, 75 MHz, acetone) 8 16.25 (Ala-p-CH3), 27.47 
(hPhe-a-CH2), 38.20 (Asn-p-CH2)' 39.65 (hPhe-y-CH2), 50.23 (hPhe-p-CH), 50.66 (Asn-
a-CH), 55.49 (Ala-a-CH), 67.74 (Bn-CH2), 118.64, 126.78, 127.58, 128.18, 128.32, 
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128.59,128. 129.18,129.38,130.06,130.14 (ArCH), 136.75, 137.46 (ArC), 146.56 
(QC~9-C), 148.80 (QC-2~C), 155.94 (CN4), 164.75 (QC-CO), 167.84 (A1a~CO), 170.65 
(Asn-CO), 1 96 (Asn-CONHz). 
(analytical, ethyl acetate) RF0.24; ES MS 635.2708 C3~35N805 (MF") 
requires mlz 635.2730. 
9.3.2. SYNTHESIS OF D-ALANINEDERNATIVES 
Preparation of (3S)-N-[3-(N-benzyloxycarbonylamino )-4-phenylbutanoic acid]-D-
alanine 4.1.4b 
p 
ZJn< ~'" o 
3.4.1 
N-Z-L-Phenylalanine diazoketone, 3.4.1 (l.0 eq., 200 mg, 0.62 mmol) was reacted 
with D-alanine benzyl ester para-toluenesulphonate (2.4 eq., mg, 1.48 mmol) in the 
presence of triethylamine (2.0 eq., 125 mg, 1.2 mmol, 0.2 mL) according to general 
procedure B. The crude reaction product was purified by flash column chromatography 
(30% ethyl acetate/petroleum ether) and a single recrystallisation (ethyl acetate/petroleum 
ether) to give dipeptide, 4.1.4b (200 mg, 65%), as a white solid. mp 149-150 DC. 
IH NMR (300 MHz, CDCh) 0 1.39 (3H, d, Ala-I3-H3), 2.39 (2H, m, 
hPhe-y-H2), 2.90 (2H, m, hPhe-a-Hz), 4.17 (lH, m, hPhe-I3-H), 4.60 (tH, q, J=7.5 Hz, 
Ala-a-H), 5.06 (2H, s, Z-Hz), 5.16 (2H, AB system, 
Hz), (IH,d, Hz,NH),6.17(lH,d,J=6.9 
.19, d, J=12.3 Hz, Bn-
7.17-7.34 (ISH, m, ArH). 
NMR (75 MHz, CDCb) 0 18.15 (Ala-I3-CH3), (hPhe-a-CH2), 40.02 
(hPhe-y-CH2), 48.09 (Ala-a-CH), 50.01 (hPhe-I3-CH), 66.49 (Z-CH2), 67.19 (Bn-CH2), 
126.57,127.89,127.96,128.12,128.43,128.52,128.59, 129.28 (ArCH), 135.22, 136.56, 
137.84 (ArC), 1 84 (Z-CH2), 170.36 (Ala-CO), 172.71 (hPhe-CO). 
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TLC (analytical, 30% ethyl acetate/petroleum ether) ES MS 475.2238 
C2sH31N20S (MH+) requires mlz 475.2233. 
Pl'eparation (lR,2' S)-l-(benzyl 
benzyloxycarbonylamino )-3-phenylpl'opane]tetrazole, 
8"'- ~ 8~ ~~ ° W ___ '" ZH·N N·N ZHN Nl(oBn ....l ~o 
H ° '" r 
4.1.4b 4.1.5b OBn 
Dipeptide, (100 mg, 0.21 mmol) was reacted according to general 
procedure C. Purification of the crude reaction mixture by radial chromatography (20%-
50% ethyl acetate/petroleum ether) and HPLC (RP-C18 preparative column, 30% 
H20/methanol, retention time 10.8 min) gave tetrazole, (15 mg, 15%). 
IH l\TMR (300 MHz, CDCh) () l.87 (3H, d, J==7.5 AJa-p-H3), 2.93 (2H, d, 
J=6.9 Hz, hPhe-y-H2), 3.02 (2H, d, J=5.7 Hz, hPhe-a-H2), 4.22 (1H, m, hPhe-f3-H), 5.00 
(2H, S, Z-H2), 5.13 S, Bn-Hz), 5.15 (IH, q, J=7.5 Hz, Ala-a-H), 5.30 (lH, d, J=7.8 
Hz, NH), 7.14-7.33 (1 m, ArH). 
l3C NMR (75 MHz, CDCh) () 16.66 (AJa-f3-CH3), 26.93 (hPhe-a-CHz), 38.99 
(hPhe-y-CH2), 50.36 (hPhe-f3-CH), 55.53 (AJa-a-CH), 66.73 (Z-CH2), 68.24 (Bn-CHz), 
126.91, 127.96, 128.16, 128.26, 128.51,128.73,129.05,129.23 (ArCH), 134.36, 136.05, 
136.81 (ArC), 152.48 (CN4), 155.81 (Z-CO), 167.67 (Ala-CO). 
TLC (analytical, 50% ethyl acetate/petroleum ether) RpO.28. 
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PrepaB'ation of (1 R,2' S)-l-(benzy I 
benzyloxycal'bonylamino)-3-pheuylpropane]-teh'azole, by l'acemisation of 
(lS,2' S)-l-(benzyl I-methyl-2-ethanoate)-5-[2-(N-benzyloxycarbonylamino)-3-
phenylpropane] tetl'azole, 
8~ :::-- N-N I .' ZHN N.N 
/yO 
OBn 
4.1.5b 
Protected tetrazole, 4.1.5a (40 mg, 0.08 mmol) was dissolved In 10% 
triethylamine/CDCb. Epimerisation was monitored by NMR (300 J\.1Hz, CDCh). 
After 48 h epimerisation oftetrazole, 4.1.5a had occurred to give a 1:1 mixture (by IH 
NMR) of tetrazoles, and 4.1.51>. The tetrazoles were separated by plate layer 
chromatography (50% ethyl acetate/petroleum ether). Tetrazole 4.1.5a (7 mg, 17%) was 
collected from a higher Rt> band (RF0.46), while tetrazole 4.1.51> (8 mg, 20%) ran as a 
lower Rrband (Rt=0.28). 
Spectral data for both compounds, 4.I.5a and 
reported. 
was identical to that already 
Preparation of (lR,2' S)-5-(2-amino-3-phenylpl'opane)-1-(benzyl I-methyl-2-
ethanoate)tetl'azole hydl'Obromide, 4.1.6b 
4.1.5b 4.!.6b 
The tetrazole, (13 mg, 0.03 mmol) was deprotected according to general 
procedure to give the amine hydrobromide salt, (9 mg, 89%), as a mixture ofC-
6 epimers (4: 1 
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IH NMR (major product 300 MHz, CD30D) 0 1.91 (3H, d, J=6.3 Hz, Ala-
i3-H3), 3.10 (2H, d, J=6.9 hPhe-y-H2), 3.36 (2H, m, hPhe-a-H2), 4.11 (lH, m, hPhe-p-
H), 5.19 (2H, s, Bn-H2), 5.69 (IH, q, J=6.3 Hz, Ala-a-H), 7.21-7.40 (lOH, m, ArH). 
DC NMR (major product 4.1.6b, 75 MHz, CD30D) 0 16.96 (Ala-CH3), 27.26 
(hPhe-a-CH2), 39.49 (hPhe-y-CH2)' 52.28 (hPhe-a-CH), (Ala-a-CH), 69.57 (Bn-
CH2), 128.93, 129.16, 129.61, 129.88, 129.94, 130.38, 130.77, 130.84 (ArCH), 136.51 
(ArC), 154.07 (CN4), 169.81 (Ala-CO). 
Preparation of (lR,2' S)-l-(benzyl I-methyl-2-ethanoate)-5-{ 2-[N-«2-
qumolinylcarbonyl)-L-asparaginyl)amino ]-3-phenylpropane} tetrazole, 4.L 7b 
4.1.7b 
The amine hydrobromide, 4.1.6b (9 mg, 0.02 mmol, as a mixture of C6 epimers 
4:1 4.L6b:4.1.6a) was coupled to N-(2-quinolinylcarbonyl)-L-asparagine, 4.2.7 (17 mg, 
0.05 mmol) according to general procedure G. The crude reaction product was purified 
by plate layer chromatography (ethyl acetate) to give protected tripeptide, 4.1.7b (3 mg, 
23%) as a mixture ofC-6 epimers (5.5:4.5 4.1.7b:4.1.7a). 
IH NMR (major product 4.1.7b, 300 MHz, CDCh) 0 1.97 (3H, d, J=8.4 Ala-
P-H3), 2.69 (2H, m, Asn-p-H2), 2.89-3.06 (4H, m, hPhe-a-H2 & hPhe-y-H2), 4.45 (lH, m, 
hPhe-J3-H), 4.89 (lH, m, Asn-a-H), 5.14 (2H, 5, Bn-H2), 5.37 (HI, q, J=8.4 Hz, Ala-a-
H), 5.87 (IH, bs, NH), 6.98-7.33 (lOH, m, ArH), 7.63 (lH, t, J=7.2 Hz, QC-6-H), 7.77 
{lH, t, J=7.2 7.88 (lH, d, J=7.8 Hz, QC-3-H), 8.18 (2H, t, J=7.8 QC-5-
H & QC-S-H), 8.30 (lH, t, J=8.1 Hz, QC-4-H), 9.24 (lH, d, J=6.3 Hz, NH). 
BC (major product 4.1.7b, acetone) 0 16.33 (Ala-p-CH3), 27.85 
(hPhe-a-CH2), 13 (Asn-p-CH2), 39.18 (hPhe-y-CH2), 49.33 (hPhe-i3-CH), 50.11 (Asn-
a-CH), 55.54 (Ala-a-CH), 67.77 (Bn-CH2), 118.88, 126.50, 128.52, 128.39, 128.50, 
CHAPTER NINE-STEREOCHEMICAL ASSIGNMENT OF TETRAZOLE-BASED INHffilTORS 1 
128.75,129. 129.85,130.60 (ArCH), 137.94,138.16 (ArC), 146.74 (QCm 9m C), 149.95 
(QC-2-C), 1 (CN4), 164.75 (QC-CO), 167.82 (Ala-CO), 170.83 (Asn-CO), 172.83 
(Asn-CONH2). 
(analytical, ethyl acetate) RFO.18; ES MS 635.2720 C3~35N805 (MHl 
requires mlz 63 O. 
CHAPTER NINE-SYNTHESIS OF a-METHYLENE TETRAZOLE-BASEO INHIBITORS 176 
9.4. SYNTHESIS OF a-METHYLENE TETRAZOLE-BASED INHIBITORS 
Prepamtion of (3S)-N-[3-(N-benzyloxycarbonylamino )-4-phenylbutanoic acid]-
glycine benzyl ester, 5.2.2 
N 
ZHNYN2 + HCl.H2NrrOBn 
° ° 3.4.1 
Gylcine benzyl ester hydrochloride (1.0 eq., 1.12 g, 3.7 mmol), was reacted with 
ot-diazoketone, 3.4.1 (1.5 eq., 1.20 g, 5.6 mmol) in the presence of triethylamine (2.0 eq., 
0.75 g, 7.4 mmol, 1.05 mL) according to general procedure B. The crude reaction product 
was purified by flash column chromatography (30% ethyl acetate/CH2Cb) and a single 
recrystallisation (ethyl acetate/petroleum ether) to give dipeptide, 5.2.2, as a white solid 
(2.19 g, 85%). mp 144-146 °C; [ot]020 -2.8° (c=0.0043, methanol). 
IH NMR (300 MHz, CDCh) 0 2.43 (2H, m, hPhe-y-H2), 2.90 (2H, m, hPhe-ot-
H2), 4.01 (2H, d, J=5.4 Hz, Gly-ot-H2), 4.16 (IH, m, hPhe-p-H), 5.04 (2H, s, Z-H2), 5.16 
(2H, S, Bn-H2), 5.76 (IH, d, J=7.8 Hz, hPhe-NH), 6.24 (IH, bs, Gly-NH), 7.18-7.34 
(15H, m, ArH). 
l3C NMR (75 MHz, CDCh) 0 38.56 (hPhe-ot-CH2), 40.06 (hPhe-y-CH2), 41.22 
(Gly-ot-CH2), 50.08 (hPhe-p-CH), 66.47 (Z-CH2), 67.22 (Bn-CH2), 126.55, 127.88, 
127.96, 128.36, 128.40, 128.51, 128.61, 129.29 (ArCH), 135.04, 136.55, 137.83 (ArC), 
155.85 (Z-CO), 169.64 (Gly-CO), 171.07 (hPhe-CO). 
TLC (analytical, 30% ethyl acetate/CH2Cb) RrO.25; IR (CDCh, em-I), 3429, 
3033,2252,1743,1712,1674,1498; FAB MS 461.2088 C2Ji29N20S (MHl requires mlz 
461.2076. 
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Preparation 
phenylpropanej-tetl'azole, 
8~~ 8-~-~ ZHN N-y°Bn---_" ZHN N·N 0 
H ° l-f 
5.2.2 5.:U OBn 
177 
Dipeptide, (502 mg, 1.0 mmol) was reacted according to general procedure 
C. The crude reaction product was purified by flash column chromatography (30% ethyl 
acetate/CHzClz) and a single recrystallisation (ethyl acetate/petroleum ether) to give 
tetrazole, (300 mg, 62%). mp 101-104 °C; [a.]DZO -14.6° (c=0,0015, methanol). 
IH NMR (300 MHz, CDCh) 0 2.89-3.04 (4H, m, hPhe-a.-Hz & hPhe-y-Hz), 4.21 
(IH, m, hPhe-~-H), 4.98 (2H, s, Z-H2), 5.00 (2M, AB system, oA=:4.93, oB=5.04, d, 
J=18.1 Gly-a.-H2) 5.16 (2H, AB system, oA=5.l4, .19, d, 
5.45 (IH, d, 5 hPhe-NH), 7.11-7.35 (I5H, m, ArB). 
l3C NMR (75 MHz, CDCh) 0 26.67 (hPhe-a.-CHz), 39.07 (hPhe-y-CH2), 47.46 
(Gly-a.-CHz), 50.64 (hPhe-~-CH), 66.48 (Z-CH2), 68.16 (Bn-CH2), 126.74, 127.97, 
128.19, 128.26, 128.37, 128.46,128.58,128.75,129.04, (ArCH), 134.11, 136.15, 136.95 
(ArC), 153 (CN4), 155.71 (Z-CO), 165.12 (Gly-CO). 
TLC (analytical, 30 % ethyl acetate/CH2Ch), RF0.40; IR (CDCh, cm-\ 3315, 
1749,1693,1535,1452,1272, 1257;FABMS486.2131 CZ7H2sNs04(MH;requiresmlz 
486.2141. 
Crystallog.'aphic structure determination of (2S)-1-(benzyl ethanoate)-5-[2-(N-
benzyloxycarbonylamino)-3-phenylpl'opane]-tetrazole, by X-ray analysis 
C27Hz7Ns04, M 485.54, mp 101-104 °C, crystal dimensions 0.8 x 0.4 x 0.02 mm, 
triclinic, a 5.0379 (3) A, b 10.1066 (7) A, c 12.7865 (9) A, a83.577 (2)°, pS1.897 (2)°, r 
76.475 (2)°, V=624.55 (7)A3, spacegroup PI, Z=I, F(000)=256, Donlc=1.291 mg/m3, 
absorption coefficient 0.089 mm-I , Orange for data collection 3.23 to 25.61, index ranges 
-1 ::;; h ::;; 5, -10::;; k::;; 11, -12::;; I::;; IS, data/restraints/parameters 1867/3/365, goodness of 
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fit on FZ was 1,063, final R indices [1>20'(1)] R1=0,0359, wRz=0,0898, R indices (all data) 
Rl=0,0427, wRz=0,0957, largest difference peak and hole 0,169 and -0,151 eA-3. 
A unique data set was measured at 160(2) K within kVrn,n"-. limit (rn scans). Of 
the 2198 reflections obtained, 1867 were unique (Rint=O.l 01 0) and were used in the full-
matrix least-squares refinement. z8 The structure was solved by direct methods.z9 
Hydrogen atoms were fixed in idealised positions. All non-hydrogen atoms were refined 
with anisotropic atomic displacement parameters. Neutral scattering factors and 
anomalous dispersion corrections for non-hydrogen atoms were taken from Ibers and 
Hamilton.30 
Preparation of (2S)-5-(2-amino-3-phenylpropane)-1-(benzyl ethanoaie)ieb'azole 
hydro bromide, 
The tetrazole, (840 mg, 1.73 mmol) was deprotected according to general 
procedure D. The hydromide, 5.4.4 (746 mg, 99%) was used without further purification. 
IH NMR (300 MHz, CD30D) b 2.58 (2H, m, hPhe-y-Hz), 2.75 (2H, m, hPhe-a-
Hz), 3.59 (IH, m, hPhe-~-H), 4.73 (2H, s, Bn-Hz), 4.94 (2H, d, J=3.0 Hz, Gly-a-Hz), 
6.77-6.89 (lOH, m, ArH). 
l3C NMR (75 MHz, CD30D) b 26.90 (hPhe-a-CHz), 39.81 (hPhe-y-CHz), 48.20 
(Gly-a-CHz), 52.30 (hPhe-~-CHz), 69.63 (Bn-CHz), 129.12, 129.88, 130.04, 130.08, 
130.55,130.77 (ArCH), 136.54, 136.60 (ArC), 154.50 (CN4), 167.83 (Gly-CO). 
FAB MS 352.1771 Cl<JIzzNs02 (MIt) requires 3 1773. 
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Preparation of (2S)-1-(benzyl ethanoate)-5-{ 2-[N-«2-quinolinylcarbonyl)-L-
aspall'aginyl)amino ]-3-phenylpll'opane} tetrazole, 5.4.5 
5.4.4 
The hydrobromide salt, 5.4.4 (1.0 eq., 630 mg, 1.49 mmol), was coupled to N-(2-
quinolinylcarbonyl)-L-asparagine, 4.2.7 (1.1 eq., 1.63 mmol, 469 mg), with BOP reagant 
(1.1eq., 723 mg, 1.63 mmol), according to general procedure G. The crude product was 
purified by flash column chromatography (ethyl acetate) and a single recrystallisation 
(methanol) to give protected tripeptide, 5.4.4 (470 mg, 51 %). mp 187-189 °C; [a]D20 
+120 (c=O.OOI, methanol). 
1H NMR (300 MHz, CDCh) cS 2.78 (AB system, cSA=2.67, cSB=2.89, J=7.2, 15.6 
Hz, Asn-p-H2), 2.98 (2H, d, J=7.5 Hz, hPhe-y-H2), 3.06 (2H, d, J=6.3 Hz, hPhe-a-H2), 
4.45 (IH, m, hPhe-p-H), 4.89 (IH, m, Asn-a-H), 5.19 (2H, s, Bn-H2), 5.21 (2H, s, Gly-a-
H2), 5.37 (IH, bs, NH), 5.80 (IH, bs, NH), 7.03-7.37 (10H, m, ArH), 7.64 (IH, t, J=6.9 
Hz, QC-6-H), 7.79 (IH, t, J=6.6Hz, QC-7-H), 7.89 (IH, d, J=7.8Hz, QC-3-H), 8.17-8.22 
(2H, m, QC-8-H & QC-5-H), 8.33 (IH, d, J=8.1 Hz, QC-4-H), 9.25 (IH, d, J=8.1 Hz, 
QC-NH). 
l3C NMR (300 MHz, CDChIDMSO-d6) cS 25.91 (hPhe-a-CH2), 36.29 (Asn-p-
CH2), 38.88 (hPhe-y-CH2), 46.92 (Gly-a-CH2), 48.80 (hPhe-p-CH), 49.07 (Asn-a-CH), 
66.82 (Bn-CH2), 117.65,125.45,126.80,127.10,127.38,127.63,128.19, 128.69, 129.23 
(ArCH), 133.61, 136.42, 136.45 (ArC), 145.36 (QC-9-C), 148.23 (QC-2-C), 152.87 
(CN4), 163.05 (QC-CO), 165.02 (Gly-CO), 169.63 (Asn-CO), 171.49 (Asn-CONH2). 
TLC (analytical, ethyl acetate), RFO.20; IR (CDCh, em-t ), 3394, 3305, 3215, 
1749, 1649, 1616, 1533, 1500, 1215; FAB MS (MIr)621.2583 C33H33NsOs requires mlz 
621.2573. 
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Preparation of (2S)-1-( ethanoic acid)-5-{ 2-[N-«2-quinolinylcarbonyl)-L-
asparaginyl)amino]-3-phenylpropane} tetmzole, 5.4.6 
~ 8~ -- 0 N-N 6)yH II ," , /. N~ ,N 
"gN ,N NO 
o = H ~ 
J-NH2 OH o 
5.4.6 
The benzyl ester, 5.4.5 (382 mg, 0.62 mmol), was hydrogenated according to 
general procedure E. The free acid was dried in vacuo over KOH to give the acid, 5.4.6 
(312 mg, 70 %), as a white solid. mp 184-185 °C; [a]D20 -36° (c=0.0005, methanol). 
IH NMR (300 MHz, CD30D) 8 2.72 (2H, d, J=5.7 Hz, Asn-~-H2), 2.94 (2H, m, 
hPhe-y-H2), 3.l2 (2H, d, J=6.6 Hz, hPhe-a-H2), 4.52 (IH, m, hPhe-~-H), 4.83 (lH, m, 
Asn-a-H), 5.30 (2H, s, Gly-a-H2), 6.95 (IH, t, J=6.9 Hz, Ph-4-H) 7.08 (2H, t, J=7.8 Hz, 
Ph-3-H2), 7.20 (2H, d, J=7.2 Hz, Ph-2-H2), 7.71 (lH, q, J=7.8 Hz, QC-6-H), 7.85 (lH, q, 
J=7.2 Hz, QC-7-H), 8.00 (lH, d, J=8.l Hz, QC-3-H), 8.l6 (2H, d, J=8.7 Hz, QC-8-H, & 
QC-5-H), 8.47 (lH, d, J=8.7 Hz, QC-4-H). 
l3C NMR (75 MHz, DMSO-d6) 8 27.17 (hPhe-a-CH2), 30.57 (Asn-~-CH2), 37.16 
(hPhe-y-CH2), 47.90 (Gly-a-CH2), 49.48 (hPhe-~-CH), 50.l8 (Asn-a-CH), 118.78, 
125.06,126.30,128.30,128.39,129.07,129.26,130.83 (ArCH), 138.14, 138.23 (ArC), 
146.04 (QC-9-C), 149.59 (QC-2-C), 153.99 (CN4), 163.59 (QC-CO), 167.99 (Asn-CO), 
170.33 (Asn-CONH2), 171.75 (Gly-COOH). 
IR (KBr, em-I) 3421, 3315, 1747,1718, 1647, 1529, 1498; EI MS 531.2099 
C2Ji27NsOs (MH+) requires mlz 351.2100. 
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Preparation of (2S)-1-[N-(1,1-dimethylethyl)ethanamide]-S-{ 2-[N-«2-
quinolinylcarbonyl)-L-asparaginyl)amino ]-3-phenylpropane} tetrazole, S.4.1 
8~ 0-----= 0 N-N 6)yH II /" I ,-; N~ ,N 
,1"yN ,N NO 
o "H ~ J-NH2 NH 
o K 
5.4.1 
The free acid, 5.4.6 (1.0 eq., 10 mg, 0.02 mmol), was coupled to tert-butyl amine 
(2.0 eq., 3 mg, 0.04 mmol, 4 ilL) with EDCI (1,5 eg., 5 mg, 0,03 mmol) and HOBt (1.5 
eg., 4 mg, 0.03 mmol) according to general procedure H The crude protected tripeptide 
was purified by HPLC (RP-C18 preparative column, 28% H20/methanol, retention time 
14 min) to give the protected tripeptide, S.4.1 (2 mg, 17%). [a]o20 +12° (c=O.OOl, 
methanol). 
IH Nl\AR (300 MHz, CD30D) () 1.30 (9H, s, C(CH3)3), 2.71 (2H, d, J=6.3 Hz 
Asn-~-H2), 2.94 (2H, m, hPhe-y-H2), 3.11 (2H, d, J=6.9 Hz, hPhe-a-H2), 4.51 (lH, m, 
hPhe-~-H), 4.83 (lH, m, Asn-a-H2), 5.08 (2H, AB system, ()A=5.09, ()B=5.12, d, J=17.1 
Hz, Gly-a-H2), 6.96 (lH, t, J=7.5 Hz, Ph-4-H), 7.08 (2H, t, J=7.8 Hz, Ph-3-H2), 7.21 (2H, 
d, J=7.2 Hz, Ph-2-H2), 7.69 (lH, t, J=6.9 Hz, QC-6-H), 7.84 (lH, t, J=7.2 Hz, QC-7-H), 
8.01 (lH, d, J=7.8 Hz, QC-3-H), 8.16 (2H, d, J=8.7 Hz, QC-8-H & QC-5-H), 8.47 (lH, d, 
J=8.4 Hz, QC-4-H). 
l3C Nl\AR (75 MHz, CD30D) () 28.05 (hPhe-a-CH2), 28.86 (C(CH3)3), 37.89 
(Asn-~-CH2), 40.96 (hPhe-y-CH2), 49.93 (Gly-a-CH2), 51.12 (hPhe-~-CH), 51.93 (Asn-
a-CH), 53.89 (C(CH3)3), 122.73, 127.89, 129.18, 129.67, 130.63, 131.12 (ArCH), 
139.18,139.02 (ArC), 148.05 (QC-9-C), 150.63 (QC-2-C), 155.79 (CN4), 165.96 (Gly-
CO), 168.70 (QC-CO), 172.89 (Asn-CO), 175.31 (Asn-CONH2). 
FAB MS 610.2878 C30H37N904Na (MHNa+) requires mlz 610.2866. 
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Preparation of (2S)-1-[N-(L-isoleudne methyl ester)ethanamidle ]-5-{ 2-[N-( (2-
quinolinylcarhonyl)-L-asparaginyl)amino ]-3-phenylpropane} tetra:wie, 5.4.2 
The free acid, 5.4.6 (1.0 eq., 58 111g, 0.11 11111101), was coupled to L-isoleucine 
methyl ester hydrochloride (1.1 eq., 22 mg, 0.12 mmo1) with EDCI (1.5 eq., 31 mg, 0.16 
mmol) and HOBt (1.5 eq., 25 mg, 0.16 11111101) according to general procedure H. The 
crude protected tetrapeptide was purified by HPLC (RP-C18 preparative column, 25% 
H20/methanol, retention time 12 min), and precipitated from ether to give the protected 
tripeptide, 5.4.2 (13 mg, 18%). mp 105-107 °C; [ex]D20 _4° (c=0.0028, methanol). 
IH NMR (300 MHz, CD30D) 0 0.87 (3H, d, J=6.3 Hz, lle-p-CH3), 0.88 (3H, t, 
J=7.5 Hz, lle-o-H3), 1.34 (2H, AB system, oA=1.24, 08=1.43, m, lIe-y-H2), 1.84 (lH, m, 
lIe-p-H), 2.70 (2H, m, Asn-p-H2), 2.94 (2H, d, J=6.9 Hz, hPhe-y-H2), 3.11 (2H, d, J=6.9 
Hz, hPhe-ex-H2), 3.67 (3H, s, OCH3), 4.28 (IlL d, J=5.7 Hz, lIe-ex-H), 4.53 (lH, m, hPhe-
P-H), 4.83 (lH, t, J=6.6 Hz, Asn-ex-H), 5.28 (2H, AB system, oA=5.24, 08=5.32, d, J= 
17.1 Hz, Gly-ex-H2), 6.96 (IH, t, J=7.2, Ph-4-H), 7.08 (2H, t, J=7.3 Hz, Ph-3-H2), 7.21 
(2H, d, J=7.5 Hz, Ph-2-H2), 7.69 (lH, t, J=7.2 Hz, QC-6-H), 7.83 (lH, t, J=7.5 Hz, QC-7-
H), 7.99 (lH, d, J=8.4 Hz, QC-3-H), 8.15 (2H, d, J=8.7 Hz, QC-5-H & QC-8-H), 8.46 
(lH, d, J=8.7 Hz, QC-4-H). 
l3C NMR (75 MHz, CD30D) 0 12.08 (lle-o-CH3), 16.24 (Ile-p-CH3) 26.56 (lle-y-
CH2) , 28.77 (hPhe-ex-CH2), 38.08 (Asn-p-CH2), 38.62 (lle-p-CH), 41.07 (hPhe-y-CH2), 
49.93 (Gly-ex-CH2), 51.27 (hPhe-p-CH), 51.91 (Aso-ex-CH), 52.91 (OCH3), 58.91 (Ile-ex-
CH), 119.94 (QC-3-CH), 127.82, 129.32, 129.73, 130.66, 131.09, 131.83 (ArCH), 
136.95,139.20,139.22 (ArC), 148.18 (QC-9-C), 150.63 (QC-2-C), 155.87 (CN4), 166.55 
(QC-CO), 167.43 (Gly-CO), 172.91 (Asn-CO), 173.66 (Ile-CO), 175.34 (Asn-CONH2). 
FAB MS 680.2933 C33H39N906Na (MHNa+) requires mlz 680.2921. 
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Prepandion of N-(L-isoleucine)-L-valine methyl ester hydrochioride31 
Commercially available N-(L-isoleucine)-L-valine (100 mg, 0.43 mmol) was 
suspended in 2,2-dimethoxypropane (4 mL). Concentrated HCI (400 J..lL) was added 
dropwise to the stirred solution. The suspension cleared upon addition of the acid and the 
reaction was allowed to stand at rt for 18 h. Solvent was removed under reduced pressure 
at <50°C to give a brown solid. A single recrystallisation (methanol/ethyl acetate/ 
petroleum ether) gave the dipeptide methyl ester (111 mg, 92%) as a white crystalline 
solid, which was dried in vacuo over KOH. mp 176-178 °C; [a]D20 +9° (c=0.0018, 
methanol). 
IH NIVJR (300 MHz, CD30D) 0 0.97 (3H, t, J=7.2 Hz, Ile-O-H3), 0.98 (6H, d, 
J=7.2 Hz, Val-y-H3), 1.05 (3H, d, J=6.6 Hz, Ile-~-CH3), 1.39 (2H, AB system, oA=1.22, 
OB=1.57, m, Ile-y-H2), 1.95 (lH, rn, ne-~-H), 2.18 (lH, m, Val-f3-H), 3.71 (3H, s, OCR3), 
3.80 (lH, d, J=5.4 Hz, Ile-a-H), 4.35 (lH, d, J=6.0 Hz, Val-a-H). 
l3C NMR (75 MHz, CD30D) 0 11.94 (lle-o-CH3), 15.44 (Ile-~-CH3), 18.87 (Val-
O-CH3), 19.66 (Val-o-CH3), 25.38 (lle-y-CH2), 3l.81 (Val-f3-CH), 38.54 (lle-~-CH), 
52.78 (OCH3), 59.14 (lle-a-CH), 59.89 (Val-a-CH), 166.34 (TIe-CO), 170.32 (Val-CO). 
IR (KEr, em-I) 3215, 2968, 2879, 1747, 1668, 1548, 1492, 1467, 1205, 1155; 
FAB MS 245.1870 C12H25N203 (MH+) requires m/z 245.1865. 
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Preparation of (2S)-1-[N-(N-(L-isoleucine )-L-valine methyl ester)ethanamide]-5-{2-
[N-( (2-quinolinykarbonyl)-L-asparaginyl)amino] -3-phenylpropane } tetrazole, 5.4.3 
8' --.c: ---..0 H 0 N-N /. N I N cC)y ~N N 
o = H '--f0 J-NH, HN{: 
5.4.3 
o NH 
"l ,.I. ~~o I"~ r 
OCH3 
The free acid, 5.4.6 (1.0 eq., 50 mg, O. 09 mmol), was coupled to N-(L-
isoleucine)-L-valine methyl ester hydrochloride (1.1 eq., 30 mg, 0.1 0 mmol), with EDCI 
(1.5 eq., 27 mg, 0.14 mmol) and HOBt (1.5 eq., 22 mg, 0.14 mmol) according to general 
procedure H. The crude protected pentapeptide was purified by HPLC (RP-C18 
preparative column, 28% H20/methanol, retention time 24 min), and precipitated from 
ether to give the protected tetrapeptide, 5.4.3 (7 mg, 11%). mp 238-240 °C; [a]o20 _4° 
(c=0.0036, methanol). 
IH NMR (300 MHz, CD30D) b 0.88 (6H, dd, J=2.4, 7.8 Hz, Val-y-H3), 0.90 (3H, 
t, J=8.1 Hz Ile-y-H3), 0.93 (3H, d, J=6.9 Hz, Ile-~-CH3), 1.39 (2H, AB system, bA=1.21, 
bB=1.57, m, Ile-y-H2), 1.86 (lH, m, Ile-~-H), 2.09 (lH, m, Val-~-H), 2.69 (2H, d, J=6.0 
Hz, Asn-~-H2), 2.93 (2H, m, hPhe-y-H2), 3.13 (2H, d, J=6.3 Hz, hPhe-a-H2), 3.68 (3H, s, 
OCH3), 4.29 (lH, d, J=6.3 Hz, Val-a-H), 4.32 (lH, d, J=8.1 Hz, Ile-a-H), 4.53 (lH, m, 
hPhe-~-H), 5.27 (2H, AB system, bA=5.25, bB=5.30, d, J=8.7 Hz, Gly-a-H2), 6.92 (lH, t, 
J=7.2 Hz, Ph-4-H), 7.06 (2H, t, J=7.8 Hz, Ph-3-H2), 7.20 (2H, d, J=7.5 Hz, Ph-2-H2), 7.69 
(lH, t, J=7.5 Hz, QC-6-H), 7.84 (IH, t, J=7.2 Hz, QC-7-H), 8.01 (lH, d, J=7.8 Hz, QC-3-
H), 8.14, 8.17 (2H, d, J=3.9 Hz, QC-5-H, & QC-8-H), 8.47 (lH, d, J=8.4 Hz, QC-4-H). 
l3C NMR (75 MHz, CD30D) b 11.66 (lle-b-CH3), 16.03 (Ile-~-CH3), 18.95 (Val-
y-CH3), 19.74 (Val-y-CH3), 26.20 (lle-y-CH2), 28.85 (hPhe-a-CH2), 31.94 (Val-~-CH), 
38.15 (Asn-~-CH2), 38.54 (lle-~-CH), 41.01 (hPhe-y-CH2), 49.49 (Gly-a-CH2), 51.27 
(hPhe-~-CH), 51.95 (Asn-a-CH2), 52.68 (OCH3), 59.67 (Ile-a-CH & Val-a-CH), 119.98 
(QC-3-CH), 127.87, 129.34, 129.73, 130.66, 131.09, 131.122, 131.87 (ArCH), 139.40, 
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139.27 (ArC), 148.05 (QC-9-C), 150.63 (QC-2-C), 1 .79 (CN4), 167.25 (Gly-CO), 
170.47 (QC-CO), 172.89 (Asn-CO), 173 
CONH2). 
(Val-CO), 174.02 (lIe-CO), 175 
FAB MS 779.3611 C38R!sNlO07Na (MHNa+) requires mlz 779.3605. 
(Asn-
Prepa..ation of (2S)-5-[2-(N-tert-butyloxyca.'bonylamino )-3-phenylpropaneJ-l-
(ethanoic acid)tetrazole, 5.4.732 
8~~-N 8~~-N I ~ t ~ ZHN N ~--. BodIN N 
~O lyO 
5.2.1 OBn 5.4.7 OH 
A solution of tetrazole, (1.0 eq., 200 mg, 0.41 mmol), di-tert-
butyldicarbonate (Boc20, 2.0 eq., 180 mg, 0.82 mmol) in methanol (10 mL) was 
hydrogenated at rt in the presence of 10% palladium on carbon (40 mg) for 5 h. The 
reaction mixture was filtered through a celite plug and solvent removed under vacuum. 
Precooled ether (10 mL) was added with vigorous stirring and the product left to stand at 
5 °c for 2 h. The white solid was removed by filtration and dried in vacuo over KOH for 
24 h. The free acid, 5.4.7 (113 mg, 76%) was thus obtained as a white solid. 
IH NMR (300 MHz, acetone) 8 1.41 (9H, s, Boc-(CH3)3), 3.08 .(2H, m, hPhe-a.-
H2), 3.29 (2H, d, J=6.3 Hz, hPhe-y-H2), 4.38 (lH, m, hPhe-p-H), 5.52 (2H, s, Gly-cx-H2), 
6.26 (IH, d, J=7.8 Hz, NH), 7.30-7.40 (SH, m, ArH). 
BC NMR (75 MHz, acetone) 8 28.92 (BOC-(CH3)3), 29.60 (hPhe-a.-CH2), 41 
(hPhe-y-CH2), 52.30 (hPhe-p-CH), 80.57 (Boc-C(CH3)3), 1 88, 129.76, 130.62 
(ArCH), 139.64 (ArC), 157.83 (CN4), 160.39 (Boe··CO). 
ES MS 362.1814 C17H24Ns04 (MH) requires mlz 362.1828. 
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Preparation of (2S)-1-[N-(N-(L-isoleucine)-L-valine methyl ester)ethanamide]-5-[2-
(N-tel't-butyloxycarbonylamino )-3-phenylpro pane] tehoazole, 5.4.8 
""-
N-N f .' 
.N 8~ BoeHN N 0 
5.48 ~c 
""'l .. l/D 
/'" T OCH3 
The tetrazole free acid, 5.4.7 (1.0 eq., 17 mg, 0.05 mmol) was coupled to N-(L-
isoleucine)-L-valine methyl ester hydrochloride (1.1 eq., 14 mg, 0.05 mmol) with EDCI 
(1.5 eq., 13 mg, 0.07 mmol), HOBt (1.5 eq., 10 mg, 0.07 mmol) and DIPEA (1.1 eq., 7 
mg, 0.05 mmol, 10 J-IL) in dry DMF (5 mL), according to general procedure H. The crude 
product was purified by flash column chromatography to give tetrazole, 5.4.8 (22 mg, 
75%) as a white solid. mp 158-160 0c. 
IH NMR (300 MHz, CD30D) D 0.84 (3H, t, J=6.3 Hz, Ile-D-H3), 0.85 (6H, d, 
J=5.7 Hz, Val-y-H3), 1.27 (9H, s, Boc-(CH3)3), 1.37 (2H, AB system, DA=1.26, DB=1.55, 
m, Ile-y-H2), 1.84 (1H, m, Ile-f3-H), 2.11 (1H, m, Val-f3-H), 2.87 (1H, d, J=6.6 Hz, hPhe-
y-H2) , 3.02 (2H, d, J=9.9 Hz, hPhe-a-H2), 3.68 (3H, s, OCH3), 4.15 (1H, m, hPhe-f3-H), 
4.25 (1H, d, J=7.8 Hz, Ile-a-H), 4.33 (1H, d, J=5.7 Hz, Val-a-H), 5.13 (2H, AB system, 
DA=5.09, DB=5.18, d, J=17.1 Hz, Gly-a-H2), 6.34 (1H, d, J=8.1 Hz, NH), 7.17-7.27 (5H, 
m, ArH). 
l3C NMR (75 MHz, CD30D) D 11.44 (Ile-D-CH3), 15.86 (Ile-f3-CH3), 18.66 (Val-
y-CH3), 19.60 (Val-y-CH3), 25.74 (Ile-y-CH2), 28.82 (Boc-(CH3)3), 29.20 (hPhe-a-CH2), 
31.51 (Val-f3-CH), 37.75 (Ile-f3-CH), 41.15 (hPhe-y-CH2), 49.74 (Gly-a-CH2), 51.36 
(hPhe-f3-CH), 52.67 (OCH3), 58.92 (Val-a-CH), 59.29 (Ile-a-CH), 80.38 (BoC-C(CH3)3), 
127.57,129.42,130.15 (ArCH), 138.70 (ArC), 155.34 (CN4), 157.21 (Boc-CO), 166.21 
(Gly-CO), 173.14 (Val-CO), 173.28 (Ile-CO). 
ES MS 588.3512 C29&6N706 (MHl requires mlz 588.3510. 
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Pll'epanltion of (25}5-[2-amino-3-phenylpll'opane ]-l-[N-(N-(L-isoleudne )-L-valine 
methyl ester)ethanamide]tetrazole trifluoroacetate, 5.4.9 
Protected tetrapeptide, 5.4.8 (22 mg, 0.04 mmol) was deprotected with 95% 
aqueous trifluoroacetic acid (5 mL) according to general procedure F to give 
trifluoroacetate, 5.4.9 (25 mg, quant.), which was used without further purification. 
NMR (300 MHz, CD30D) 0 0.87 (12H, m, Val-y-H3, Ile-y-H3, Ile-p-CH3), 
1.37 (2H, system, oA=1.22, oB=1.52, m, Ile-y-H2), 1.86 (lH, m, lle-p-H), 2.07 (IH, 
m, Val-p-H), 3.12 (2H, m, hPhe-y-H2), 3.29 (2H, m, hPhe-a-H2), 3.62 (3H, s, OCH3), 
4.1 0 (IH, m, hPhe-p-H), 4.24 (2H, m, lIe-a-H, Val-a-H), 5.31 (2H, bs, Gly-a-H2), 7.23-
7.29 (5H, m, ArH). 
l3C NMR (75 MHz, CD30D) 0 11.54 (lle-o-CH3), 15.80 (Ile-p-CH3), 18.77 (Val-
y-CH3), 19.43 (Val-y-CH3), 25.61 (Ile-y-CH2), 26.12 (hPhe-a-CH2), 31.29 (Val-p-CH), 
37.98 (Ile-p-CH), 39.17 (hPhe-y-CH2), 48.95 (Gly-a-CH2), 52.l0 (hPhe-p-CH), 52.45 
(OCH3), 59.11 (Val-a-CH), 59.43 (lle-a-CH), 128.43, 129.91, 130.40 (ArCH), 136.21 
(ArC), 154.21 (CN4), 166.52 (Gly-CO), 173.14 (Val-CO), 173.25 (lie-CO). 
MS 488.2991 C2Ji3SN704 (MHl requires mlz 488.2985. 
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of (2S)-1- [N-(N-(L-isoleucine )-L-valine methyl ester)ethanamideJ-5-{ 
[N-( (2-quinolinyical'honyl)-L-as pal'aginyl)amino ] -3-phenylpropane } 
The tetrazole methyl ester trifluoroacetate, 5.4.9 (1.0 eq., mg, 0.04 mmol) was 
coupled to N-(2-quinolinylcarbonyl)-L-asparagine, 4.2.7 (1.0 eq., 12 mg, 0.04 mmol) 
with EDeI (1.5 eq., 12 mg, 0.06 mmol), HOBt (1.5 eq., 9 mg, 0.06 mmol) and DIPEA 
(1.0 eq., 5 mg, 0.04 mmol, 7 j..LL) in dry DMF (5 mL) according to general procedure 
The crude coupled product was purified by plate layer chromatography (ethyl acetate), to 
give the protected pentapeptide, 5.4.3 (12 mg, 40%) as a white solid. 
Spectral data was identical to that previously recorded for this compound. 
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9.5. SYNTHESIS OF a-KETO THE TETRAZOLE ISOSTERE 
9.5.1. FUNCTIONALISATION OF TETRAZOLE-BASED DIPEPTIDE MIMIcs 
Preparation of N-[(N-benzyloxycarbonyl)glydne]glydne benzyl estel', 6.2.11 
H 0 
ZHNTrN.J(oBn 
o 
6.2.11 
189 
N-Z-Glycine (1.0 g, 4.8 mmol) was coupled to glycine benzyl ester para-
toluenesulphonate (1.0 eq., 1.6 g, 4.8 mmol) with BOP reagant (1.1 eq., 2.3 g, 5.3 mmol) 
in the presence of triethylamine (3.0 eq., 1.4 g, 14.3 mmol) according to general 
procedure G. A single recrystallisation (ethyl acetate/petroleum ether) of the crude 
reaction product gave dipeptide, 6.2.11 (1.65 g, 96%). mp 103-105 °C. 
IH NMR (300 MHz, CDCh) 8 3.89 (2H, d, J=5.1 Hz, Gly-a-H2), 4.03 (2H, d, 
J=5.4 Hz, Gly-a-H2), 5.09 (2H, s, Z-H2) , 5.14 (2H, s, Bn-H2), 5.72 (IH, bs, NH), 6.84 
(IH, bs, NH), 7.31-7.33 (lOH, m, ArH). 
l3C NMR (75 MHz, CDCh) 8 41.16 (Gly-a-CH2), 44.29 (Gly-a-CH2), 67.15 (Z-
CH2), 67.20 (Bn-CH2), 128.00, 128.17, 128.28, 128.47, 128.58 (ArCH), l35.01, l36.03 
(ArC), 156.63 (Z-CO), 169.48 (Gly-CO), 169.60 (Gly-CO). 
IR (KBr, em-I) 3379, 3062, 3035,2962,1708,1651,1454,1411,1253,1199,975, 
948, 752, 725; FAB M8 357.1456 Cl9H21N20s (MI-t) requires mlz 357.1450. 
Attempted preparation of 5-[l-(N-benzyloxycarbonylamino )methane ]-l-(benzyl 
ethanoate )tetrazole, 6.2.12 
H )9 ZHN r_.pBn ZHN~N,,- ~OBn-~V(:-------- ~ , \\ II 1"'\ ' F-l;T 0 
o N ·N N 
6.2.11 6.2.12 
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The dipeptide, 6.2.11 (50 mg, 0.14 mmol) was reacted according to general 
procedure C. IH NMR (300 MHz, CDCh) of the crude reaction mixture showed 
unreacted starting material, dipeptide 6.2.11. 
Preparation of N-[(N-«9H)-fluonmylmethyloxycarbonyl)glycine]glycine benzyl 
ester, 6.2.13 
H 0 
FmOcHN"TrNJloBn 
o 
6.2.13 
N-Fmoc-Glycine (1.0 eq., 1.0 g, 3.4 mmol) was coupled to glycine benzyl ester 
para-toluenesulphonate (1.1 eq., 1.2 g, 3.7 mmol) in the presence ofHOBt (1.5 eq., 680 
mg, 5.0 mmol), EDCI (1.5 eq., 970 mg, 5.0 mmol) and triethylamine (1.1 eq., 374 mg, 
3.7 mmol) according to general procedure H. A single recrystallisation (ethyl 
acetate/petroleum ether) gave dipeptide, 6.2.13 (1.28 g, 85%), as a white solid. mp 125-
126°C. 
IH NMR (300 MHz, CDCh) 8 3.91 (2H, d, J=5.4 Hz, Gly-a-H2), 4.07 (2H, d, 
J=5.1 Hz, Gly-a-H2), 4.20 (lH, t, J=6.9 Hz, Fmoc-~-H), 4.42 (2H, d, J=6.9 Hz, Fmoc-a-
H2), 5.15 (2H, s, Bn-H2), 5.56 (lH, bs, NH), 7.25-7.40 (8H, m, ArH), 7.57 (2H, d, J=7.5 
Hz, ArH), 7.74 (2H, d, J=7.2 Hz, ArH). 
l3C NMR (75 MHz, CDCh) 841.25 (Gly-a-CH2), 47.07 (Gly-a-CH2), 67.30 (Bn-
CH2), 119.69, 124.89, 127.06, 127.71, 128.29, 128.36, 128.57, 128.62 (ArCH), 135.00, 
141.26, 143.67 (ArC), 156.60 (Fmoc-CO), 169.21 (Gly-CO), 169.49 (Gly-CO). 
IR(KBr, em-I) 3332,1732,1651,1535,1442,1245,1203,1110,991,952,756, 
736; FAB MS 445.1769 C26H2SN20s (MH+) requires mlz 445.1763. 
CHAPTER NINE-SYNTHESIS OF a-KETo THE TETRAZOLE ISOSTERE 191 
Attempted preparation of 1-(lbenzyl ethanoate)-5-{1-[N-(9H)-
fluorenylmethyloxycarlbonylamino )methane ]tetrazole, 6.2.14 
H 0 OBn K_A _---'~*_-~.FmocHN, r--i 
FmocHNlr OBn A lI"J:i 0 
o NN,N 
6.2.13 6.2.14 
The dipeptide, 6.2.13 (50 mg, 0.11 mmol) was reacted according to general 
procedure C. IH NMR (300 MHz, CDCb) of the crude reaction mixture showed 
unreacted starting material, dipeptide 6.2.13. 
Preparation of (3S)-3-(N-lbenzyloxycarlbonylamino )-4-phenyllbutanoic acid, 4.1.322 
ZHN~~ ------.ZHN~OH 
o 
3.4.1 4.1.3 
A solution of silver (1) oxide (360 mg, 1.5 mmol), sodium carbonate (75 mg, 0.71 
mmol), Na2S203.5H20 (160 mg, 0.64 mmol) in water (5 mL), was heated to 80 DC in a 
two-necked flask fitted with a condenser. A solution of diazoketone, 3.4.1 (506 mg, 1.5 
mmol) in dioxane (5 mL), was added dropwise over 1.5 h to the stirred solution.33 Then a 
further portion of silver (1) oxide (180 mg) was added in two portions. Stirring was 
continued until the evolution ofN2 had ceased. The cooled reaction was filtered, diluted 
with water (20 mL) and extracted with ether (3 x 50 mL). The aqueous layer was 
acidified to pH=1 with 1 M aqueous HCI and extracted with ethyl acetate (3 x 30 mL). 
The pooled organic washes were dried (MgS04), filtered and evaporated. The free acid 
was dried in vacuo over KOH for 24 h to yield acid, 4.1.3 (322 mg, 68%) as a white 
solid. mp 119-120 DC (lit. 22 118-119 DC). 
IH NMR (300 MHz, CD30D) 0 2.47 (2H, d, J=6.3 Hz, hPhe-y-H2), 2.80 (2H, m, 
hPhe-a.-H2), 4.18 (1H, m, hPhe-p-H), 4.99 (2H, AB system, oA=4.96, oB=5.01, d, J=13.2 
Hz, Z-H2), 7.17-7.32 (10H, m, ArH). 
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13C NMR (75 MHz, CD30D) () 40.04 (hPhe-a-CH2), 4l.85 (hPhe-y-CH2), 5l.50 
(hPhe-p-CH), 67.44 (Z-CH2), 127.74, 128.85, 129.11, 129.67, 130.72 (ArCH), 138.69, 
139.83 (ArC), 158.33 (Z-CO), 175.14 (hPhe-COOH). 
IR (KEr, cm-l) 3328, 3031, 2920, 1685, 1535, 1450, 1286, 1218, 1053748,698; 
ElMS 222.0763 CllH12N04 (M-C7H/) requires mlz 222.0766; ElMS mlz (reI. intensity) 
108 (25), 91 (l00), 79 (25), 65 (20). 
Preparation of (3S)-N-[3-(N-benzyloxycarbonylamino)-4-phenylbutanoic 
acid]benzyl amine, 6.2.15 
B ZHN -0 N'0 
H V 
6.2.15 
N-Z-L-Homophenylalanine, 4.1.3 (500 mg, l.59 mmol) was coupled to benzyl 
amine (l.2 eq., 170 mg, l.91 mmol) in the presence of EDCI (l.3 eq., 400 mg, 2.07 
mmol), HOBt (l.5 eq., 323 mg, 2.39 mmol), and DIPEA (1.2 eq., 247 mg, l.91 mmol) 
according to general procedure H. Recrystallisation of the crude reaction product gave 
amide, 6.2.15 (581 mg, 91 %) as a white solid. mp 181-182 °C. 
IH NMR (300 MHz, CDCb) () 2.40 (2H, m, hPhe-a-H2), 2.93 (2H, m, hPhe-y-
H2), 4.l6 (IH, m, hPhe-p-H), 4.40 (2H, AB system, (}A=4.34, (}B=4.45, dd, J=5.7, 14.7 
Hz, Bn-a-H2), 5.05 (2H, S, Z-H2), 5.82 (IH, bs, NH), 5.98 (IH, bs, NH), 7.13-7.35 (15H, 
m,ArH). 
13C NMR (75 MHz, CDCh) () 38.79 (hPhe-a-CH2), 40.19 (hPhe-y-CH2), 43.54 
(Bn-a-CH2), 50.14 (hPhe-p-CH), 66.52 (Z-CH2), 126.60, 127.62, 127.82, 127.90, 128.01, 
128.46, 128.55, 128.74, 129.24 (ArCH), 137.86, 137.88 (ArC), 155.68 (Z-CO), 165.35 
(hPhe-CO). 
TLC (analytical, 25% ethyl acetate/petroleum ether) RFO.66; IR (KEr, em-I) 
3305,3028, 1693, 1639, 1527, 1265, 1056,748,698; ES MS 425.1860 C2sH26N203Na 
(MNa 1 requires mlz 425.l841. 
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Preparation of (2S)~ I-benzyl-5-[2~(N-benzyloxycarbonylamino )-3-pbenyJpropane]-
tetrazole, 
B~~ 8-~N. ZHN iiV ----,. ZHN N·N 
~ 6.2.15 6.2.16 V 
The amide, 6,2.15 (340 mg, 0.84 mmol) was reacted according to general 
procedure C. Flash column chromatography (5% ethyl acetate/ether) of the crude product 
gave tetrazole, (256 mg, 71 %). mp 116-118 °c. 
IH NMR (300 MHz, CDCh) 0 2.80-3.03 (4H, m, hPhe-a.-H2 & hPhe-,),-H2), 4.24 
(IH, m, hPhe-~-H), 5.03 (2H, 5, Z-H2), 5.32 (2H, AB system, oA=5.29, oB=5.36, d, 
J=15.6 Bn-H2), 5.37 (IH, d, J=8.4 Hz, NH), 7.07-7.37 (15H, m, ArH). 
DC NMR (75 MHz, CDCh) 0 26.77 (hPhe-a.-CH2), 39.27 (hPhe-,),-CH2), 50.46 
(hPhe-~-CH), 50.66 (Z-CH2), 126.89, 127.52, 127.95, 128.13, 128.49, 128.74, 128.84, 
129.08,129.14 (ArCH), 133.07, 136.23, 136.97 (ArC), 152.19 (CN4), 155.75 (Z-CO). 
TLC (analytical, 25% ethyl acetate/petroleum ether) RFO.81; IR (KBr, em-I) 
3394, 3024, 1701, 1519, 1450, 1242, 1060, 732, 702; ES MS 428.2090 C2sH26Ns02 
(MW) requires mlz 428.2087. 
Preparation of (2S,2' RS)-5-[2-(N-benzyloxycarbonylamino )-J-phenylpropane]-I-(2-
phenylethane)tetl'azole, 6.2.17a and and (lRS,2S,2' R)-5-[2-N-
benzyloxycarbonylamino )-I-methyl-3-phenylpropane]-1-(2-phenylethane )tetl'azole, 
6.2.18 
8-N. 8-N. qNN 
ZHN ~-:---. ZI1N ~ + ZIIN Yo 
6.2.16 6.2.17a (6S) 6.2.18 (6R) 
6.2.17b (6R) 
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solution ofLiHMDS (3.0 eq., 140 ilL, 1,0 M in THF) in dry THF (2 mL), was 
prepared in a f1ame~dried flask under N2. The solution was cooled to -78°C prior to the 
dropwise addition of a solution of tetrazole, 6,2.16 (20 mg, 0.05 mmol) in dry (2 
mL) over 15 min. The reaction was stirred at -78°C for 30 min. A solution of 
iodomethane (1.1 eq., 7.3 mg, 0.05 mmol) in dry THF (2 mL) was added to the reaction 
dropwise over 10 min. The reaction was stirred at -78°C for a further 30 min, then 
allowed to warm to rt. The reaction was quenched with saturated aqueous Na2S03 (5 mL) 
and the aqueous phase extracted with ethyl acetate (3 x 20 mL). The pooled organics 
were washed with 10% aqueous citric acid (3 x 25 mL), 0.5 M aqueous NaHC03 (3 x 
mL) and saturated aqueous NaCI (3 x 25 mL), dried (MgS04), filtered and evaporated. 
The crude reaction products were purified by plate layer chromatography (10% ethyl 
acetatate/CH2Ch) to give; 
and 6.2.17b (1:1 by IH NlV1R, 15 mg, 86%). 
IH NMR (300 MHz, CDCh) 0 1.87 (3H, d, J=7.5 Hz, Bn-~~H3), 2.65-2.94 (4H, 
m, hPhe~a-H2 & hPhe-y-H2), 4.13 (IH, m, hPhe-~-H), 4.92, 4.95 (2H, s, Z-H2), 5.28 (IH, 
q, J=6.9 Hz, (6S)-Bn-a-H), 5.35 (IH, d, J=8.4 Hz, NH), 5.37 (lH, q, (6R)-Bn-
a-H), 5.56 (IH, d, J=7.8 Hz, NH), 6.91-7.28 (15H, m, ArH). 
BC NMR (75 MHz, CDCh) 0 21.94, 22.21 (Bn-~-CH3), 26.87, 27.05 (hPhe-a-
CH2), 38.92, 39.51 (hPhe-y-CH2), 50.39 (hPhe-~-CH), 58.11 «6S)-Bn-a-CH), 58.27 
«6R)-Bn-a-CH), 66.65 (Z-CH2), 125.97,126.08,126.74,126.85,127.89,128.06,128.44, 
128.55,128.58,128.63,128.68,129.04,129.11 (ArCH), 136.22, 136.34, 136.96, 137.06, 
139.01 (ArC), 151.84,151.94 (CN4), 155.69, 155.78 (Z-CO). 
TLC (analytical, 10% ethyl acetate/petroleum ether) Rt=0.50; 
C26H2SNs0 2 (MW) requires m/z 442.2243. 
(4 mg, 14%). 
MS 442.2256 
NMR (300 MHz, CDCh) 0 1.27 (3H, d, hPhe-o-H3), 1.92 (3H, d, 
J=6.9 Bn-~-H3), 2.35 (2H, AB system, oA=2.22, oB=2.48, dd, J=6.9, 14.4 Hz, hPhe-y-
H2), 3.18 (lH, m, hPhe-a-H), 4.11 (lH, m, hPhe-~-H), 4.98 (2H, s, 5.47 (lH, q, 
(6R)-Bn-a-H), 6.13 (lH, d, J=9, 0 Hz, NIl), 6.56-7.28 (ISH, 111, ArH). 
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l3C NMR (75 I\.1Hz, CDCb) 0 16.70 (hPhe~o~CH3), 23.04 (Bn-I3-CH3), 31.74 
(hPhe~ct-CH), 38.83 (hPhe-y-CH3), 55.46 (hPhe-p-CH), 58.16 (6R)-Bn-ct-CH), 66.58 (Z-
CHz), 126.41, 127.77, 127.97, 1 128.66, 128.74, (ArCH), 136.41, 137.14, 
139.19 (ArC), 155.91 (CN4), 156.40 (Z-CO). 
TLC (analytical, 10% ethyl acetate/petroleum ether) Rt=0.43; 
Preparation of 2-amino-2-cyclopentane carboxy late para-toluenesulp hona te 34 
2-Arnino-2-cyclopentane carboxylic acid (500 mg, 3.87 mmol), and para-
toluenesulphonic acid (1.02 eq., 751 mg, 3.95 mmol) were refluxed in benzyl alcohol in a 
Dean-Stark apparatus with the receiver packed with 4 A molecular sieves. The mixture 
was refluxed for 4 h, after which time any solid particulate had dissolved. The reaction 
was allowed to cool. The excess benzyl alcohol was removed to one quarter the original 
volume by vacuum distillation. Pre-cooled ether (20 mL) was added and the mixture left 
to stand at 5 °C for 16 h. The white precipitate that formed was filtered offand dried in 
vacuo over KOH for 24 h to give the benzyl ester (699 mg, 50%). 
lH NMR (300 MHz, CD30D) 0 1.88 (8H, m, Cp-P-Hz & Cp-y-H2), 2.35 (3H, s, 
pTsOH-H3), (2H, s, Bn-H2), 7.22 (2H, d, J=7.8 Hz, Ph-3-H2), 7.38 (5H, m, ArH), 
7.70 (2H, d, Ph-2-H2). 
BC NMR (75 MHz, CD30D) 0 21.60 (pTsOH-CH3), 26.80 (Cp-y-CH2), 37.94 
(Cp-/3-CH2), 66.44 (Cp-ct-C), 69.57 (Bn-CH2), 127.25, 129.91, 130.05, 130.11, 130.53 
(ArCH), 136.76, 141.93, 143.86 (ArC), 1 .45 (Cp-CO). 
IR (KBr, cm-I) 3413,2360, 1739, 1616, 1188, 1122, 1010,682; ES MS 220.1330 
C13HISN02 (MF") requires mlz 220.1338. 
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Preparation of (3S)-N-[3-(N-benzyloxycarbonylamino )-4-phenylbutanoic add]-2-
amino-2-cydopentane carboxylic acid benzyl ester, 6.2.19 
The diazoketone, 3.4.1 (1.0 eq., 572 mg, 1.76 mmol) was reacted with 2-amino-2-
cyclopentane carboxylic acid benzyl ester (1.1 eq., 699 mg, 1.94 mmol) in the presence 
of triethylamine (1.1 eq., 196 mg, 1.94 mmol) according to general procedure B. Flash 
column chromatography (30% ethyl acetate/petroleum ether) of the crude reaction 
product gave amide, 6.2.19 (224 mg, 25%) as a white solid. mp 134-135 °C 
IH NMR (300 MHz, CDCb) 81.66-1.94 (8H, m, Cp-~-H2 & Cp-y-H2), 2.23-2.38 
(2H, m, hPhe-y-H2), 2.83 (2H, m, hPhe-a-H2), 4.09 (lH, m, hPhe-~-H), 5.05 (2H, s, Z-
H2), 5.15 (2H, s, Bn-H2), 5.75 (lH, d, J=7.2 Hz, NH), 5.98 (lH, s, NH), 7.16-7.31 (15H, 
m,ArH). 
13C NMR (75 MHz, CDCb) 8 24.54 (Cp-y-CH2), 37.24 (Cp-~-CH2), 37.27 (Cp-~­
CH2), 38.26 (hPhe-a-CH2), 39.89 (hPhe-y-H2), 50.13 (hPhe-~-CH), 65.98 (Cp-a-C), 
66.41 (Z-CH2), 67.08 (Bn-CH2), 126.47, 126.96, 127.84, 127.94,128.16,128.19,128.39, 
128.46, 129.25 (ArCH), 135.70, 136.55, 138.01 (ArC), 155.88 (Z-CO), 170.72 (hPhe-
CO), 173.69 (Cp-COOBn). 
IR (KBr, em-I) 3363, 3328, 2962, 1708, 1670, 1527, 1454, 1315, 1249, 1211, 
1076,1018,702; ES MS 515.2568 C3lH3SN20S (MW) requires mlz 515.2546. 
Attempted pl'eparation of (2S)-5- [2-(N-benzyloxycarbonylamino )-3-
phenylpropane]-1-(2-cydopentane carboxylic acid benzyl ester)tetrazole, 6.2.20 
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Amide, 6.2.19 (50 mg, 0.1 mmol) was reacted according to general procedure C. 
Flash column chromatography of the crude reaction product gave starting amide, 6.2.19. 
9.5.2. SYNTHESIS OF THE a-KETO TETRAZOLE ISOS1ERE BY DIRECT ALKYLATION OF THE 
TETRAZOLE HETEROCYCLE 
Preparation of 1-(benzyloxymethyl)-IH-tetrazole, 6.3.835 
N'N, N'N, 
II 'N --_. u...}! + 
"-N N 
H '--OBn 
6.3.8 6.3.9 
Sodium hexamethyldisilazide (NalIJ\tIDS, 1.0 eq., 28.5 mL of a 1.0 M solution in 
THF, 28.5 mmol) was added dropwise to a stirred solution of 1H-tetrazole (2.0 g, 28.5 
mmol) in dry THF (100 mL) in a flame-dried flask under Ar, over 30 min at 0 DC. After a 
further 30 min at 0 °C freshly distilled benzyl chloromethylether (l.0 eq., 4.47 g, 28.5 
mmol, 4.0 mL) was added and the white mixture stirred at rt for 2 h. The reaction mixture 
was partitioned between ethyl acetate (50 mL) and water (50 mL). The organic layer was 
separated and the aqueous phase extracted with ethyl acetate (2 x 50 mL). The pooled 
organic phases were washed with saturated aqueous NaCI (2 x 50 mL), dried (MgS04), 
filtered and dried in vacuo. The desired N-1 regioisomer 6.3.8 (0.9 g, 20%) was isolated 
from the oily residue by flash column chromatography (20% ether/petroleum ether), as a 
clear oil. 
IH N1VIR (300 MHz, CDCh) 04.65 (2H, s, Bn-H2), 5.95 (2H, s, CN4-a-H2), 7.34 
(5H, m, ArH), 8.59 (lH, s, CN4-H). 
l3C NMR (75 MHz, CDCb) 0 72.20 (Bn-CH2), 79.66 (CN4-a-CH2), 128.49, 
128.68, 128.85 (ArCH), 135.83 (ArC), 153.62 (CN4). 
TLC (analytical, 30% ethyl acetate/petroleum ether) RFO.51; ES MS 191.0931 
C9HllN40 (MHl requires mlz 191.0933. 
Further elution gave the undesired N-2 regioisomer, 6.3.9. 
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Preparation of (2S)~N-(N,O-dimethylhydroxyl)-2-(N-tert-butyloxycarbonylamino)-3-
phenylpl'opanamide, 
):) BO""H~H 
o 
e~: ___ , N BocNH 'OCH3 
o 
6.3.10 
N-Boc-L-Phenylalanine (l.0 g, 3.8 mmol) was coupled to Weinreb amIne 
hydrochloride14 (N,D-dimethylhydroxylamine hydrochloride, 1.1 eq., 0.41 g, 4.2 mmol) 
with BOP reagant (1.0 eq., 1.7 g, 3.8 mmol) in the presence of triethylamine (2.1 eq., 
0.80 g, 8.0 mmol, 1.05 mL) in dry CH2Ch (40 mL), according to general procedure G. 
Purification of the crude reaction mixture by flash column chromatography (50% ethyl 
acetate/petroleum ether) gave amide, 6.3.10 (0.96 g, 82%) as a viscous oil. 
IH NMR (300 MHz, CDCb) 8 l.38 (9R, s, Boc-(CR3)3), 2.96 (2H, AB system, 
8A=2.87, oB=3.05, dd, 12.9 Hz, Phe-p-H2), 3.16 (3H, s, NCR3) , 3.65 (3H, s, 
NOCH3), 4.95 (IH, m, Phe-a-R), 5.19 (lH, d, J=7.8 Hz, NH), 7.16-7.30 (SH, m, ArR). 
TLC (analytical, 30% ethyl acetate/petroleum ether) RFO.33; 
C1JI25N204(MH") requires mlz 309.1814. 
MS 309.1806 
Preparation of (2S)-I-(benzyloxymethyl)-5-[2-(N-benzyloxycarbonylamino )-1-oxo-3-
phenylpropane]-tetrazole, 6.3.1135 
8~~ljN I . ZHN N 
o '--OBn 
6.3.11 
To a solution oftetrazole, 6.3.8 (3.0 eq., 170 mg, 0.89 mmol) in dry (2 mL) 
was prepared in a flame-dried flask under Ar and cooled to -78°C. n-Butyllithium (3.0 
eq., 640 !J.L ofa 1.4 M in n-hexanes) was added dropwise to the stirred solution to give a 
deep purple colour. After 5 min Weinreb amide, 3.1.25 (1.0 eq., 100 mg, 0.30 mmol), as 
a solution in dry (2 mL), was added dropwise and the reaction was stirred at -78°C 
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for 15 min. The reaction was allowed to slowly warm to rt over a period of30 min, 
before quenching with saturated aqueous NH4Cl (5 mL). The reaction mixture was 
extracted with ethyl acetate (3 x 10 mL) and the pooled organics washed with saturated 
aqueous NaCI (20 mL), dried (MgS04), filtered and dried in vacuo. The crude reaction 
product was purified by flash column chromatography (30% ethyl acetate/petroleum 
ether) and gave 1 ,5-disubstituted tetrazole, 6.3.11 (83 mg, 60%) as a clear oil. 
IHNMR(300 MHz, CDCh) 03.24 (2H, AB system, oA=3.l2, oB=3.35, dd, J=6.9, 
14.1 Hz, hPhe-y-H2), 4.70 (2H, s, Bn-H2), 5.07 (2H, s, Z-H2), 5. (IH, d, J=7.8 Hz, NH), 
5.68 (IH, m, hPhe-~-H), 5.99 (2H, s, CN4-a-H2), 7.05-7.34 (15H, m, ArH). 
l3C NMR (75 MHz, CDCb) 838.87 (hPhe-y-CH2), 58.64 (hPhe-~-CH), 66.45 (Z-
CH2), 72.47 (Bn-CH2), 80.35 (CN4-a-CH2), 127.04, 127.32 128.18, 128.54, 128.59, 
128.63, 128.93, 129.34 (ArCH), 135.1 1, 135.28, 137.82 (ArC), 155.02 (CN4), 156.87 (Z-
CO), 189.76 (hPhe-a-CO). 
TLC (analytical, 30% ethyl acetate/petroleum ether) RF0.28; ES MS 472.1989 
C2&H26Ns04 (MIr) requires mlz 472.1985. 
Preparation of (2S)-1-(benzyloxymethyl)-5-[2-(N-tert-butyloxycarbonylamino )-1-
oxo-3-phenylpropane]-tetrazole, 6.3.12 
(i, ""'-N·}f· I N 
BocHN 't 
o OBll 
6.3.12 
To a solution oftetrazole, 6.3.8 (3.0 eq., 170 mg, 0.89 mmol) in dry THF (2 mL) 
was prepared in a flame-dried flask under Ar and cooled to -78°C. n-Butyllithium (3.0 
eq., 640 JlL of a 1.4 M in n-hexanes) was added dropwise to the stirred solution to give a 
deep purple colour. After 5 min Weinreb amide, 0 (1.0 eq., 90 mg, 0.30 mmol) as a 
solution in dry THF (2 mL) was added dropwise and the reaction was stirred at -78°C 
for 15 min. The reaction was allowed to slowly warm to rt over a period of 30 min, 
before quenching with saturated aqueous ~CI (5 mL). The reaction mixture was 
extracted with ethyl acetate (3 x 10 mL) and the pooled organics washed with saturated 
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aqueous NaCI (20 mL), dried (MgS04), filtered and dried in vacuo. The crude reaction 
product was purified by flash column chromatography (20% ethyl acetate/petroleum 
ether) to 1 ,5-disubstituted tetrazole, 6.3.12 (77 mg, 60%) as a white solid. mp 96-97 
DC. 
IH NMR (300 IVll:Iz, CDCh) 8 1.40 (9H, s, Boc-(CH3)3), 3.20 (2H, AB system, 
8A=3.08, 
J=7.5 
ArH). 
.33, dd, J=6.9, 13.5 Hz, hPhe-hPhe-H2), 4.70 (2H, s, Bn-H2), 5.27 (lH, d, 
NH), 5.62 (lH, m, hPhe-~-H), 6.00 (2H, S, CN4-a-H2), 7.10-7.39 (lOH, m, 
l3C NMR (75 MHz, CDCh) 8 28.18 (BOC-(CH3)3), 38.03 (hPhe-y-CH2), 58.64 
(hPhe-~-CH), 72.47 (Bn-CH2), 80.11 (BoC-C(CRJ)3), 80.36 (CN4-a-CH2), 127.04, 
128.18, 128.54, 128.63, 129.34 (ArCH), 135.11, 135.28 (ArC), 155.02 (CN4) , 161.20 
(Boc-CO), 189.76 (hPhe-a-CO). 
TLC (analytical, 20% ethyl acetate/petroleum ether) RF0.18; ES MS 438.2142 
C23H2&Ns04 (MH+) requires mlz 438.2141. 
Preparation of (lRS,2 .. \1-5-[2-(N-tel't-butyloxycarbonylamino )-1-hydroxyl-3-
phenylpropane]-lH-tetl'azole, 6.3.13a and 6.3.13b 
8~~·N. 8~~·N. I '.N I '.N BocHN 11 --_. BocHN N 
o ~OBn OH H 
6.3.12 6.3.133 (3R) 
6.l.13b (3S) 
The 1,5-disubstituted tetrazole, 6.3.12 (220 mg, 0.5 mmol) in methanol (15 mL), 
was catalytically hydrogenated in the presence of 10% palladium on carbon (220 mg) for 
24 h according to general procedure E. Upon work-up the reaction a-hydroxy 
tetrazoles, 6.3.13a and 6.3.13b, in 90% yield, as a mixture ofC2 epimers, which were not 
separated. 
NMR (300 
2.90 (2H, AB system, 
CD30D, for the mixture) 8 1.23, 1.26 (9H, s, Boc-(CH3h), 
88=3.03, dd, J=6.9, 13.2 Hz, hPhe-y-H2), 4.07, 4.12 (lH, 
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m, hPhe-~-H), 5.01 (IH, d, J=6.6 Hz, NH), 5.08, 5.13 (lH, bs, hPhe-a.-H), 7.17-7.28 (5H, 
m,ArH). 
13CNMR (75 
39.52 (hPhe-y-CH2), 
CD30D, for the mixture) 0 28.36, 28.82 (Boe-(CH3)3), 38.37, 
59.42 (hPhe-~-CH), 67.22,69.01 (hPhe-a.-CH), 80.50, 80.55 
(Boe-C(CH3)J), 127.46, 127.67, 129.43, 129.63, 130.50 (ArCH), 139.38, 139.39 (ArC), 
157.51 (CN4), 159.99, 160.02 (Boe-CO). 
ES MS 320.1721 ClsH22Ns03 (MH+) requires mlz 320.1723. 
Preparation of (2L~-1-(benzyl ethanoate )-5-[2-{N-tert-butyloxycarbonylamino )-1-
oxo-3-phenylpropane]-tetrazole, 6.3.16, and (2S)-2-(benzyl ethanoate)-5-[2-{N-tert-
butyloxycarbonylamino )-I-oxo-3-phenylpropane]-tetrazole, 6.3.17 
8~~·~ I .:N __ ..... BodIN 11 
OR 
6.3.13a (3R) 
6.3.13b (68) 
a~ ~ N'~ BodIN I {~. 
RO ,0 
6.3.14a (6R) OBn 
6.3.14b (68) 
+ 
R'~N BOCHNYt ~ 
° ,0 
6.3.16 OBn 
+ 
6.3.15a (6R) 6.3.17 
6.3.15b (68) 
A solution of IH-tetrazole as a mixture of 6.3.13a and (1.0 eq., 110 mg, 
0.35 mmol) in dry CH2Ch (5 mL) was prepared in a flame-dried flask under Ar. DlPEA 
(3.0 eq., 130 mg, 1.04 mmol, 175 j.!L) was added dropwise to the stirred solution at rt. 
After 5 min benzyl bromoacetate (2.0 eq., 160 mg, 0.70 mmol, 110 j.!L) was added 
dropwise and the reaction was stirred for 24 h. The reaction was diluted with ethyl acetate 
(20 mL), washed with 10% aqueous HCl (2 x 10 mL), 1 M aqueous NaOH (2 x 10 mL), 
saturated aqueous NaCl (10 mL), dried (MgS04), filtered and evaporated. The crude 
reaction product was purified by flash column chromatography {40% ethyl 
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acetate/petroleum ether) to give a-hydroxy tetrazoles, and 
6.3.15b (127 mg, 77%), which were not separated. 
IH NMR (300 CDCb, for the mixture) 6 1.32 (9H, bs, Boc-(CH3)3), 3.04 
(2H, m, hPhe-y-H2), 4,20 (IH, m, hPhe-p-H), 4.96 (IH, d, NH), 5.06 (lH, d, 
J=3,0 Hz, hPhe-a-H), 5.14 (IH, d, J=5.1 Hz, hPhe-a-H), 5.20 (2H, bs, Bn-Hz), 5.41 (2H, 
bs, Gly-a-Hz), 7.17-7.36 (lOH, m, ArH). 
TLC (analytical, 40% ethyl acetate/petroleum ether) RF=0.17, 
The mixture of a-hydroxy tetrazoies, 6.3.14 and (127 mg, 0.3 mmol), as a 
solution in CHzClz (6 mL) was added to a solution of TEMP036 (4 mg, 0.03 mmol) and 
potassium bromide (3 mg, 0.03 mmol) in water (ca. 120 JlL) at 0 °C. A 5.25% aqueous 
sodium hypochlorite solution (4.5 mL) was added dropwise over 5 min with vigorous 
stirring. After 30 min at 0 °C the reaction was diluted with ethyl acetate (20 rnL) and 
10% aqueous HCI (20 mL). The organic layer was separated and the aqueous layer 
extracted with ethyl acetate (2 x 20 mL). The combined organic phases were dried 
(MgS04), filtered and evaporated. The regiomeric a-keto tetrazole products were 
separated by flash column chromatography (30% ethyl acetate/petroleum ether). The less 
polar 1,5-disubstituted tetrazole, 6.3.16 (41 mg, 30%), eluted first as a clear oil. 
IH NMR (300 MHz, CDCh) 6 1.35 (9H, s, Boc-(CH3)3), 3 (2H, AB system, 
6A=3.07, .37, dd, J=8.1, 14.1 Hz, hPhe-y-H2), 5.12 (IH, d, J=6.6 Hz, NH), 5.21 (2H, 
d, J=4.8 Bn-H2), 5.42 (IH, m, hPhe-p-H), 5.47 d, J=3.0 Hz, Gly-a-H2), 7.13-
7.38 (lOH, m, ArR). 
l3C NMR (75 MHz, CDCh) 6 27.97 (Boc-(CH3)3), 37.02 (hPhe-),-CHz), 50.11 
(Gly-a-CHz), 59.48 (hPhe-f3-CH) 68.14 (Bn-CHz), 80.25 (BoC-C(CH3)3), 124.03, 127.06, 
128.38, 128.55, 128.68,129.18 (ArCH), 134.14, 135.13 (ArC), 148.09 (CN4), 154.00 
(Boc-CO), 164.71 (Gly-CO), 189.05 (hPhe-a-CO). 
TLC (analytical, 30% ethyl acetate/petroleum ether) RF0.39; IR (CDCb, cm-l), 
3392,3324, 15,1756,1632,1603,1528,1497,1230; ES MS 466.2097 CzJIzsNsOs 
(MlI") requires m/z 466.2090. 
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Further elution gave the 2,5-regioisomer, 6,3.17 (65 mg, 48%), as a white solid. 
mp 120-121 °C; [a]D20 8.3 (c=0,00010, methanol). 
IH NMR (300 CDCh) 0 1.39 (9H, s, Boc-(CH3)3), 3.19 (2H, AB system, 
oA=3.06, oB=3.33, dd, J=6.9, 13.8 Hz, hPhe-y-H2), 5.24 (IH, d, NH), 5.29 (2H, 
s, Bn-H2), 5.53 (2H, s, Gly-a-H2), 5.58 (lH, m, hPhe-~-H), 7.05-7.34 (lOH, m, ArH). 
l3C NMR (75 MHz, CDCb) 0 28.18 (BOC-(CH3)3), 37.93 (hPhe-y-CH2), 53.76 
(Gly-a-CH2), 58.70 (hPhe-~-CH) 58.57 (Bn-CH2), 80.11 (BoC-C(CH3)3), 127.05, 128.52, 
128.60,128.74,128.95,129.34 (ArCH), 134.01, 135.24 (ArC), 155.00 (Boc-CO), 161.15 
(CN4), 164.03 (Gly-CO), 189.32 (hPhe-a-CO). 
TLC (analytical, 30% ethyl acetate/petroleum ether) RF0.29; IR (CDCb, cm-I ), 
3395, 3307,3215, 1756, 1649, 1610, 1533, 1500; ES MS 466.2096 C2~28N505 (MIt) 
requires mlz 466.2090. 
Crystallographic determination of (2S)-Z-(benzyl ethanoate)-5-[2-(N-tert-
butyloxycarbonylamino )-1-oxo-3-phenylpropane ]-tetrazole, 6.3.17, by X-ray 
analysis 
C2~27N505, M 465.51, mp 120-121 °C, crystal dimensions 0.55 x 0.26 x 0.02 
mm, orthorhombic, a 6.140 (3) A, b 16.264 (7) A, c 23.523 (10) A, a90 (2)°, /390 (2)°, r 
90 (2)°, V=2349.0 (17) A3, spacegroup P2(1)2(1)2(1), F(000)=984, Dcalc=I.316 
mg/m3, absorption coefficient 0.096 mm-\ () range for data collection 2.14 to 26.45, 
index ranges ::;; h::;; 7, -20::;; k::;; 18, -29 S 1::;; 29, data/restraints/parameters 4837/0/307, 
goodness of fit on was 0.794, final R indices [1>2cr(1)] R l=0.0448, wR2=0.0714, R 
indices (all data) R1=0.1525, wR2=0.0904, largest difference peak and hole 0.174 and 
0.355 eA-3. 
A unique data set was measured at 173(2) K within 28max=57° limit (rn scans). 
the 30663 reflections obtained, 4837 were unique (R11lt=0.1593) and were used in the full-
matrix least-squares refinement, 28 The structure was solved by direct methods.z9 
Hydrogen atoms were fixed in idealised positions. All non-hydrogen atoms were refined 
with anisotropic atomic displacement parameters. Neutral scattering fuctors and 
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anomalous dispersion corrections for non-hydrogen atoms were taken from Ibers and 
Hamilton.30 
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9.6. SOLID-STATE STRUCTURES OF TETRAZOLE-BASED DIPEPTIDE MIMICS 
Preparation of (2S)-1-(benzyl ethanoate)-5-[2-(N-benzyloxycarbonylamino )-3-
phenylpropane]-tetrazole, 5.2.1, see Chapter 9.3. 
Preparation of cyclo-{[(2S)-5-(2-amino-3-phenylpropane )-1-ethanamide] tetmzole}, 
7.2.1 
5.4.7 5.4.4 
~~ " HN J ~N O~N. -N' 
N' 
7.2.1 
A solution of benzyl ester hydrobromide, 5.4.4 (1.1 eg., 80 mg, 0.19 mmol) and 
triethylamine (1.1 eq., 19 mg, 0.19 mmol) in dry DMF (2 mL) was added to a solution of 
dipeptide acid, 5.4.7 (1.0 eq., 55 mg, 0.15 mmol), EDCI(1.5 eq., 43 mg, 0.22 mmol) and 
ROBt (1.5 eq., 30 mg, 0.22 mmol) in dry DlvtF (2 mL). The reaction was stirred at rt for 
24 h. The reaction was diluted with water (20 mL) and extracted with ethyl acetate (3 x 
20 mL). The pooled organics were washed with 1 M aqueous HCI (2 x 25 mL), saturated 
aqueous NaHC03 (2 x 25 mL) and saturated aqueous NaCI (2 x 25 mL), dried (MgS04), 
filtered and evaporated. The crude reaction product was purified by flash column 
chromatography (50% ethyl acetate/CH2Ch). The major product, cyclic tetrazole 
peptidomimetic, 7.2.1 (43 mg, 93% of starting benzyl ester) was recrystallised from 
methanol. mp 198- 200°C; [a,]D 20 -10.7 0 (c=O. 0005, methanol). 
IH NMR (300 MHz, CDCb) 8 2.91-3.43 (4H, m, hPhe-a,-H2 & hPhe-y-H2), 4.26 
(IR, m, hPhe-~-H), 5.28 (2H, s, Gly-a,-H2), 7.27-7.41 (5H, m, ArR). 
l3C NMR (75 MHz, CDCh/CD30D) 8 30.36 (hPhe-a-CH2), 39.92 (hPhe-y-CH2), 
50.00 (hPhe-~-CH), 51.35 (Gly-a,-CH2), 127.26, 128.77 (ArCH), 135.40 (ArC), 15l.97 
(CN4), 166.04 (Gly-CO). 
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TLC (analytical, 50% ethyl acetate/CH2Ch) RF0.30; IR em-I) 3548, 3471, 
3406,1697,1639,1438,1411,1091,705,644,601; ES MS 244.1196 C12HI~50 (MHl 
requires mlz 244.1198. 
Crystallographic determination of cyclo- U(2S)-5-(2-amino-3-phenylpropane )-1-
ethanamide]tetrazole}, 7.2.1, by X-ray analysis 
CI'z.H13NsO, M 243.27, mp 198-200 °C, crystal dimensions 0.63 x 0.24 x 0.21 
mm, orthorhombic, a 56.374 (2) A, b 8.621 (3) A, c 120.890 (7) A, a90 (2)°, p 90 (2)°, r 
90 (2)°, V=1147.8 (7) A3, spacegroup P2(1)2(1)2(l), F(000)=512, Dcnlc= 1.408 
mg/m3, absorption coefficient 0.096 mm-\ e range for data collection 2.56 to 26.42, 
index ranges -4 ~ h ~ 7, -10 ~ k ~ 10, -26 ~ I ~ 25, data/restraints/parameters 2338/0/163, 
goodness of fit onP2 was 1.063, final R indices [1>20'(1)] RI=0.0323, wR2=0.0827, R 
indices (all data) Rl=0.0374, wR2=0.0853, largest difference peak and hole 0.148 and -
0.191 ek3. 
A unique data set was measured at 163(2) K within 26max=57° limit (m scans). Of 
the 14344 reflections obtained, 2338 were unique (Rmt=0.0271) and were used in the full-
matrix least-squares refinement. 28 The structure was solved by direct methods.z9 
Hydrogen atoms were fixed in idealised positions. All non-hydrogen atoms were refined 
with anisotropic atomic displacement parameters. Neutral scattering factors and 
anomalous dispersion corrections for non-hydrogen atoms were taken from Ibers and 
HamiIton?O 
Preparation of (2S)-2-(benzyl ethanoate )-5-[2-(N-tert-butyloxycarbonylamino )-1-
oxo-3-phenylpropane]-tetrazole, 6.3.17, see Chapter 
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